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1. Riassunto 
 
Introduzione 
La vaccinazione è considerata lo strumento a breve e medio termine più idoneo, 
efficace, ed economico per proteggere le popolazioni dalle malattie infettive. Le 
malattie infettive rappresentano il 23% di tutte le malattie che affliggono l’umanità, 
ma colpiscono in maniera sproporzionata (98.9%) le popolazioni dei paesi a medio e 
basso reddito e soprattutto i bambini. In particolare, le infezioni enteriche, causate da 
batteri come Salmonella, Shigella, Campylobacter jejuni, ETEC o da virus, 
rappresentano la terza causa d’infezione globale e, escludendo le condizioni 
perinatali, la seconda causa di morte tra i bambini sotto i 5 anni. Le Salmonelle non 
tifoidee (NTS), i cui sierotipi più comuni sono Typhimurium ed Enteritidis, sebbene 
siano solamente una causa di gastroenterite senza particolari complicanze nei paesi 
industrializzati, sono invece una delle principali cause di setticemia in Africa, 
soprattutto tra bambini e i soggetti immunocompromessi nella regione subsahariana. 
Pur essendo un importante problema di salute pubblica, con un tasso di mortalità che 
raggiunge il 20-25% nel caso di setticemia, NTS è sorprendentemente una malattia 
negletta principalmente a causa della sua presentazione clinica complessa, che ne 
rende difficile la diagnosi, e della mancanza di strumenti diagnostici adeguati. Mentre 
sono stati prodotti vaccini contro le infezioni da Salmonella di tipo tifoideo, non 
esistono attualmente vaccini contro NTS.  Maggiore interesse è sorto negli ultimi anni 
verso questa malattia, di pari passo con il preoccupante emergere di ceppi 
antibiotico-resistenti, e diversi tipi di vaccini sono attualmente in sviluppo, come 
gliconiugati, organismi attenuati, GMMA e  vaccini a subunità proteica.   
Un vaccino glicoconiugato si genera con l’unione tramite legame chimico covalente, 
o coniugazione, di un saccaride a una proteina immunogenica, avente la funzione di 
carrier. La coniugazione tra saccaride e proteina può avvenire direttamente, o previa 
attivazione, di una o entrambe le biomolecole, con molecole aventi la funzione di 
spaziatore. Le cellule di molti agenti patogeni sono infatti ricoperte da un denso 
strato di carboidrati complessi noto come glicocalice, costituito da glicoproteine, 
proteoglicani e glicolipidi, la cui esposizione sulla superficie le rende capaci di 
interagire con le componenti del sistema immunitario, esercitando una funzione 
protettiva nei confronti della difesa immunitaria dell’ospite e rappresentando quindi 
un’importante fattore di virulenza del microorganismo. In particolare, batteri 
incapsulati come Streptococcus pneumoniae, Haemophilus influenzae, Neisseria 
meningitidis e Salmonella typhi presentano un guscio polisaccaridico (noto come 
capsula) che circonda la parete e che è stato utilizzato per la produzione di vaccini 
polisaccaridici. I vaccini polisaccaridici possiedono tuttavia una grave limitazione: 
essi non sono capaci di generare memoria immunologica e sono inefficaci nei 
neonati e nei pazienti immunodepressi. Infatti, i polisaccaridi sono antigeni cellule T-
indipendenti, importanti componenti della risposta immunitaria adattiva, e risultano 
dunque attivi unicamente sulle cellule B. Viceversa, le proteine sono antigeni T-
dipendenti e la loro coniugazione chimica a un polisaccaride conferisce a 
quest’ultimo la capacità di stimolare i linfociti T, migliorando così la risposta 
immunogenicità e conferendo  memoria immunitaria. Sono stati sviluppati per 
migliorare l’immunogenicità dei vaccini polisaccaridici e, molto probabilmente, in un 
futuro non remoto, li andranno a sostituire completamente. Non esiste un altro 
esempio in cui l’introduzione di un nuovo approccio allo sviluppo di vaccini ha avuto 
un effetto così rapido e positivo nella prevenzione delle infezioni da patogeni umani, 
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come Haemophilus influenzae di tipo b (Hib), Neisseria meningitidis e Streptococcus 
pneumoniae, e questo successo ha aperto la strada a nuove applicazioni possibili 
come i vaccini terapeutici per il cancro e l’Alzheimer e vaccini coniugati per la 
dipendenza da droghe. L'antigene O (OAg) del lipopolisaccaride è il principale 
polisaccaride di superficie per le specie NTS. Il lipopolisaccaride è un componente 
della parete cellulare esterna dei batteri Gram-negativi, composto da una porzione 
glicolipidica, il lipide A; un porzione oligosaccaridica, definita Core; e dall’OAg, una 
catena polisaccaridica immunodominante la cui composizione conferisce specificità 
sierologica all’organismo. 
La coniugazione dell’OAg a proteine carrier ha permesso lo sviluppo di vaccini 
glicoconiugati efficaci nel produrre anticorpi e in grado di proteggere da infezioni letali 
di Salmonella in modelli animali. Non esistono dati clinici su vaccini glicoconiugati 
contro NTS, ma un vaccino glicoconiugato basato sull’OAg di S. Paratyphi A si è 
dimostrato immunogenico ed efficace in studi clinici in fase 1 e 2 su adulti e bambini 
vietnamiti, dimostrando la bontà di questo tipo di approccio. 
Diverse variabili possono influenzare l'immunogenicità di un vaccino glicoconiugato. 
Parametri come la lunghezza della catena saccaridica, il rapporto saccaride/proteina, 
il tipo di coniugazione chimica, la proteina carrier usata conferiscono ai glicoconiugati 
diverse caratteristiche chimico-fisiche che possono determinare diverse proprietà 
immunologiche. Una comprensione razionale degli effetti di questi parametri differenti 
sull’immunogenicità potrebbe portare a un disegno più razionale dei vaccini 
glicoconiugati, con conseguente maggiore efficacia e protezione a lungo termine. 
Tuttavia, questo non è semplice per diverse ragioni. In primo luogo, la risposta 
immunitaria è altamente antigene dipendente, e perciò risultati contrastanti possono 
essere ottenuti lavorando con diversi polisaccaridi. Inoltre, studi effettuati finora 
hanno confrontato l'immunogenicità di vaccini che differiscono per più parametri 
contemporaneamente, rendendo quindi difficile assegnare l'importanza relativa di 
una singola variabile sull'immunogenicità. Infine, parametri come la lunghezza della 
catena saccaridica, il rapporto saccaride/proteina e il tipo di chimica di coniugazione 
sono fortemente interconnessi. A causa di questa complessità, l'importanza relativa 
di ogni variabile dovrebbe essere indagata per ciascun antigene polisaccaridico, ogni 
volta che un vaccino glicoconiugato è in fase di sviluppo. 
Il progetto vaccini glicoconiugati contro NTS a NVGH 
NVGH sta lavorando allo sviluppo di un vaccino bivalente glicoconiugato che 
protegga contro le infezioni da S. Typhimurium e S. Enteritidis. L’approccio prevede 
l’estrazione e purificazione dell’OAg dai rispettivi ceppi e la coniugazione con la 
proteina carrier CRM197, una variante non tossica della tossina difterica che è già 
stata ampiamente utilizzata con successo nello sviluppo di altri vaccini gliconiugati 
((Hib, pneumococco ( 7 e 13 valente ), meningococco tetravalente (ACWY)). 
NVGH ha sviluppato un metodo semplice, rapido e a basso impatto ambientale per 
l'estrazione e la purificazione dell’OAg. Sulla crescita batterica, viene effettuata 
un’idrolisi acida che rompendo il legame tra il KDO e il lipide A, permette il rilascio 
dell’OAg direttamente nel sopranatante. Una serie di processi successivi, per lo più 
precipitazioni e filtrazioni, permette la purificazione dell’OAg da altre impurità 
presenti, come proteine o acidi nucleici. La chimica di coniugazione in precedenza 
sviluppata da NVGH per un vaccino glicoconiugato contro S. Paratyphi A, è stata 
applicata al progetto NTS. Questo metodo utilizza l'unità terminale KDO della catena 
dell’OAg per la coniugazione con la proteina, senza modificare le unità ripetitive della 
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catena polisaccaridica. Studi preliminari su topi hanno mostrato che il coniugato 
ottenuto con questa chimica produce alti titoli anti-OAg con attività battericida. 
Obiettivi del progetto di dottorato 
All’interno del progetto vaccini glicoconiugati contro NTS, Il mio lavoro di dottorato si 
è interessato di tre aspetti correlati: 
1. Caratterizzazione strutturale degli antigeni polisaccaridici di S. Typhimurium e S. 
Enteritidis purificati da diversi ceppi. 
2. Disegno, sintesi e valutazione immunologica di un pannello di vaccini 
glicoconiugati contro NTS, che differiscono per alcuni parametri noti influenzare la 
risposta immunologica: il ceppo di derivazione dell’OAg (e quindi caratteristiche 
strutturali come glucosilazione e l’O-acetilazione), la chimica di coniugazione, il 
rapporto OAg/proteina.  
3. Progettazione e sviluppo di efficaci metodologie di coniugazione, che permettano 
la sintesi di glicoconiugati altamente specifici e selettivi, la semplificazione del 
processo di purificazione e il riciclo dell’OAg, consentendo così una riduzione 
globale dei costi di processo. 
Impatto della struttura dell’OAg sull’immunogenicità di vaccini glicoconiugati 
contro NTS 
L’OAg è stato estratto e purificato da sei ceppi S. Typhimurium (un isolato umano, tre 
animali e due ceppi di laboratorio ) e 4 ceppi S. Enteritidis ( un isolato umano e tre 
animali). L’utilizzo di metodi analitici, come NMR, HPAEC-PAD, GLC-MS e HPLC–
SEC, ha permesso la caratterizzazione strutturale delle unità ripetitive della catena 
polisaccaridica dei diversi OAg. Gli OAg di Typhimurium testati sono risultati simili in 
termini di distribuzione di pesi molecolari, ma diversi per quanto riguarda posizione e 
grado di glucosilazione e O-acetilazione. In particolare, l’OAg D2380, estratto da un 
isolato clinico del Malawi, ha presentato non solo gruppi O-acetile sul C-2 
dell’Abequosio, ma anche sul C-2 e C-3 del Ramnosio. Il glucosio, a seconda del 
ceppo di origine, è risultato legato 1 → 4 o 1 → 6 al galattosio in percentuali diverse. 
Gli OAg estratti sono strutturalmente più omogenei e tutti caratterizzati da bassi livelli 
di glucosilazione e O-acetilazione. Tutti gli OAg sono stati utilizzati per la sintesi dei 
rispettivi vaccini glicoconiugati, usando CRM197 come proteina carrier. L’OAg è stato 
legato alla proteina attraverso lo zucchero terminale KDO, senza alterare la struttura 
saccaridica della catena polisaccaridica e consentendo quindi la generazione di un 
gruppo di coniugati strutturalmente definiti, che differiscono unicamente per le 
caratteristiche strutturali delle unità ripetitive dell’OAg. Tutti i glicoconiugati testati 
sono stati immunogenici nei topi, e in grado di produrre anticorpi con attività 
battericida. L’eterogeneità strutturale dell’OAg si è mostrata essere un parametro in 
grado di influenzare l’immunogenicità dei vaccini glicoconiugati. In particolare, la 
produzione di anticorpi anti-OAg ceppo-specifici per il D23580 S. Typhimurium è 
verosimilmente legata alla presenza di gruppi O-acetile sul Ramnosio, caratteristica 
strutturale non presente negli altri ceppi S. Typhimurium testati. Le differenze nei 
livelli e nelle posizioni di glucosilazione e O-acetilazione sembrano avere un impatto 
sull’attività battericida degli anticorpi prodotti. Questo lavoro pone l’accento 
sull’importanza del processo di selezione del ceppo fonte di OAg per la produzione di 
vaccini glicoconiugati. L’analisi di un maggior numero di ceppi sarà necessaria per 
evidenziare in maniera più chiara la relazione tra le caratteristiche strutturali dell’OAg 
e la risposta immunologica dei corrispondenti vaccini glicoconiugati contro NTS. 
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Impatto della chimica di coniugazione sull’immunogenicità di vaccini 
glicoconiugati contro S. Typhimurium 
La chimica di coniugazione usata nella sintesi del vaccino glicoconiugato può 
influenzare la risposta immunologica. In questo studio, diversi glicoconiugati sono 
stati sintetizzati e testati nei topi, utilizzando CRM197 come proteina carrier e il ceppo 
2192 come fonte di OAg. Due diverse strategie sono state considerate: la 
derivatizzazione su molteplici e casuali posizioni lungo la catena dell’OAg, approccio 
“random”, seguita da coniugazione; o l'attivazione selettiva dello zucchero terminale 
KDO con molecole spaziatori previa coniugazione con la proteina. In particolare, per 
l’approccio selettivo sono stati considerati due spaziatori di lunghezza diversa, NH2-
SIDEA e ADH-SIDEA, mentre per l’approccio casuale sono state considerate due 
chimiche di ossidazione, TEMPO e NaIO4, che differiscono notevolmente per il tipo di 
modifica strutturale e conformazionale che causano allo zucchero. 
Tutti i coniugati testati hanno prodotto un alto e simile titolo di anticorpi anti OAg-IgG. 
Tuttavia, una correlazione inversa è stata verificata tra il grado di modifica della 
catena dell’OAg e la capacità degli anticorpi indotti di proteggere contro l’infezione, 
indicando che eccessive modifiche strutturali sugli epitopi possono poi inficiare la 
risposta degli anticorpi in vivo. I coniugati prodotti tramite chimica casuale hanno 
indotto anticorpi a maggiore attività battericida di quelli selettivi. In accordo con lo 
studio SBA, le analisi FACS hanno mostrato come i tipo di derivatizzazione casuale 
investigati non hanno influenzato negativamente sulla capacità dei corrispondenti 
coniugati di indurre anticorpi capaci di riconoscere epitopi strutturali. 
Oltre alle considerazioni immunologiche, nello sviluppo di un vaccino è anche 
importante valutare la resa del prodotto, il numero totale di reazioni coinvolte, e le 
problematiche legate alla purificazione e caratterizzazione dei materiali di partenza, 
degli intermedi e del vaccino finale. La chimica casuale offre vantaggi anche sotto 
quest’aspetto: numero minore di reazioni coinvolte e maggiore resa di coniugazione, 
anche se la complessa e casuale struttura del glicoconiugato risultante ne rende più 
difficile la caratterizzazione chimico-biologica. 
Click chemistry: una metodologia efficace per la sintesi di vaccini 
glicoconiugati  
Lo sviluppo di metodi che permettono la coniugazione di precisi punti nel saccaride a 
determinati aminoacidi nelle proteine, oltre a fornire a fornire vantaggi dal punto di 
vista di riproducibilità del processo e facilità di caratterizzazione del prodotto finale, 
può essere anche un elemento chiave nel chiarire le relazioni struttura-attività 
immunologica dei glicoconiugati. Tuttavia, la sintesi di vaccini gliconiugati 
strutturalmente definiti è una sfida difficile che richiede una efficace chimica di 
coniugazione.   
Due strategie sono state inizialmente indagate per la coniugazione dell’OAg 2192 di 
S. Typhimurium al CRM197: la chimica dei tioli e la click chemistry. In entrambi i casi, 
l'unità terminale KDO dello zucchero è stata selettivamente attivata con uno 
spaziatore e fatta reagire con la proteina in precedenza attivata coinvolgendo diversi 
amminoacidi e inserendo un numero variabile di spaziatori. La chimica dei tioli è 
stata investigata inserendo un gruppo SH sull’unità KDO dell’OAg e facendolo 
reagire con CRM197 in precedenza attivato con gruppi reattivi, quali maleimmide o 
bromoacetile. Questo tipo di chimica ha permesso la coniugazione solo in presenza 
di almeno 8 linkers sulla proteina. La metodologia click chemistry per la coniugazione 
è stata esplorata inserendo una funzionalità alchino sull’unità KDO dell’OAg e 
facendolo reagire con il CRM197 in precedenza attivato con gruppi azide. 
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Contrariamente a quanto visto per la chimica dei tioli, utilizzando la click chemistry è 
stato possibile sintetizzare coniugati ad alta resa anche quando poche posizioni sulla 
proteina sono attivate (mediamente 4, >80% proteina coniugata) o addirittura quando 
una sola posizione è risultata coinvolta nel legame (38% proteina coniugata). Un 
altro vantaggio di questo tipo di chimica è la possibilità di riciclare l’OAg non 
coniugato dalla miscela di reazione e utilizzarlo per la sintesi di un nuovo lotto di 
glicoconiugato. Sulla base di questo importante risultato, è stato sviluppato un 
metodo di coniugazione in fase solida in cui l’OAg coniuga con  la proteina carrier 
immmobilizzata per interazione ionica in una matrice solida. Lo zucchero non reagito 
può essere facilmente rimosso dalla resina tramite lavaggi, permettendo così la 
successiva eluizione di coniugato “puro”, che non necessità di altre purificazioni. 
Questo processo può avere un grande impatto sulla riduzione dei costi associati allo 
sviluppo di un vaccino glicoconiugato, tramite il recupero dello zucchero non 
coniugato e il suo riutilizzo per coniugazioni successive e la semplificazione 
dell’intero processo di purificazione.  
Conclusioni 
Lo sviluppo di un vaccino glicoconiugato contro NTS basato sull’OAg deve prevedere 
un’attenta analisi delle variabili che possono influenzare l’immunogenicità e il 
processo di produzione. In primo luogo, la selezione del ceppo da cui estrarre l’OAg 
è importante, dal momento che differenze strutturali nella catena polisaccaridica 
influiscono sull’immunogenicità. Un ampio pannello di metodi analitici ha permesso la 
caratterizzazione completa di OAg estratti da ceppi diversi e potrà essere impiegato 
per la valutazione di altri ceppi.  
La chimica di coniugazione è un altro parametro da considerare. Sulla base delle 
chimiche testate in questo studio, l’approccio “random”, che prevede l’attivazione di 
molteplici e casuali posizioni sullo zucchero, sembra essere preferibile rispetto a una 
chimica che coniuga selettivamente una posizione dell’OAg alla proteina, sia da un 
punto di vista immunologico che considerando le rese globali di processo. D’altra 
parte, un approccio selettivo può avere dei vantaggi da un punto di vista di 
riproducibilità del processo e facilità di caratterizzazione del prodotto ottenuto. Inoltre,  
lo sviluppo di metodi che permettono la coniugazione di precisi punti del saccaride a 
determinati aminoacidi della proteina può essere un elemento chiave nel chiarire le 
relazioni struttura-attività immunologica dei glicoconiugati. Recenti lavori hanno 
dimostrato come il sito di coniugazione e il numero di connessioni tra il saccaride e la 
proteina possono essere parametri cruciali nel determinare l'immunogenicità dei 
vaccini glicoconiugati. La click chemistry è un metodo di coniugazione altamente 
efficace nel consentire il legame selettivo tra punti specifici della proteina e lo 
zucchero. La metodologia di coniugazione sviluppata consente anche il riciclo dello 
zucchero non coniugato ed è stata applicata con successo alla sintesi di coniugati in 
fase solida. Utilizzando la coniugazione click, abbiamo intenzione di coniugare l’OAg 
di S. Typhimurium a diversi amminoacidi del CRM197, per introdurre un numero 
controllato e diverso di unita saccaridiche per proteina. L'immunogenicità dei 
corrispondenti glicoconiugati sarà testata nei topi. Questi coniugati rappresenteranno 
il primo esempio di vaccini glicoconiugati a struttura altamente definita contro NTS. 
Oltre alla rilevanza per lo sviluppo di vaccini contro NTS, questo studio potrebbe 
aggiungere informazioni utili sui fattori che influenzano la presentazione 
dell'antigene, l'elaborazione e la cooperazione tra le cellule B e T, aggiungendo 
quindi importanti informazioni per la progettazione razionale dei vaccini coniugati di 
nuova generazione. 
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2. Introduction 
 
2.1 The global burden of infectious diseases 
Infectious diseases are caused by pathogenic microorganisms: bacteria, viruses, 
parasites or fungi. In humans and animals these pathogens enter the host at different 
sites and produce disease symptoms by a variety of mechanisms. The diseases can 
be spread, directly or indirectly, from one individual to another.  
The Global Burden of Diseases (GBD) concept, first published in 1996, constitutes a 
comprehensive and consistent set of estimates of mortality and morbidity (1), and 
GBD estimates are revised at intervals by the World Health Organization (WHO) at 
regional and global level for a set of more than 135 causes of disease and injury (2), 
with the aim to quantify the burden of premature mortality and disability for major 
diseases or disease groups. The DALY (Disability-Adjusted Life Year) is used as a 
summary measure of population health, to combine estimates of the years of life lost 
and years lived with disabilities.  
Infectious diseases (including parasitic infections) are the leading cause of DALY and 
the second leading cause of death worldwide (2). According to the published data in 
2012, they were responsible for the death of more than 8.7 million people worldwide 
in 2008 (3). Morbidity and mortality caused by infectious diseases disproportionately 
affect the poorest populations of the world, and contributed to their misery (2) (4). 
Data published in 2008 reported that 98.9 % of DALYs and 96.9 % of deaths due to 
infectious diseases occur in the middle and low income countries (5) (Figure 2.1). In 
addition, infectious diseases disproportionately affect the youngest populations and 
54% of DALYS and 43% of deaths from infectious disease are in < 5 year old 
children. This is 10.8 fold as many DALYs per 1000 population and 16.4 fold as many 
deaths per 1000 population compared to > 5 year old subjects (6). Interestingly, this 
excess of morbidity and mortality in poor and young populations is not seen for non-
infectious diseases (6). According to 2010 estimates by WHO, approximately 7.6 
million children die each year before reaching the age of five (7). 
While, in the long term, access to clean water, better hygiene, adequate nutrition, 
and improvement of sanitary measures would have the greatest impact on infectious 
diseases, immunization against specific diseases is the best strategy for the short- 
and mid-term (8).  
 
 
Figure 2.1 DALYs (Disability-adjusted life years) for infectious diseases by country (per 
100,000 inhabitants). (Figure reproduced from (2)).   
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2.2 Vaccines 
2.2.1 Mechanism of function 
Disease control or elimination requires the induction of protective immunity in a 
sufficient proportion of the population. This is best achieved by immunization 
programs capable of inducing long-term protection, a hallmark of adaptive immunity 
that contrasts to the brisk but short-lasting innate immune responses.  
Long-term immunity is conferred by the maintenance of antigen-specific immune 
effectors and/or by the induction of immune memory cells that may be sufficiently 
efficient and rapidly reactivated in case of subsequent encounters with the same 
pathogen (9). 
Vaccination is the deliberate induction of adaptive immunity to a pathogen by 
injecting a killed or attenuated (nonpathogenic) live form of the pathogen or its 
antigens (subunit vaccine) (10). Vaccines are prophylactic in the sense that they are 
administered to healthy individuals to prevent a disease. Nevertheless, there is a 
growing trend to use vaccines to alleviate the suffering of those already with disease. 
Prophylactic vaccines represent the possibility to prevent global epidemics of 
infectious diseases. 
Vaccine-induced immune effectors are essentially antibodies, produced by B 
lymphocytes, and capable of binding specifically to a toxin or a pathogen (11). They 
prevent or reduce infections by extra- and intracellular agents and clear extracellular 
pathogens. Other potential effectors are cytotoxic CD8+T cells, which reduce, control 
and clear intracellular pathogen by recognizing and killing infected cells or secreting 
specific antiviral cytokines; and CD4+T cells which participate to the reduction, control 
and clearance of extra- and intracellular agents by producing IFN-γ, TNF-α/-β, IL-2 
and IL-3 and supporting activation and differentiation of B cells, CD8+T cells and 
macrophages (Th1cells) or by producing IL-4, IL-5, IL-13, IL-6 and IL-10 and 
supporting B cell activation and differentiation (Th2 cells). These effectors are partly 
controlled by regulatory T cells (Treg) that are involved in maintaining immune 
tolerance(12). The nature of the vaccine has a direct influence on the type of immune 
effectors that are predominantly elicited and mediate protective immunity (9). 
B lymphocytes are cells that originate in the bone marrow, mature in secondary 
lymphoid tissues, become activated in the spleen/nodes when their surface 
immunoglobulins bind to an antigen and differentiate either into antibody secreting 
cells (plasma cells) or in memory B cells. T lymphocytes are cells that originate in the 
bone marrow, migrate to the thymus, mature in the periphery, become activated in 
the spleen/nodes if 1) their T cell receptor bind to an antigen presented by an MHC 
molecule and 2) they receive additional costimulation signals driving them to acquire 
killing (mainly CD8+ T cells) or supporting (mainly CD4+ T cells) functions. The 
induction of antigen-specific B and T cell responses requires their activation by 
specific antigen presenting cells (APC), essentially dendritic cells (DC) that are 
recruited into the immune reaction. Immature DCs patrol throughout the body. When 
exposed to pathogens, they undergo a brisk maturation, modulate specific surface 
receptors and migrate towards secondary lymph nodes, where the induction of T and 
B cell responses occurs. The central role for mature DCs in the induction of vaccine 
responses reflects their unique capacity to provide both antigen-specific and 
costimulation signals required to activate naïve T cells (13). The very first 
requirement to elicit vaccine responses is therefore to provide sufficient danger 
signals through vaccine antigens and/or adjuvants, to trigger an inflammatory 
reaction that is mediated by cells of the innate immune system (14) (Figure 2.2). 
8 
 
 
 
 
Figure 2.2 Initiation of a vaccine response: following injections (11), the pathogen-associated 
molecular patterns (PAMPS) contained in a vaccine attracts dendritic cells, monocytes and 
neutrophils that patrol throughout the body (12). If vaccine antigens/adjuvants elicit sufficient 
“danger signals”, this activates monocytes and dendritic cells (15) which changes their 
surface receptors and induces their migration along lymphatic vessels (16) to the draining 
lymph nodes (17) where the activation of T and B lymphocytes will take place (Figure 
reproduced from (9)).  . 
 
2.2.2 A brief history of vaccination 
Origin of vaccination is usually attributed to Edward Jenner, who observed, in the late 
18th century, that the relatively mild disease of cowpox, or vaccinia, seemed to confer 
protection, by the inoculation with pus from infected lesions, against the often fatal 
disease of smallpox. He called the procedure vaccination from vacca, Latin for cow, 
and Pasteur, in his honor, extended the term to the stimulation of protection against 
other infectious agents. This term is still used to describe the inoculation of healthy 
individuals with weakened or attenuated strains of disease-causing agents to provide 
protection from disease. Louis Pasteur in 1885 developed the first rabies human 
vaccine based on attenuated viruses. He brought a breakthrough in the prevention of 
infectious diseases by establishing the basis of vaccinology, meaning the principle of 
isolation, inactivation, and administration of disease causing pathogens (18). 
Vaccine development in the early part of the 20th century followed two empirical 
approaches. The first was the search for attenuated organisms with reduced 
pathogenicity, which would stimulate protective immunity but not cause disease (e.g., 
Bacillus Calmette Guerin BCG, pertussis, and smallpox). In the second half of 20th 
century improvements and innovation in mammalian cell culture technology led to the 
growth of viruses and development of live attenuated “second generation” vaccines 
such as polio (Sabin oral), measles, rubella, mumps, and varicella. More recently, the 
use of inactivated polio vaccine (Salk type) together with the oral vaccine has almost 
eradicated polio from the world thanks to global vaccination (19). This approach 
continues into the present with the design of genetically-attenuated pathogens in 
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which desirable mutations are introduced into the organism by recombinant DNA 
technologies. This idea is being applied to important pathogens, such as malaria, for 
which vaccines are currently unavailable, and may be important in the future for 
designing vaccines against influenza and HIV/AIDS. 
The second approach was the development of vaccines based on killed organisms 
(diphtheria, tuberculosis and plague) and, subsequently, on purified components of 
organisms that would be as effective as live whole organisms (i.e. subunit vaccines, 
such as Hepatitis B or Influenza). Killed vaccines were desirable because any live 
vaccine, including vaccinia, can cause lethal systemic infection in 
immunosuppressed people. The last decades have seen the development of 
polysaccharide and glycoconjugate vaccines and the emergence of a new approach, 
reverse vaccinology, which has been used to identify candidate protein antigens. 
Ligands that activate Toll-like receptors (TLR) or other innate sensors have been 
used as adjuvants to enhance responses to simple antigens. 
 
2.3 Infectious diseases in need for a vaccine 
There are still many diseases for which an effective vaccine is lacking (Table 2.1). 
For many pathogens, natural infection does not necessarily generate protective 
immunity, and infections can become chronic or recurrent. In many infections of this 
type, antibodies are insufficient to prevent reinfection and to eliminate the pathogen, 
and cell-mediated immunity may be more important in controlling the pathogen, but is 
insufficient to provide full immunity, for example against malaria, tuberculosis, and 
HIV. It is not the absence of an immune response to the pathogen that is the problem, 
but rather that this response does not clear the pathogen, eliminate pathogenesis, or 
prevent reinfection. 
Even when a vaccine can be used effectively in developed countries, technical and 
economic problems can prevent its widespread use in developing countries, where 
mortality from infectious diseases is still high. Therefore the development of vaccines 
remains an important goal of immunology, and the latter half of the 20th century saw 
a shift to a more rational approach based on a detailed molecular understanding of 
microbial pathogenicity, analysis of the protective host response to pathogenic 
organisms, and an understanding of the regulation of the immune system to generate 
effective T- and B-lymphocyte responses (20). 
 
 
Table 2.1 Diseases for which effective vaccines are still needed (2) (Table 
adapted  from (20))  
Disease Estimated annual mortality 
Respiratory infections  4 milion 
Diarrheal disease  2.2 milion 
HIV/AIDS  2 milion 
Tuberculosis 1.5 milion 
Malaria 889,000 
Schistosomiasis 41,000 
Intestinal worm infestation 6,000 
 
A successful vaccine must be safe and able to produce protective immunity in a very 
high proportion of the people to whom it is given; particularly in poorer countries 
where it is impracticable to give regular 'booster' vaccinations to dispersed rural 
populations. In addition a vaccine must generate long-lived immunological memory. 
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Fourth, vaccines must be very cheap if they are to be administered to large 
populations. Vaccines are one of the most cost-effective measures in health care, but 
this benefit is eroded as the cost per dose rises. Another benefit of an effective 
vaccination program is the 'herd immunity' that it confers: by lowering the number of 
susceptible members of a population, vaccination decreases the natural reservoir of 
infected individuals in that population and so reduces the probability of transmission 
of infection. Thus, even unvaccinated members will be protected because their 
individual chance of encountering the pathogen is decreased. However, the herd 
immunity effect is only seen at relatively high levels of vaccination within a population; 
for mumps it is estimated to be around 80%, and below this level sporadic epidemics 
can occur (20).  
In the last century vaccines have been of unquestionable value, saving more than 
700 million cases of disease and more than 150 million deaths (18). Vaccination 
prevents an estimated 2.5 million deaths each year (21).  
 
2.4 Diarrheal diseases 
Enteric infections rank third among all causes of disease burden worldwide, being 
responsible for about 2.2 milions of deaths per year, mostly in young children and 
infants in developing countries (8). Diarrhea is also the second leading cause of 
death among children under 5 years of age, excluding perinatal conditions (22).  
Over the past two decades, treatment and prevention measures including fluid 
replacement, zinc treatment or promotion of hand washing have been responsible for 
the decline of mortality from diarrhea from an estimated 5 million to about 1.5 million 
deaths  among young children in 2004 (23). However, although the number of deaths 
is decreasing, the high incidence is still a major issue. Furthermore, long-term 
consequences on physical and mental development of children have been reported 
as a result of childhood diarrhea (24) (25) (26). Main infectious agents responsible for 
human enteric infections include several viruses (enteric adenoviruses, astroviruses, 
human caliciviruses (HuCV), rotaviruses (RV)) and several bacterial agents, such as 
Campylobacter jejuni, a variety of pathogenic Escherichia coli strains including 
enterotoxigenic Escherichia coli (ETEC), several Shigella species, various 
Salmonella strains including S. Typhi, S. Paratyphi, non typhoidal Salmonellae and 
Vibrio cholera. 
Diarrheal diseases represent a major health problem also for travellers who visit 
these countries, especially in the tropics (27). Up to 80 % of diarrheal episodes in 
travellers are bacterial in nature, caused principally by ETEC strains, followed by 
Shigella, Campylobacter and Salmonella spp. (28).  
The increased frequency of antibacterial drug-resistance among these pathogens is 
a source of major concern (29) (30). The development of vaccines against enteric 
diseases seems a good strategy to reduce diarrheal diseases. However, covering the 
large number of pathogens and serotypes constitutes a serious challenge. 
 
2.5 Salmonella disease 
Salmonella belongs to the group of Enterobacteriaceae that are aerobic, gram 
negative rods and approximately 1–3 μm × 0.5 μm in size (31) (32). Salmonella was 
first identified in 1880 by Eberth from the mesenteric nodes and spleen of a patient 
dying from typhoid fever (33). In 1884 Gaffky was able to isolate the bacillus and a 
year later Salmon (the name Salmonella was coined in 1900 as a tribute to him) and 
Smith described a bacillus, now known to be Salmonella Choleraesuis, the first 
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affecting both humans and animals (34). Currently there are roughly 2400 species of 
Salmonella. Salmonellae are divided into two subspecies: S. enterica and S. bongori. 
S. bongori contains 8 serovars and S. enterica contains the other serovars (35). 
Antisera against Vi (which forms a polysaccharide (PS) capsule around S. Typhi and 
also S. Paratyphi C and S. Dublin), O-antigen (OAg) of lipopolysaccharide (LPS) (O 
somatic antigen) and flagella (H antigens) have long been used for the typing of 
Salmonella serovars according to the Kauffmann-White scheme. 
Salmonellae are capable of causing disease in a wide range of species and are 
essentially intestinal parasites of humans and animals including domestic pets, farm 
animals, birds, reptiles and rodents. They are found in the environment and have 
been isolated from rivers, sewage and soil where, under the correct conditions, they 
can survive for many years. They have been detected in animal feeds as well as food 
such as fruit and vegetables. The vast majority of salmonellosis cases are a result of 
consumption of contaminated food (including milk) or water, or by direct faecal-oral 
spread. 
In humans, serovars of Salmonella enterica are a cause of diarrhea illness in 
developed countries, while they are responsible for invasive disease in the 
developing world. S. enterica serovar Typhi (S. Typhi) and S. enterica serovar 
Paratyphi A (S. Paratyphi A) are causes of enteric fever, with high prevalence in 
South and Southeast Asia, while non-typhoidal Salmonella serotypes (frequently 
referred to as NTS serotypes) (36) are major cause of invasive disease in Africa. 
S. Typhi is the commonest pathogen isolated from blood cultures in South Asia (37), 
though in some areas enteric fever caused by S. Paratyphi A is more common (38). 
The annual global burden of disease due to typhoid fever was estimated at 21.7 
million cases in 2000 with a case-fatality rate of 1% resulting in 217,000 deaths (39). 
The highest burden was reported in pre-school and school-aged children (40) (41) 
(42). The global burden of disease attributable to S. Paratyphi A in 2000 was 5.4 
million cases (39).   
Currently two main vaccines are licensed targeting S. Typhi only: the live attenuated 
vaccine, Ty21a, and the Vi capsular PS vaccine, but neither is licensed for use in 
children under the age of two years.  
The Ty21a vaccine was derived from S. Typhi through nonspecific chemical 
mutagenesis of the wild-type strain Ty2 (43). It is distributed as enteric-coated 
capsules and is not licensed in children below 5 years of age. Protective efficacy has 
been demonstrated for adults and children above 5 years with a cumulative three-
dose efficacy of 51% (44). Ty21a is not immunogenic in infants and there are 
reduced levels of seroconversion in young children compared with adults. However 
there is evidence that it can induce herd protection and, as a live attenuated vaccine, 
Ty21a has good potential to induce T cell immunity and cross-protection against non-
Typhi serovars (45) (46) (47). 
Several manufacturers produce unconjugated Vi PS vaccine. Despite its different 
mechanism of action (48), Vi PS has shown a similar three year efficacy of 55% 
against typhoid fever to that of Ty21a (44), but after only one vaccination dose. 
However, being a T-independent type 2 antigen, the Vi PS is not immunogenic in 
infants and consequently is only licensed for children over two years of age (49) (50). 
Its effectiveness in children between two and five years is uncertain, since two cluster 
randomized-controlled trails in this age group gave different results, with protective 
efficacy only demonstrated in one study (51) (52). As with other PS vaccines, Vi is 
not able to induce immunological memory. Both Vi PS and Ty21a suffer from 
drawbacks that have limited their implementation in developing country vaccination 
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programs. They are not immunogenic in infants (53) and cannot be added into 
existing EPI programs. Both have issues with thermal stability; Ty21a needs multiple 
doses and a particular concern with Vi is the phenomenon of hyporesponsiveness 
after re-vaccination (54). For all these limitations, there is interest to develop new 
generation vaccines, that are immunogenic and safe in infants and more protective in 
older children and adults. No vaccines is currently available against S. Paratyphi A 
(55). 
New vaccines against typhoidal diseases are currently under development such as 
glycoconjugates, new generation live attenuated and protein based vaccines (56) (57) 
(58). Some groups are aiming at a bivalent vaccine to prevent enteric fever (59), by 
separately conjugating Vi and S. Paratyphi A OAg to CRM197 or diphtheria toxoid (DT) 
as carrier proteins.  
 
2.6 Nontyphoidal Salmonella: a disease in need for a vaccine 
Nontyphoidal Salmonellae (NTS) predominantly cause self-limiting diarrheal illness in 
developed countries, where bloodstream infection is rare (60) and mainly occurs in 
individuals with specific risk factors (61). By contrast, in many parts of Africa, NTS 
are a leading cause of bacteremia (Figure 2.3)  (62) (63) (64) (65) (66). Incidence of 
disease caused by different serovars varies depending upon the country, but S. 
Enteritidis and S. Typhimurium are responsible for the majority of infections, (36) (67), 
although investigators at some sites report contributions from other serotypes, such 
as S. Isangi (68), S. Concord (69) and S. Dublin (70). Invasive NTS (iNTS) disease 
was recently estimated at 2.58 million cases per year with a 20-25% case-fatality rate 
leading to 517,000 deaths (36). Young children with malaria, anemia and malnutrition 
(71) (72) (73) (74) (75) and HIV infected individuals (65) (76) are particularly affected. 
A recent study from Mozambique found an incidence of 388/100,000 in children less 
than one year and 262/100,000 in those aged one to five years (62). There is no 
distinctive clinical syndrome association with this disease, (36) (77), making 
diagnosis and treatment a challenge for health-care workers in low-resource settings. 
Blood culture and microbiological diagnosis of Salmonella requires technical 
expertise and investment in infrastructure, consumables, and quality control, all of 
which must be strengthened (78). An urgent need exists for the development of rapid, 
accurate point-of-care diagnostics biology. Targets for a non-typhoidal Salmonella 
rapid multi-plexed PCR diagnostic have been identified (70), but low numbers of the 
bacilli in blood make this process a technical challenge (79). Other approaches for 
rapid screening are promising but need validation and translation to real-world 
application (80) (36). 
Salmonellae were once susceptible to a broad range of affordable and effective 
antimicrobial drugs, but multidrug-resistant strains (63) (81) have emerged in Africa. 
In a recent study around 90% of invasive NTS isolates in Malawi have been found to 
be multidrug resistant (63), emphasizing the need for development of alternative 
interventions. 
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Figure 2.3 Map of Africa showing results of a meta-analysis of studies investigating the 
cause of bloodstream infection (BSI) in febrile adults and children in Africa (Figure 
reproduced from (64)). 
 
2.6.1 Vaccines in development against nontyphoidal Salmonella 
While new vaccines against typhoid fever are in advanced stages of development 
and some glycoconjugate vaccines have been recently licensed in specific countries 
(56) (57), the development of vaccines against NTS is a long way behind, despite the 
comparable burden of disease they cause. This is likely to be attributable to a 
general lack of appreciation and awareness of the problem of NTS in the global 
health community (MacLennan and Levine, 2013a). Vaccine development against 
NTS is also complicated by the immunocompromised nature of susceptible patients 
(82) (83), which should be addressed early in clinical development. 
However, the enhanced activity in the field of vaccine development against 
Salmonella in the recent years has also increased the attention on NTS and different 
vaccines are currently in development (Table 2.2). 
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Table 2.2. Vaccines in development against NTS 
Name Description Advantage/Disadvantages 
O:4,5/O:9-flagellin (84) 
(85) 
Glycoconjugate 
+   High potential efficacy 
+   T-dependent antibody response 
+   Potential for inducing memory 
+   Potential for affinity maturation 
+   Low reactogenicity 
 
-   Protection only against serovars   
    with same OAg specificity 
O:4,5/O:9-CRM197 (86) 
WT05 (87) 
Live attenuated 
+   Potential to induce Salmonella-  
     specific B and T cell immunity 
+   Potential to clear residual infection 
 
-   Attenuating for optimal balance of  
    immunity and reactogenicity 
-   Breadth of coverage may be limited  
    by insufficient expression of key   
    antigens 
-   Possibility of disease in   
    immunocompromised subjects 
CVD 1921 and CVD 
1941 (88) 
S. Typhimuirum ruvB 
mutant (89) 
Salmonella hfq deletion 
mutant (90) 
SA186 (91) 
MT13 (92) 
OmpD (93) 
Outer membrane 
protein 
+   Potential to induce Salmonella- 
     specific B and T cell immunity 
+   Potential for pan-specific immunity 
+   Low reactogenicity 
 
-   Difficulties with purification of  
    integral proteins 
 
NTS GMMA (50) (94) GMMA 
+ Potential to induce Salmonella-specific B 
and T cell immunity 
+ Potential for pan-specific immunity 
+ Enrichment of membrane antigens 
+ Easy manufacture 
 
- Level of reactogenicity uncertain 
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2.6.2 O-antigen based vaccines against NTS 
Previous work has highlighted the potential importance of antibody in African children 
for complement-dependent cell-free killing of NTS, and opsonization of NTS for 
uptake by blood phagocytes and killing by oxidative burst (71) (95), making an 
antibody-inducing vaccine an attractive goal for prevention of NTS disease in Africa. 
While other Salmonella species express a capsular PS (for example S. Typhi Vi 
capsule), NTS (with rare exceptions) do not express PS capsules. Their surface PS 
are the OAg of LPS.  
Salmonella LPS is both a virulence factor and a target for protective antibodies. LPS 
consists of lipid A linked to the 3-deoxy-D-manno-octulosonic acid (KDO) terminus of 
a conserved core saccharide region (96), which is linked to a variable PS chain of 
repeating units, the OAg chain (Figure 2.4). Lipid A is highly conserved and exerts 
endotoxic activity, while the OAg chain differs between species and is responsible for 
the serological specificity of bacteria. This serovar-specific OAg chain is the 
immunodominant portion of the molecule.  
OAg are usually obtained by detoxification of the LPS by acetic acid hydrolysis or by 
hydrazinolysis (97). The first procedure is preferred as it allows the retaining of the 
OAg O-acetylation level, which can be important for immunogenicity (97). 
The majority of invasive Salmonella isolates from humans fall into Salmonella groups 
A, B, C or D. OAg of Salmonella groups A, B and D are similar in overall structure 
and share a common backbone, but differ in their branching carbohydrate moieties, 
α-(3,6)-dideoxyhexose-(1,3) linked to D-mannose (Man). With regard to the two most 
common NTS serovars, the dideoxyhexoses are abequose (Abe), conferring O:4 
specificity to S. Typhimuirum and tyvelose (Tyv), conferring O:9 specificity to S. 
Enteritidis (Figure 2.5) (98). The OAg chain can be partially O-acetylated. O-
acetylation at the C-2 position of Abe adds specificity 5 to O:4 (Figure 2.5). 
Antibodies directed toward the OAg mediate killing of NTS (77) (99) and confer 
protection against NTS infections. 
Little is known regarding the immunogenicity of purified Salmonella OAg in humans 
administered parenterally as a PS vaccine, however evidences from studies in mice 
suggest that Salmonella OAg as an isolated PS is a poor immunogen (100) (84) (98). 
In contrast, conjugation of Salmonella OAg to protein carriers results in vaccines that 
have been effective in generating anti-OAg antibodies in animal models (100) (101) 
(102) (84) (98). NTS OAg conjugate vaccines have also demonstrated protection 
against mortality in the mouse model of lethal Salmonella infection. In one study, 
conjugation of S. Typhimurium OAg to the homologous strain porin proteins elicited 
anti-OAg IgG, protective against challenge with virulent S. Typhimurium (102). This 
conjugate in mice, as well as a conjugate with bovine serum albumin (BSA) in 
rabbits, induced functional opsonophagocytic antibodies that could transfer protection 
by passive immunization (101) (102) (103). Similar results were seen following 
immunization of mice with a conjugate of S. Typhimurium OAg with tetanus toxoid 
(TT) (98). A conjugate vaccine consisting of S. Enteritidis OAg linked to the 
homologous serovar flagellin elicited LPS-specific IgG and protected mice against 
lethal challenge with virulent S. Enteritidis (84). 
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Figure 2.4 Model of Salmonella LPS, composed by the polysaccharidic OAg chain and the 
oligosaccharidic core region, linked to the lipid A by the reducing sugar KDO.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. A) Structure of the S. Typhimurium OAg chain linked to the core region (96) after 
acetic acid hydrolysis. Hydrolysis removes lipid A leaving the OAg chain attached to the core. 
The core region is common to all Salmonella strains. B) Structure of the repeating units of 
the OAg from S. Enteritidis.  
 
 
 
 
 
 
A) 
B) 
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2.6.3 Other vaccines under development against NTS 
 Live-attenuated vaccines 
Live-attenuated vaccines have the ability to elicit Salmonella-specific T cell 
responses required for clearance of residual infection, can be given orally and have 
good capacity to induce mucosal immunity through lymphocyte expression of 
mucosal homing receptors (104). The delivery of multiple Salmonella antigens to the 
immune system increases the possibility of inducing broad protection against 
different Salmonella serovars. The increased ability to introduce targeted mutations 
and genetic modifications combined with the full availability of the bacterial genomes 
from whole genome sequencing has improved the capacity to rationally design new 
live-attenuated vaccines. The major challenge in the development of live-attenuated 
vaccines is obtaining an optimal level of attenuation without compromising 
immunogenicity as immunogenicity often decreases together with reactogenicity 
when Salmonellae are attenuated (105).  
Preclinical studies have been performed with live iNTS vaccines consisting of S. 
Typhimurium and S. Enteritidis with deleted guaBA and clpP genes. These vaccines 
were able to protect against lethal challenge with the homologous serovars in mice 
(88). A S. Typhimurium strain with aroC and ssaV attenuations is the only live-
attenuated iNTS vaccine that has been tested in man to date. This Phase 1 study 
showed prolonged stool shedding in volunteers for up to 23 days (87). 
 Protein-based subunit vaccines 
Surface proteins constitute an other target of protective immunity. 
These potentially have the advantage of cross-protection if carefully selected through 
bioinformatic analysis of whole genome sequences through a reverse vaccinology 
approach. As proteins, such vaccines can induce both antibody and T cell responses, 
though the former can be problematic for membrane proteins with multiple 
membrane-spanning domains.  
The proteins that have received most attention to date have been flagellin (85)  and 
OmpD porin (93). Preclinical studies have demonstrated promise for all of these 
antigens with immunization resulting in protection against Salmonella challenge (93, 
106-108). Nevertheless, the purification and production processes to make these 
vaccines are quite complicated. Furthermore it may be crucial to preserve the correct 
conformation of these antigens to generate protection in mice (109).  
 GMMA vaccines 
GMMA (Generalized Modules for Membrane Antigens) are vesicles released from  
the surface of Gram-negative bacteria, e.g. Salmonella, genetically modified in the 
genes encoding proteins that span the periplasm and maintain the integrity of the 
inner and outer membranes, such as the tolR gene of the Tol-Pal system, to enhance 
vesicles release (94). These particles are 10-300 nm proteoliposomes (110) (111) 
and reflect the composition of the bacterial outer membrane, containing LPS, 
glycerophospholipids, outer membrane proteins in their natural conformation, and 
enclosing periplasmic components (112) (110). Further deletions are incorporated to 
reduce reactogenicity, such as htrB and msbB (113), but unlike live-attenuated 
vaccines, there is no possibility of infection.  
Advantages of GMMA vaccines include simplicity and low cost of production, ability 
to induce strong immunogenicity and a potential self-adjuvanting effect due to the 
presence of innate signaling molecules such as TLR ligands. GMMA constitute a 
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promising platform for the delivery of both surface PS and outer membrane proteins 
to the immune system in their correct conformation and orientation. GMMA also have 
good potential to induce Salmonella-specific T cell immunity. 
 
2.7 Polysaccharide vaccines 
The outermost surfaces of most bacteria are coated with PS (114) (115). PS 
expressed in pathogenic bacteria (e.g., Haemophilus influenzae, Streptococcus 
pneumoniae and Neisseria meningitidis) play major roles in the virulence of these 
organisms. PS protect bacteria from the immune response and therefore act as 
virulence factors through numerous mechanisms such as inhibiting complement 
activation, increasing bacterial attachment to host tissues, preventing phagocytosis 
and helping bacteria escape immune surveillance by mimicking host-glycans (116). 
Around the 1930s the protective role of antibodies induced by pneumococcal PS 
started to be investigated and in 1945 the first vaccine composed of purified PS from 
selected pneumococcal serotypes was tested in man (117) (118). 
The research for vaccine development was subsequently slowed down by the 
introduction of antibiotics. However, with the emergence of drug-resistant strains, the 
development of PS vaccines started again and a number of them were tested in large 
clinical trials (119) (120). Polysaccharide vaccines against meningococcus serogroup 
ACWY, Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) were 
licensed between the seventies and eighties. Examples of pure PS vaccines used 
today include a multi-valent vaccine of PS obtained from 23 different Streptococcus 
pneumoniae serotypes; Vi PS from S. Typhi; and PS from serotypes A, C, W135 and 
Y of Neisseria meningitidis (121). 
Although these vaccines have variable degrees of success in adults, they are poorly 
protective in high-risk populations such as children below two years and 
immunocompromised patients (16). These characteristics are due to the fact that PS 
are T-cell independent (TI) antigens. Polysaccharide antigens directly activate PS-
specific B cells which differentiate into plasma cells to produce antibodies, but 
memory B cells are not formed. In addition, the antibody response to bacterial PS is 
weakly affected by adjuvants, IgM represents the major class of antibodies induced 
and, since their immune response does not induce memory, it is not boosted by 
subsequent immunizations. 
 
2.8 Glycoconjugate vaccines 
Glycoconjugate vaccines are composed of a weak antigen (hapten), containing only 
B-cell epitopes, but lacking T-cell epitopes, covalently linked to a protein as a source 
of T-cell epitopes (carrier) (122). 
The concept of glycoconjugate vaccine has its origin in 1929, when Avery and 
Goebel demonstrated that derivatives of non-immunogenic glucose and galactose, 
when conjugated to proteins, were able to induce specific antibodies in rabbits (123). 
The first protein-PS conjugate vaccines were developed against Haemophilus 
influenzae type b and licensed between 1987 and 1990. Subsequently, 
glycoconjugate vaccines have been developed against Neisseria meningitidis, 
Streptococcus pneumoniae and group B streptococcus (124) (125) (126). Covalent 
conjugation to an appropriate carrier protein (121) provides T cell-dependent 
immunogenicity against the saccharide hapten. With the involvement of T cells, 
immunological memory is invoked, and avidity maturation and isotype switching 
occur. Importantly, glycoconjugate vaccines are effective in young infants.   
  
19 
Today glycoconjugate vaccines are among the safest and most efficacious vaccines 
developed and are used in the immunization schedules of different countries (Table 
2.3). 
 
Table 2.3 Glycoconjugate vaccines licensed or in advanced development in the EU, US and 
WHO (Table adapted  from (127)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Many studies have been performed to understand the mechanisms of internalization 
and processing of the glycoconjugate molecules by the immune system (128) (49) 
(129) (130) (115). 
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According to the classical mechanism proposed, the polysaccharidic component of 
the vaccine binds to surface immunoglobulin of PS-specific B cells. Following 
internalization of the vaccine, the protein component is processed and resulting 
peptide fragments are presented to the T cell receptor of CD4+ peptide-specific T 
cells in the peptide-binding groove of major histocompatibility complex class II 
molecules (MHCII). In addition to this cognate interaction, further signals are 
essential in eliciting CD4+ T cell help for the B cell (131) (132) (Figure 2.5). When B 
cells receive T cell help, they proliferate and differentiate, with class switching 
particularly to IgG, into plasma cells and memory B cells. These can rapidly 
proliferate and differentiate into plasma cells on subsequent encounter of the specific 
antigen producing high antibody titers (133) (134) (135) (136) (137). Antibody avidity 
is increased through affinity maturation in germinal centers (138).  Not all PS are 
strictly T-independent antigens and zwitterionic PS, such as PS A from Bacteroides 
fragilis, containing both positive and negative charges, are able to stimulate T cell 
help (115) (139) (139) (140) (141). Recently it has been found that the carbohydrate 
fragments of the glycopeptides, produced by glycoconjugate vaccine processing, 
recognizes CD4+ T cells with the peptide portions useful for  binding to MHCII 
molecules (142) (128).  
 
 
 
 
Figure 2.5 Mechanism of action proposed for conjugate vaccines (122). 
 
The process of developing T cell mediated immunity by a glycoconjugate vaccine can 
be influenced by the formulation. The adjuvants can be used for various purposes: (i) 
to increase the immunogenicity of the antigens; (ii) to reduce the amount of antigens 
or the number of immunizations needed for protective immunity; (iii) to improve the 
efficacy of vaccines in newborns, the elderly, or immunocompromised individuals; 
and (iv) as delivery systems to facilitate the uptake of antigens by the mucosa (143). 
Some of the adjuvants commonly used in clinical and preclinical settings have been 
recently reviewed (127) and can be classified as mineral salts (144), carbohydrates 
(145), lipids (146), glycolipids (147), lipopeptides (148), TLR agonists (149), saponins 
and bacterial toxins (150). Many of these adjuvants have been successfully used 
alone or in combination with conjugates of carbohydrate antigens (151). 
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2.8.1. The chemistry of glycoconjugation  
Conjugate formation requires the covalent linkage of the PS to the carrier protein. 
Different conjugation strategies have been used to prepare conjugate vaccines and 
two main approaches have been developed: one based on random chemical 
activation along the PS chain, followed by conjugation and the other based on 
coupling of the protein through activation of the saccharide terminal group (122). The 
random approach often results in complex mixtures of cross-linked glycoproteins with 
variable saccharide loading and antigen positioning.  
The selective approach is often applied to oligosaccharides. Oligosaccharides can 
also be synthesized starting from suitable monosaccharides. This methodology is 
increasingly attractive as it provides homogeneous, well-defined and well-
characterized molecules with built-in chemical terminal functionalities suitable for 
conjugation to carrier proteins. (152) (153) (154) (155).  
Covalent linkage of PS to proteins is generally achieved by targeting the amines of 
lysines, the carboxylic groups of aspartic/glutamic acids or the sulfhydryls of 
cysteines on the protein. There are now novel methodologies that enable also the 
precise glycosylation of proteins and that may be used to improve the consistency 
and characterization of glycoprotein vaccine candidates. The possibility of designing 
and synthesizing chemically-defined glycoconjugate vaccines with different 
carbohydrate densities, conformations, and shapes, could potentially lead to the 
selection of candidates with enhanced efficacy. 
A new bioconjugation approach, called protein glycan coupling technology (PGCT), is 
based on glyco-engineering the N-glycosylation pathway in bacteria such as 
Escherichia coli. The PS, encoded by the inserted genes, is produced on a 
polyisoprenoid carrier and then is transferred to an asparagine residue of the carrier 
protein which has to contain at least one (native or engineered) N-glycosylation site 
(156) (157) (158) (159). Although this new in vivo conjugation technology is currently 
limited in the variety of glycan or protein substrates it can utilize, it has great potential 
to generate new-generation vaccines, in which the conjugation reactions are well 
controlled and conjugation products are homogeneous and structurally defined. 
Moreover the use of such methodology avoids the need for pathogenic bacteria from 
which to isolate PS and/or proteins since both glycan and protein synthesis and 
glycoconjugate assembly occur exclusively in an E. coli system (160). Recently 
PGCT has been used to generate novel glycoconjugate vaccines against Shigella 
dysenteriae type 1 (159). 
 
2.8.2. Parameters that affect glycoconjugate immunogenicity  
Several parameters can affect the immunogenicity of conjugate vaccines (122). 
Saccharide chain length, saccharide to protein ratio in the purified conjugate, 
conjugation chemistry, the nature of the linkers used for saccharide and/or protein 
derivatization and of the protein carrier are key parameters to investigate. Studies 
performed so far have compared the immunogenicity of vaccines differing for multiple 
parameters at the same time, making therefore difficult to assign the relative 
importance of the single variables to immunogenicity. However, it is clear that the 
influence of conjugation variables varies for different carbohydrate antigens and 
these variables are strongly interconnected. 
Some studies have investigated the impact of these parameters on the 
immunogenicity of OAg glycoconjugate vaccines. 
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 Size of the saccharide moiety  
When tetra-, octa-, and dodecasaccharides from the OAg of S. Typhimurium were 
conjugated through the terminal reducing ends to BSA, anti-LPS antibody titers 
increased with saccharide size in mice and rabbits (101). S. Paratyphi A conjugates, 
with random coupling of OAg to TT using an adipic acid dihydrazide (ADH) linker, 
elicited high antibody levels with high MW OAg and no detectable antibodies with low 
MW OAg (average MW 122 and 23.4 kDa respectively) (161).  
In contrast, Shigella dysenteriae type 1 and Shigella sonnei conjugates significantly 
improved with lower MW saccharides compared with full length OAg, bound at their 
reducing ends to the protein carrier at defined densities. Similarly, a study with 
synthetic Shigella dysenteriae type 1 oligosaccharides coupled to human serum 
albumin at multiple attachment points, found that conjugates with short 
oligosaccharides (2, 3 and 4 repeating units respectively) elicited higher antibody 
levels than a conjugate with full length OAg (approximately 27 repeating units) (162). 
Also Shigella sonnei conjugates with low MW OAg fragments (average of 3.5 
repeating units) terminally linked to BSA or DT induced significantly higher antibody 
levels in mice than the full length OAg (approximately 29 repeating units) conjugated 
to rEPA by random chemistry (163). For Shigella flexneri 6, OAg with an average of 
seven repeating units and full length OAg induced similar antibody levels (164). 
Phalipon et al. found that a synthetic sequence of three repeating units of the 
Shigella flexneri 2a OAg conjugated to TT had higher immunogenicity and better 
protective efficacy in mice compared to conjugates with one or two repeating units 
(165). The nature of the OAg seems to influence the effect that saccharide chain 
length can have on immunogenicity and there is likely to be a minimum chain length 
required to induce a strong immunological response for each saccharide type (166) 
(167). 
However, this parameter seems to be affected also by other factors. For example, 
Phalipon and Pozsgay have reported a strong correlation between saccharide chain 
length and saccharide loading (165) (162). Also the conjugation chemistry used can 
have an impact. Use of low MW saccharide may maximize the T cell help afforded by 
the carrier protein, but such glycoconjugates can fail to raise anti-PS antibodies if key 
conformational epitopes on the whole PS are lost (168). Probably due to the 
complexity of the immune response and the high number of variables associated, it is 
not always possible to see a clear correlation between the variation of MW and the 
immunological response for a given antigen. However, OAg-based glycoconjugate 
investigations for Salmonella seem to indicate that the immunological response 
would benefit from the use of higher MW saccharide hapten.   
 Conjugation chemistry and linker 
The choice of conjugation strategy and linker have an important effect on efficiency 
of conjugation, saccharide to protein ratio and vaccine size, with consequent impact 
on immunogenicity (Beuvery et al., 1983) (Carmenate et al., 2004). 
The linker (or spacer) is a short linear molecule that is generally linked to the sugar 
chain or to the protein or to both moieties, depending on the coupling chemistry used. 
Linkers differ in length, flexibility and functional groups involved and facilitate the 
saccharide-protein coupling by alleviating the steric hindrance factors. The creation 
of immunogenic neoepitopes as a result of the linker/conjugation chemistry used 
might drive the antibody response of the conjugate away from targeted epitopes 
located on the hapten (122).  
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With regard to OAg based vaccines, S. Typhimurium OAg-TT conjugates produced 
by random activation and ADH linker were more immunogenic in mice than when 
selective chemistry with the same linker was used. Immunogenicity was also affected 
by the amount of linker incorporated (98). Similarly, Vibrio cholerae O1 serotype 
Inaba deacylated LPS conjugated to cholera toxin (CT) were more immunogenic 
when obtained by random chemistry with ADH than when produced by single-point 
attachment, even if a different linker, SPDP, was used for the last approach (169). 
The same antibody levels and protection were obtained by comparing S. Enteritidis 
OAg conjugated directly to flagellin monomers by random activation or with selective 
chemistry through diaminooxy cysteamine and N-(-maleimidobutyloxy)-
sulfosuccinimide ester linkers (106). 
Escherichia hermannii OAg linked directly to BSA gave earlier and more persistent 
antibody response in mice than when ADH linker was used (170). For Escherichia 
coli O111 OAg-TT conjugates, for immunogenicity in mice, ADH was a more effective 
linker than SPDP (171).  Other studies did not find an influence of linkers on 
immunogenicity and for example linkers of three different chain lengths did not 
impact on the immunogenicity of Vibrio cholerae O1, Ogawa serotype 
hexasaccharide-BSA conjugates tested in mice (172). 
The choice of conjugation chemistry is also related with the efficiency and 
consistency of the process: if the sugar MW is too high, it is not trivial to obtain a 
selective derivatization in a single point while it is much easier to apply random 
derivatization chemistry. However, a single selective derivatization impacts to a 
lesser extent on the antigenicity of the saccharide hapten and enables vaccines 
which are easier to be characterized, and because of that some authors have 
suggested this as the preferred strategy (122). 
 Saccharide to protein ratio 
Considering OAg-based glycoconjugates, reported studies have confirmed an 
influence of this parameter on conjugate vaccine immunogenicity. For example, 
Svenson (101) found that immunogenicity of  
S. Typhimurium octasaccharide-BSA conjugates in mice was enhanced by 
increasing the molar ratio of saccharide to protein from 7 to 23 (101). For Shigella 
flexneri 2a conjugates with a synthetic pentadecasaccharide, an average molar ratio 
of two induced no anti-LPS antibodies in mice, and an average ratio of 14 was more 
immunogenic than eight (165). With terminally-linked saccharides, immunogenicity 
usually increases with increasing molar saccharide to protein ratio (173) (174) (165). 
This is likely to result from better cross-linking and activation of saccharide-specific B 
cells with increased sugar loading. However, with high saccharide-to-protein ratios, 
essential carrier epitopes may be hidden from the immune system, hindering 
recognition of the conjugate vaccine as a T-dependent antigen. Pozgay, testing the 
immunogenicity of Shigella dysenteriae type 1 conjugates in mice, found that the 
optimal carbohydrate chain density differed with oligosaccharide length, highlighting 
the connection between these two parameters (162). 
 Carrier protein 
Carrier proteins used for carbohydrate antigen conjugation are preferably proteins 
that are non-toxic, non-reactogenic and can be obtained in sufficient amount and 
purity. They should also be stable under standard chemical conditions 
(concentration, pH, ionic strength) of conjugation procedures. Current proteins used 
in commercial or under development conjugate vaccines include: DT, nontoxic cross 
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reactive material of diphtheria toxin (CRM197), TT, keyhole limpet hemocyanin (KLH), 
the outer membrane protein of N. meningitidis (OMPC), recombinant exoprotein 
Pseudomonas aeruginosa (rEPA) and, more recently, protein D derived from non-
typeable H. influenzae. In some cases, bacterial PS have been conjugated to a 
protein from the same pathogen to combine the effects of the carbohydrate and the 
protein antigens (84) (127). 
Most animal studies indicate that the choice of the carrier protein has an impact on 
conjugate vaccine immunogenicity (122), but few studies have investigated on the 
effect of carrier protein on the immunogenicity of OAg-based glycoconjugate 
vaccines. Vaccination in healthy adults using OAg of Shigella sonnei conjugated to 
native or succinylated rEPA or Corynebacterium diphtheriae toxin mutant CRM9 by 
random chemistry and with ADH as linker, gave the same anti-LPS IgG levels (175). 
With Shigella flexneri 2a OAg, the rEPAsucc conjugate gave instead significantly 
higher antibody levels (175). The opposite result was obtained in mice, with 
succinylated Shigella flexneri 2a-CRM9 being more immunogenic than succinylated 
Shigella flexneri 2a-rEPA (176). S. Enteritidis OAg conjugates were similarly 
immunogenic in mice when coupled to S. Enteritidis flagellin monomers, polymers or 
CRM197 by random conjugation with no linker (177). 
 
2.9 NTS glycoconjugate project at NVGH 
NVGH is working on the development of a bivalent glycoconjugate vaccine covering 
both S. Typhimurium and S. Enteritidis. OAg purified from the two strains will be 
independently conjugated to CRM197 (178) as carrier protein. 
CRM197 is a non-toxic variant of DT that does not require chemical detoxification. 
Because of that, CRM197 has a well-defined physico-chemical profile, consistent from 
one preparation to another one. It has been successfully used as carrier for many 
glycoconjugate vaccines against Hib, Pneumococcus (7 and 13 valent) and recently 
for a tetravalent (ACWY) meningococcal conjugate vaccine which have been proved 
to be safe and immunogenic for all ages (179). 
NVGH has developed a simplified method for OAg extraction and purification (86). In 
the adopted strategy, the labile linkage between the KDO of the core and the lipid A 
is cleaved directly in the bacterial growth medium; the OAg, still linked to the core, is 
then easily purified from the cells and used for the production of conjugate vaccines. 
In this way, LPS purification from bacterial membranes, a very time-consuming and 
often hazardous process, is avoided. The conjugation chemistry developed for S. 
Paratyphi A OAg (180) has been applied to NTS OAg. This method uses the terminal 
KDO unit of the OAg chain for linkage to the protein, without modifying the sugar 
moiety. Preliminary studies in mice showed that the conjugate obtained by this 
chemistry with the OAg from S. Typhimurium strain D23580 induced high anti-OAg 
titers with bactericidal activity. 
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2.10 PhD project aims 
In the contest of the NTS glycoconjugate vaccine project, my PhD project has been 
focused in three related aspects:  
 
1) Structural and biological characterization of NTS polysaccharide purified from 
different S. Typhimurium and S. Enteritidis strains. 
2) Synthesis, characterization and immunological evaluation of a panel of NTS 
glycoconjugate vaccine variants (OAg source, conjugation chemistry, OAg/protein 
ratio) to better understand the key factors in glycoconjugate vaccine design required 
for optimal antibody-mediated immunity.  
3) Design of new efficient glycoconjugation methodologies which allow the synthesis 
of structurally high-defined glycoconjugate vaccines and simplify the conjugation 
process. 
 
These studies will contribute to design an improved conjugate vaccine against NTS. 
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3. Impact of OAg structure on the immunogenicity 
of NTS glycoconjugate vaccines 
 
3.1 Abstract 
The influence of parameters like saccharide chain length and O-acetylation level has 
been investigated for several antigens and can impact on the immunogenicity of their 
corresponding conjugate vaccines. Here, OAg from 6 different S. Typhimurium and 4 
different S. Enteritidis strains were purified and fully characterized and 
immunogenicity of corresponding glycoconjugates evaluated in mice. 
S. Typhimurium OAg showed a similar bimodal molecular weight distribution, but 
differed with respect to the amount and position of O-acetylation and glucosylation. 
For the D23580 strain, O-acetyl groups were found not only on C-2 of abequose 
(factor 5 specificity), but also on C-2 and C-3 of rhamnose; glucose was found to be 
linked 1→4 or 1→6 to galactose in different amounts according to the strain of origin. 
S. Enteritidis OAg were not only similar for average chain length but also for sugar 
composition, all characterized by low O-acetylation and glucosylation levels.  
Corresponding conjugates were synthesized using CRM197 as carrier protein, without 
altering the OAg chain, in order to examine the impact of OAg structure on 
immunogenicity. All the NTS glycoconjugates were immunogenic in mice and able to 
elicit bactericidal antibodies. OAg fine specificities appeared to influence 
glycoconjugate immunogenicity. In particular, the presence of additional O-acetyl 
groups on rhamnose for S. Typhimurium D23580 OAg resulted in the production of 
strain-specific anti-OAg antibodies. O-acetylation and glucosylation appeared to have 
an impact on the bactericidal activity when antibodies produced in mice were tested 
against a broad panel of S. Typhimurium endemic strains. 
 
3.2 Introduction 
Bacterial LPS can demonstrate high levels of heterogeneity, particularly LPS from 
NTS. OAg can vary in chain length and other modifications, like glucosylation and O-
acetylation of the repeating units, which can constitute additional specific OAg factors 
(181). 
In particular, with regards to S. Typhimurium and S. Enteritidis OAg, galactose (Gal) 
may be α(1→6) or α(1→4) glucosylated, giving the factor 1 or factor 122 specificity 
respectively (181) (182) (183) (184). For S. Typhimurium, the abequose (Abe) may 
be 2-O-acetylated, which adds O:5 specificity in the Kauffman-White scheme . Wollin 
et al. (185) reported the O-acetylation of C-2 and C-3 of rhamnose (Rha) as a new, 
hitherto unknown modification of S. Typhimurium OAg chain. In S. Enteritidis, 
instead, some of the glucose (Glc) residues have been found to be O-acetylated at 
C-2 (184). 
O-acetylation level of glycoconjugate vaccines has been investigated for several 
antigens and can have an impact on immunogenicity (186) (97) (187) (188) (189) 
(190), but few data has been reported for NTS conjugate vaccines (98). Wollin et al. 
showed that O-acetyl groups on Rha did not elicit specific antibodies in rabbits. No 
data have been reported so far on the influence of glucosylation level and/or position. 
Here OAg chains purified from six different S. Typhimurium strains and four different 
S. Enteritidis strains have been fully characterized. The results obtained are 
important for understanding to what extent structural variability of NTS LPS can be 
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associated with the strain of origin. Corresponding conjugate vaccines have been 
synthesized by using CRM197 as carrier protein without altering the OAg chain 
structure in order to investigate if this structural variability can have an impact on the 
immunogenicity of corresponding glycoconjugate vaccines. This in turn is required to 
verify the importance of the selection of the NTS strain used as OAg source for the 
development of a candidate conjugate vaccine with broad coverage against NTS. 
 
3.3 Material and methods 
Reagents 
The following chemicals were used in this study: triethylamine (TEA), adipic acid 
dihydrazide (ADH), sodium cyanoborohydride (NaBH3CN), sodium acetate (AcONa), 
dimethyl sulfoxide (DMSO), sodium phosphate monobasic (NaH2PO4), sodium 
chloride (NaCl), hydrochloric acid 37% (HCl) [Sigma]; acetonitrile (CH3CN) [LC-MS 
Chromasolv]; adipic acid bis(N-hydroxysuccinimmide) (SIDEA) [PFANSTIEHL 
Laboratories]; absolute ethanol [Carlo Erba]. CRM197 was obtained from Novartis 
Vaccines and Diagnostics (NV&D).  
 
Origin and growth of S. Typhimurium and S. Enteritidis strains  
The clinical isolate D23580 was obtained from the Malawi-Liverpool-Wellcome Trust 
Clinical Research Programme, Blantyre, Malawi. D23580 is a typical and 
representative Malawian invasive NTS isolate belonging to the ST313 sequence type 
and pathovar (81). 1418, 2189 and 2192 are animal isolates (191) (192) and were 
obtained from the University of Calgary. The laboratory strains NVGH1791 and LT2 
(193) were obtained from the University of Birmingham, UK, and Novartis Master 
Culture Collection, respectively. SEN animal strains 502, 618 and IV3456074 were 
obtained from Quotient Bioresearch Limited, UK, and were isolated by the European 
Antimicrobial Susceptibility Surveillance in Animals (EASSA), coordinated by the 
European Animal Health Study Centre, Brussels (CEESA). Those strains belonged to 
CEESA EASSA collections II and III (de Jong, Intern Journ Antimicrob Agents 2013). 
SEN D24359 is a human isolate obtained from the Malawi-Liverpool-Wellcome Trust 
Clinical Research Programme, Blantyre, Malawi. 
All S. Typhimurium and Enteritidis strains (except for 618) were grown in a chemically 
defined medium, using glycerol as the carbon source. S. Enteritidis 618 was grown in 
a complex medium containing: 10 g/L Soytone, 5g/L ultrafiltered yeast extract (Difco), 
10 g/L NaCl, 3% glycerol. All strains were fermented in a 7 L bioreactor (EZ-Control, 
Applikon) as previously described (86) (194). 
 
OAg purification 
S. Typhimurium and S. Enteritidis OAg were purified as previously described (86). 
Briefly, acid hydrolysis (2% acetic acid at 100°C for 3 hours) was performed directly 
on the fermentation culture and the supernatant, containing the released OAg chains 
linked to the core sugars, was recovered following centrifugation. Lower MW 
impurities were removed and the supernatant concentrated by tangential flow 
filtration (TFF), using a Hydrosart 30 kD membrane. Protein and nucleic acid 
impurities were co-precipitated in citrate buffer 20 mM at pH 3. The protein content 
was further reduced by ion exchange chromatography. Nucleic acids were further 
removed by precipitation in 18 mM Na2HPO4, 24% EtOH and 200 mM CaCl2, pH > 
4.5. OAg was then recovered in water by a second TFF 30 kD step. 
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OAg characterization 
Phenol sulfuric acid assay was used for total sugar quantification (195); micro BCA 
for protein quantification (using bovine serum albumin (BSA) as a reference following 
the manufacturer’s instructions [Thermo Scientific]); UV spectroscopy for nucleic acid 
content (assuming that a nucleic acid concentration of 50 µg/mL gives an OD 260 = 
1) and chromogenic kinetic LAL (Limulus Amoebocyte Lysate) for endotoxin level 
(Charles River Endosafe-PTS instrument). Size-Exclusion High Pressure Liquid 
Chromatography (HPLC-SEC) with differential refractive index (dRI) detection was 
used to estimate the molecular size distribution of OAg populations (86). Samples 
were run on a TSK gel G3000 PWXL column (30 cm x 7.8 mm; particle size 7 μm; 
cod. 808021) with TSK gel PWXL guard column (4.0 cm x 6.0 mm; particle size 12 
μm; cod.808033) (Tosoh Bioscience). The mobile phase was 0.1 M NaCl, 0.1 M 
NaH2PO4, 5% CH3CN, pH 7.2 at the flow rate of 0.5 mL/min (isocratic method for 30 
min). Void and bed volume calibration was performed with λ-DNA (λ-DNA Molecular 
Weight Marker III 0.12-21.2 Kbp, Roche) and sodium azide (NaN3, Merck), 
respectively and dextrans were used as standards. For Kd determination, the 
following equation was used: Kd = (Te-T0)/(Tt-T0) where: Te = elution time of the 
analyte, T0 = elution time of the biggest fragment of λ-DNA and Tt = elution time of 
NaN3. The sugar monomers constituting the OAg repeating unit and N-acetyl 
glucosamine (GlcNAc), a unique sugar of the core region, were quantified by use of 
HPAEC-PAD (86). KDO amount was calculated by semicarbazide/HPLC-SEC 
method (180). 1D1H NMR analysis was recorded on all OAg samples to confirm 
identity and purity and to calculate the level of O-acetylation (86). Sugar composition 
analysis was also performed by GLC, after hydrolysis of the polysaccharides with 2 M 
TFA at 125°C for 1 h, and derivatization to alditol acetates (196). The sugar linkage 
positions were determined by GLC-MS after per-methylation of the samples (197), 
hydrolysis with 2 M TFA at 125°C for 1 h, followed by reduction and per-acetylation to 
obtain the partially methylated alditol acetate (PMAA) derivatives. Peak areas were 
corrected by using the effective carbon response factors (198); for Abe the response 
factor of 6-deoxy hexose were applied. Determination of the absolute configuration of 
the sugar residues of OAg samples  was performed as previously described (199).   
In order to determine the position of the O-acetyl groups, the OAg were per-
methylated following the method of Prehm (200), which leaves the O-acetyl groups in 
their native positions. Samples were then treated as above to obtain the PMAA 
derivatives, which were then analyzed by GLC and GLC-MS. Analytical GLC was 
performed on a Perkin Elmer Autosystem XL gas chromatograph equipped with a 
flame ionization detector and a SP2330 capillary column (Supelco, 30 m), using He 
as carrier gas. The following temperature programs were used: for alditol acetates, 
200–245 °C at 4 °C/min; for PMAA, 150–250 °C at 4°C/min. Separation of the 
trimethylsilylated (+)-2-butyl glycosides, for determining the absolute configuration of 
the sugars, was obtained on a HP1 column (Hewlett–Packard, 50 m), using the 
following temperature program: 50 °C 1 min, 50-130 °C at 45 °C/min, hold 1 min, 
130–240 °C at 1 °C/ min, hold 20 min. GC–MS analyses were carried out on an 
Agilent Technologies 7890A gas chromatograph coupled to an Agilent Technologies 
5975C VL MSD.  
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Synthesis of OAg-ADH-SIDEA-CRM197 conjugates 
The following procedure was applied to the OAg purified from all the different strains. 
OAg was solubilized in 100 mM AcONa pH 4.5 at a concentration of 40 mg/mL. ADH 
and NaBH3CN were added as solids, both with a ratio 1.2:1 by weight with respect to 
the OAg. The solution was mixed at 30°C for 1 h. The reaction mixture was desalted 
against water on a HiPrep™ 26/10 desalting column 53 mL, prepacked with 
Sephadex™ G-25 Superfine [GE Healthcare]. 
For introduction of the second linker, SIDEA, OAg-ADH was dissolved in 
water/DMSO 1:9 (v/v) at a concentration of 50 mg/mL. When the derivatised  
OAg was completely solubilized, TEA was added (molar ratio TEA/total NH2 groups = 
5; total NH2 groups included both phosphoethanolamine groups on the OAg and the 
hydrazide groups introduced with the linker ADH) and then SIDEA (molar ratio 
SIDEA/total NH2 groups = 12). The solution was mixed at RT for 3 h. Purification was 
performed precipitating OAg-ADH-SIDEA by addition of dioxane (90% volume in the 
resulting solution) and then washing the pellet with the same organic solvent (ten 
times with 1/3 of the volume added for the precipitation) to remove residual free 
SIDEA. Working with the OAg from LT2 and all S. Enteritidis strains, the OAg-ADH-
SIDEA was purified in a different way. The reaction mixture was added to a volume 
(equal to two times the reaction mixture volume) of HCl 82.5 ppm and mixed at 4°C 
for 30 min. Under these conditions, unreacted SIDEA precipitated and was separated 
by centrifugation. OAg-ADH-SIDEA was recovered from the supernatant by 
precipitation with EtOH/HCl 55 ppm (80% final). The pellet was washed twice with 
100% EtOH (1.5 times the reaction mixture volume) and lyophilised. 
For conjugation to CRM197, OAg-ADH-SIDEA was solubilized in NaH2PO4 buffer pH 
7.2 and CRM197 was added to give a protein concentration of 20 mg/mL, final buffer 
capacity of 100 mM and a molar ratio of OAg active ester groups to CRM197 of 30 to 
1. The reaction was mixed at RT for 3 h.  
Conjugates were purified by hydrophobic interaction chromatography on a Phenyl HP 
column [GE Healthcare], loading 500 µg of protein for mL of resin in 50 mM NaH2PO4 
3M NaCl pH 7.2. The purified conjugate was eluted in water at 1 mL/min and the 
collected fractions were dialysed against 10 mM NaH2PO4 pH 7.2. 
 
Characterization of OAg-ADH-SIDEA-CRM197 conjugates 
Total saccharide was quantified by phenol sulfuric assay (195), protein content by 
micro BCA (using BSA as standard and following manufacturer’s instructions 
[Thermo Scientifics]) and the ratio of saccharide to protein calculated. HPLC-SEC 
analysis was used to characterize conjugates, in comparison with free OAg and free 
CRM197. All samples were eluted on a TSK gel 6000PW (30 cm x 7.5 mm) column 
(particle size 17 μm; Sigma 8-05765) connected in series with a TSK gel 5000PW 
(30 cm x 7.5 mm) column (particle size 17 μm; Sigma 8-05764) with TSK gel PWH 
guard column (7.5 mm ID x 7.5 cm L; particle size 13 µm ; Sigma 8-06732) (Tosoh 
Bioscience). The use of the two columns in series gave better separation of 
conjugate from free saccharide and protein, allowing the conjugate to enter into the 
column.  The mobile phase was 0.1 M NaCl, 0.1 M NaH2PO4, 5% CH3CN, pH 7.2 at 
the flow rate of 0.5 mL/min (isocratic method for 60 min). Void and bed volume 
calibration was performed with λ-DNA (λ-DNA Molecular Weight Marker III 0.12-21.2 
Kbp, Roche) and sodium azide (NaN3, Merck), respectively. OAg peaks were 
detected by dRI, while UV detection at 214 nm and 280 nm was used for free protein 
and conjugate detection. Protein and conjugate peaks were also detected using 
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tryptophan fluorescence (emission spectrum at 336 nm, with excitation wavelength at 
280 nm). Kd values were determined using the equation reported before for free OAg 
characterization. Free protein was estimated by HPLC-SEC, running a calibration 
curve of the un-conjugated protein in the range 5-50 μg/mL under the same 
conditions as for the conjugate. The percentage of unconjugated CRM197 was 
calculated by dividing the amount of free protein detected by HPLC-SEC by the total 
amount of protein quantified in the sample by micro BCA. A method for free 
saccharide determination is currently under development. O-acetylation level was 
calculated by 1H NMR in 200 mM NaOD (180).  
Derivatized OAg intermediates were all characterized by phenol sulfuric assay for 
sugar content and by HPLC-SEC for verifying aggregation or degradation after 
modification. Introduction of NH2 groups was verified by TNBS colorimetric method 
(201) using ADH as standard and subtracting the number of NH2 groups already 
present on the un-derivatized OAg sample. Free ADH was detected by RP-HPLC 
(180). Activation on the terminus KDO was calculated as moles of linked ADH/moles 
of KDO %, indicating the % of OAg chain activated. Total active ester groups 
introduced with SIDEA were quantified by A260 (Miron and Wilchek 433-35) and free 
SIDEA was detected by RP-HPLC (Micoli et al. paratyphi). Percentage of 
derivatization with SIDEA was calculated as molar ratio % of linked active ester 
groups/total NH2 groups by TNBS before derivatization, indicating the moles % of 
NH2 groups activated by this reaction. 
 
Immunogenicity studies in mice 
Groups of 8 mice (C57BL/6, female, 5 weeks old), purchased from Charles River 
Laboratory and maintained at Novartis Vaccines and Diagnostics, were immunized in 
a three-dose immunization regimen at 14 days-interval with 1 and 8 µg/dose of OAg 
with 200 µL/dose.  
Mice were bleed before the first immunization (day 0) and on immunization days 14 
and 28. Mice were sacrificed and sera collected 2 weeks after the third immunization, 
on day 42. All animal protocols were approved by the local animal ethical committee 
(approval N. AEC201018) and by the Italian Minister of Health in accordance with 
Italian laws. 
 
Serum antibody analysis by ELISA 
Serum IgG levels against OAg and CRM197 were measured by ELISA as previously 
described (86) (194). Unconjugated purified OAg used for making glycoconjugates at 
either 5 or 15 µg/Ml and CRM197 at 2 µg/mL were used for ELISA coating. Mouse 
sera were diluted 1:200 in PBS containing 0.05% Tween 20 and 0.1% BSA. ELISA 
units were expressed relative to mouse anti-OAg or anti-CRM197 IgG standard serum 
curves, with best 4 parameter fit determined by modified Hill Plot. One ELISA unit 
was defined as the reciprocal of the standard serum dilution that gives an 
absorbance value equal to 1 in this assay. Each mouse serum was run in triplicate. 
Data are presented as scatter plots of individual mouse ELISA units, and geometric 
mean of each group.  
Statistical analysis of ELISA results was conducted on day 42 samples. Groups were 
compared using Kruskal-Wallis One-Way ANOVA.  Post hoc analysis was performed 
using Student-Newman-Keuls test for both anti-OAg and anti-CRM197 antibody units 
(using α = 0.05). 
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Serum bactericidal activity (SBA) 
Equal volumes of day 42 mouse serum, belonging to the same immunization group, 
were pooled together for SBA experiments. S. Typhimurium D23580 strain was 
grown in Luria Bertani (LB) medium to log-phase (OD: 0.2), diluted 1:30,000 in SBA 
buffer (50 mM phosphate; 0.041% MgCl2 6H2O; 33 mg/mL CaCl2; 0.5% BSA) to 
approximately 3 X 103 colony forming units (CFU)/mL and distributed into sterile 
polystyrene U bottom 96-well microtiter plates (12.5 µL/well). To each well (final 
volume 50 µL, ~620 CFU/mL), serum samples serially diluted 1:3 (starting from 1:20-
1:100 dilution) were added. Sera were heated at 56ºC for 30 min to inactivate 
endogenous complement. Active Baby Rabbit Complement (BRC, Pel-Freez lot 
0405/lot 12521) used at 50% of the final volume was added to each well. BRC 
source, lot and percentage used in SBA reaction mixture were previously selected by 
lowest toxicity against S. Typhimurium. To evaluate possible nonspecific inhibitory 
effects of BRC on mouse serum, bacteria were also incubated with: a. the same 
tested sera plus heat-inactivated BRC (HI-BRC); b. sera alone (no BRC); c. SBA 
buffer and active BRC.  Each sample and control was tested in triplicate. Seven 
microliter reaction mixture from each well was spotted on LB-agar plates at time zero 
(T0) to assess initial colony forming units (CFU), and at 1.5 h (T90) after incubation at 
37ºC. LB-agar plates were incubated overnight at 37ºC and resulting CFU were 
counted the following day. Bactericidal activity was determined as percent CFU 
counted in each pooled serum dilution with active/inactive BRC, compared with CFU 
of the same sera dilutions with no BRC. SBA graphs show bacterial growth inhibition 
as a function of anti-OAg ELISA units detected in each tested serum pool. 
 
3.4 Results 
 
Characterization of OAg purified from different S. Typhimurium strains 
S. Typhimurium OAg were purified from 6 different strains, and characterized. 
Independently from the strain of origin, OAg were similar in terms of molecular weight 
(MW) distribution (Figure 3.1), with two main populations at relatively higher (HMW) 
and lower MW (LMW) in the range of 80-87 and 28-31 kDa respectively, as 
determined by HPLC-SEC using dextrans as standards. Only 2192 OAg showed one 
main peak at average MW of 34.5 kDa. For this more homogeneous sample, 
average MW was also calculated based on the molar ratio of Rha (OAg chain) to 
GlcNAc (unique sugar of the core region), equal to 28, and according to the sugar 
composition analysis by HPAEC-PAD and to the O-acetylation level by 1H NMR, and 
corresponded to 20.5 kDa. 
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Figure 3.1 HPLC-SEC profiles for S. Typhimurium OAg isolated from six different strains. 
TSKgel 3000 PWXL, 0.5 mL/min, 100 mM NaCl 100 mM NaH2PO4 5% CH3CN pH 7.2; Vtot 
23.29 min; V0 11.20 min; dRI detection. 
 
Sugar composition analysis by HPAEC-PAD confirmed the presence of Rha, Gal and 
Man, the sugars constituting the backbone of the OAg chain, in a ratio 1:1:1 for all 
the samples examined, while a variable amount of glucosylation was found 
depending on the strain of origin (Table 3.1). In the absence of a monomer standard, 
Abe was quantified by 1HNMR analysis which yielded the expected molar ratio of 1:1 
with respect to Man for all samples (Fig. 3.2). Analysis by 1H NMR performed after 
the addition of 200 mM NaOD revealed different O-acetylation levels according to the 
source of OAg (Table 3.1). In D2O all samples contained the characteristic signal 
near 2.13 ppm assigned to OAc on C-2 Abe, with D23580 OAg having additional 
OAc signals at 2.23 and 2.19 ppm (Figure 3.3). Further structural analysis was 
performed on all purified OAg, except NVGH 1791 which was similar to the other 
laboratory strain (LT2) from this preliminary characterization (Table 3.1). 
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Figure 3.2 OAg chain structure resolved by HPAEC-PAD, GC, GC-MS, and NMR 
investigation for S. Typhimurium (A). OAg chain structure reported in literature for S. 
Enteritidis (B) and confirmed by HPAEC-PAD and NMR investigations.   
 
Table 3.1 Main differences detected for OAg purified from different S. Typhimurium strains. 
OAg 
source 
Glc % Glc linkage 
OAc on 
Rha 
% OAc avMW 
1418 
(animal isolate) 
84 
1→4 Gal (8%)  
1→6 Gal (92%) 
no 73  87.0 and 30.4 kDa 
2189 
(animal isolate) 
51 
1→4 Gal (86%) 
1→6 Gal (14%) 
no 58  80.8 and 31.6 kDa 
2192 
(animal isolate) 
24 
1→4 Gal (56%) 
1→6 Gal (44%) 
no 100  34.5 kDa 
D23580 
(human isolate) 
39 1→4 Gal yes 200  82.6 and 28.3 kDa 
LT2 
(laboratory strain) 
11 1→4 Gal no 65  82.6 and 28.3 kDa 
NVGH1791 
(laboratory strain) 
8 nd no 75  82.6 and 28.3 kDa 
Glucosylation level calculated as molar ratio % to Man by HPAEC-PAD analysis. Glc linkage 
to Gal determined by GLC-MS analysis of PMAA derivatives.  O-acetylation level calculated 
by 1H NMR of de-O-acetylated samples (integral of acetate ion peak compared to Rha-H6 
peak).  Average molecular weight (avMW) expressed in kDa using dextrans as standards on 
the TSK gel 3000 PWXL column (flow rate: 0.5 mL/min; eluent: 100 mM NaH2PO4 100 mM 
NaCl 5% CH3CN pH 7.2). nd: not determined 
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Figure 3.3 1H NMR comparison of D23580 (red) and 2192 OAg (black), showing the 
presence of additional OAc groups for D23580 OAg (at 2.23 and 2.19 ppm) with respect to 
2192 OAg (at 2.11 ppm). 
 
Composition of the OAg chain found by HPAEC-PAD was confirmed by GLC analysis 
of the alditol acetates derivatives (Table 3.2). The linkage positions for the 
constituent sugars of the OAg samples were determined by GLC and GLC–MS of the 
PMAA derivatives (Table 3.3). As expected (101), the OAg chains from all sources 
contained terminal non-reducing 3,6 dideoxyhexose, identified as Abe by NMR (t-
Abe), 4-linked Rha (4-Rha), terminal non-reducing glucose (t-Glc) (its peak overlaps 
with that of 4-Rha and was not quantified in samples with a low level of 
glucosylation), 3-linked Gal (3-Gal), 2,3 linked Man (2,3-Man). Glc was found to be 
linked to Gal in position 4 or 6, in different amounts according to the strain of origin. 
LT2 and D23580 had Glc linked 1→4 to Gal, as shown by the presence of 3,4-Gal 
(Table 3.3). For 1418 OAg, Glc was predominantly linked 1→6 to Gal, as shown by 
the presence of 3,6-Gal rather than 3,4-Gal (Table 3.3), while the opposite was found 
for 2189 OAg. 2192 sample showed equal amounts of Glc linked 1→4 and 1→6. The 
amount of t-Glc determined was variable in the different OAg samples (183) and the 
sum of 3,4-Gal and 3,6-Gal for each sample was in agreement with the total amount 
of Glc determined by GLC analysis of the alditol acetates (Table 3.2). The results are 
consistent with the structural variations reported for the S. Typhimurium OAg (202) 
(101), (Figure 3.2.). GLC analysis of the chiral glycosides of all the OAg samples 
showed that the hexoses were in the D absolute configuration and Rha in the L 
absolute configuration. As before, the absence of a standard meant that this analysis 
could not be performed for Abe, and its D configuration was established by NMR 
glycosylation shifts. 
 
 
 
D23580 
2192 
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In order to determine the position of the additional O-acetyl groups found for D23580 
OAg and to confirm that OAc on Abe was at C-2, the OAg were permethylated 
following the method of Prehm (200), which leaves the O-acetyl groups in their native 
positions. Analysis of the corresponding PMAA derivatives was performed by GLC 
and GLC–MS. Figure 3.4 shows the GLC chromatograms of the PMAA derivatives 
for the D23580 OAg, as an example, obtained without (A) and with (B) retention of 
the O-acetyl groups. Comparison of the two chromatograms showed that new peaks 
were present when PMAA derivatives were obtained with retention of O-acetyl 
position. 2-Abe was a new signal, confirming esterification with O-acetyl on C-2 of the 
terminal Abe. In addition, the expected 4-Rha, 3,4-Rh and 2,4-Rha were also 
present, indicating partial esterification of the 4-linked Rha on C-2 or C-3. Separation 
of the 4-Rha into three derivatives also resulted in the partial separation of the peak 
assigned to t-Glc from that of 4-Rha. In the chromatogram obtained without retention 
of O-acetyl groups (Fig. 3.3 A), t-Glc was a shoulder on the side of the 4-Rha peak 
and therefore its integration was not possible (Table 3.3). This analysis was 
Table 3.2 Sugar composition analysis by HPAEC-PAD for all 
S. Typhimurium O-antigen was confirmed by GLC. 
Molar ratio to Man 1418 2189 2192 D23580  LT2  
Rha 
1.05 
(1.34) 
0.99 
(1.37) 
1.01 
(1.13) 
0.95 
(1.18) 
0.97 
(1.06) 
Gal 
1.10 
(1.02) 
1.08 
(1.03) 
1.07 
(1.06) 
1.03 
(1.01) 
0.94 
(1.03) 
Glc 
(0.84) 
(0.85) 
0.51 
(0.48) 
0.24 
(0.23) 
0.39 
 (0.28) 
0.11  
(0.08) 
Sugar composition analysis by GLC is reported in brackets 
Table 3.3 Determination of glycosidic linkages in S. Typhimurium  
O-antigen by GLC-MS of PMAA derivatives. 
Linkage RRTa 1418 2189 2192 D23580 LT2 
t-Abeb 0.45 0.16 0.05 0.42 0.07 0.15 
4-Rha 0.72 0.87 0.84 1.12 1.00 1.40 
t-Glc 0.73 0.63 0.29 ndc ndc ndc 
3-Gal 0.91 0.22 0.56 0.91 0.76 0.85 
2,3-Man 1.00 1.00 1.00 1.00 1.00 1.00 
3,4-Gal 1.03 ~0.05 0.37 0.10 0.26 ~0.04 
3,6-Gal 1.14 0.59 0.06 0.08 - - 
a Relative retention time; b t-Abe = the amount of this derivative is 
underestimated because it is acid labile. c nd = not determined because 
t-Glc peak overlaps with that of 4-Rha and was not quantified in samples 
with a low level of glucosylation. 
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performed on all the OAg samples (Table 3.4) and confirmed the results from 1H 
NMR analysis (Table 3.1): all OAg were variably O-acetylated on C-2 of Abe, 
whereas only the D23580 sample had additional OAc groups on Rha (Table 3.4). 
According to the analysis, OAc were on C-2 and C-3 of Rha (Fig. 3.2). This has been 
confirmed by NMR analysis (203). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 GLC chromatograms of the PMAA derivatives from D23580 OAg obtained without 
(A) and with (B) retention of O-acetyl position. Peak assignments are reported:  
t-Abe = terminal non-reducing Abe; t-Abe-2Ac = terminal non-reducing Abe acetylated on  
C-2. The numbers indicate the position of hydroxyl functions engaged in linkages. Similar 
chromatograms were obtained for the other OAg and the results are summarized in Table 
3.4. 
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Characterization of OAg purified from different S. Enteritidis strains 
OAg from 4 different S. Enteritidis strains were purified. Characterization by HPLC-
SEC showed that they were similar in terms of MW distribution: all showed a main 
peak at relatevely lower MW (in the range 29.6-32.6 kDa, as determined using 
dextrans as standards) with a shoulder, except SA 618, at higher MW (in the range 
77-82.6 kDa). For SA 618, average MW was also calculated based on the molar ratio 
of Rha to GlcNAc, equal to 27, and according to the sugar composition analysis by 
HPAEC-PAD and to the O-acetylation level by 1H NMR, and corresponded to 18.9 
kDa. Analysis by HPAEC-PAD for sugar composition and by 1H NMR for O-
acetylation level revealed low heterogeneity: all the OAg were in fact characterized 
by low glucosylation and O-acetylation level (Table 3.5; Figure1.5). Due to the low 
variability found for S. Enteritidis OAg, no further structural investigations have been 
perfomed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 1H NMR spectrum of D24359 OAg, as an example of the S. Enteritidis strains 
analyzed. 
  
 
 
 
 
 
 
 
Table 3.4 Deduced OAc position and quantification of 
substitution based on the relative molar ratios of O-antigen 
PMAA derivatives obtained with and without retention of O-acetyl 
substituents. 
Residue 1418 2189 2192 D23580 LT2 
t-Abe 48% 63% 20% 37% 37% 
t-Abe-2Ac 52% 37% 80% 63% 63% 
4-Rha 100% 100% 100% 22% 100% 
4-Rha-3Ac - - - 43% - 
4-Rha-2Ac - - - 35% - 
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Table 3.5 Fine specificities for S. Enteritidis OAg.  
OAg source avMW Glc % % OAc 
D24359 
(human isolate) 
32.6 (and 82.5) 
kDa 
9 35 
SA 502 
(animal isolate) 
30.5 (and 77) kDa 12 22 
IV3453219 
(animal isolate) 
(30.5 (and 82.6) 
kDa 
11 32 
SA 618 
(animal isolate) 
29.6 kDa 15 10 
Glucosylation level calculated as molar ratio % to Man by HPAEC-PAD 
analysis. O-acetylation level calculated by 1H NMR of de-O-acetylated 
samples (integral of acetate ion peak compared to Rha-H6 peak). . Average 
molecular weight (avMW) expressed in kDa using dextrans as standards on 
the TSK gel 3000 PWXL column (flow rate: 0.5 mL/min; eluent: 100 mM 
NaH2PO4 100 mM NaCl 5% CH3CN pH 7.2).  
 
Synthesis and characterization of OAg-ADH-SIDEA-CRM197 conjugates 
Acid hydrolysis, performed for extracting OAg from bacteria, cleaves the labile 
linkage between the toxic lipid A and the KDO sugar at the proximal end of the core 
region releasing OAg. The KDO sugar has been used for introducing ADH and then 
SIDEA linkers, and for binding OAg to the carrier protein, CRM197. The choice of a 
selective conjugation chemistry was driven by the need of not impacting the OAg 
chain, since the aim of the study was to evaluate the influence of fine specificities on 
immunogenicity (Figure 3.6) (180). 
 OAg derivatization with ADH and then SIDEA was characterized by good 
reproducibility both in terms of sugar recovery and percentage of activation for all the 
samples. In all cases, sugar recovery was >75%. For the ADH-derivatization step, 
activations >90% were obtained with free ADH <5% in moles.  The reaction with 
SIDEA resulted in about 70% of NH2 groups modified in active ester groups and free 
SIDEA determined to be <10% in moles. 
The main characteristics of the conjugates synthesized and then tested in mice are 
reported in Table 3.6, where also the main differences of the corresponding 
unconjugated OAg are highlighted. For all the conjugates, kd values were higher than 
those of free OAg and free protein (kd of CRM197 of 0.72), confirming the formation of 
the conjugate at higher MW. Analysis by HPLC-SEC showed that free CRM197 was 
not detectable. All the conjugates were characterized by a similar weight ratio of 
saccharide to protein and MW distribution of the OAg (Table 3.6). A saccharide to 
protein molar ratio of 4.8 and 3.7 was estimated for 2192 and SA 618 OAg 
respectively, based on the MW of 20.5 and 18.9 kDa calculated for these more 
homogeneous OAg samples. Analysis of the conjugates by 1H NMR confirmed that 
O-acetylation levels remained unchanged after conjugation to the protein (180). 
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Table 3.6 Characterization of conjugates tested in mice. 
OAg Strain 
OAg/CRM
197 
(w/w) 
Kd 
conjugate 
Kd free 
OAg 
O-acetylation  
% (OAg) 
Glucosylation 
 % (OAg) 
O:4,5 
D23580 2.1 0.44 
0.58 and 
0.68 
200 (Abe/Rha) 39 
NVGH 
1791 
2.1 0.43 
0.58 and 
0.68 
75 (Abe) 
7 
LT2 1.9 0.47 
0.58 and 
0.68 
64 (Abe) 
11 
2192 1.7 0.49 0.67 
100 (Abe) 
24 
2189 2.0 0.46 
0.57 and 
0.68 
58 (Abe) 
51 
1418 1.7 0.48 
0.56 and 
0.67 
73 (Abe) 
84 
O:9 
SA 502 
1.7 0.50 
0.62 and 
0.53 
22.4  12 
D24359 
1.2 0.52 0.62 35.4  9 
SA 618 
1.2 0.55 0.62 10.0 15 
IV3453219 
1.8 0.52 
0.62 and 
0.52 
31.6  11 
OAg/CRM197 ratios were calculated based on OAg concentration by phenol sulphuric 
assay and protein concentration by micro BCA. Kd values were calculated by HPLC-
SEC analysis on TSK gel 6000-5000 PW columns (flow rate: 0.5 mL/min; eluent: 100 
mM NaH2PO4 100 mM NaCl 5% CH3CN pH 7.2) using ʎ-DNA and NaN3 for determining 
void and total volume respectively. O-acetylation and glucosylation level of unconjugated 
OAg were calculated by 1H NMR and HPAEC-PAD analysis respectively.  
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Figure 3.6 OAg-ADH-SIDEA-CRM197 conjugation scheme. OAg is derivatized with adipic 
acid dihydrazide (ADH), then with adipic acid bis(N-hydroxysuccinimmide (SIDEA) and 
conjugated to CRM197. 
 
Immunogenicity of OAg-ADH-SIDEA-CRM197 conjugates in mice 
All the conjugates (Table 3.6) were tested in mice, with the objective to determine if 
OAg structural differences can impact on the immunogenicity of the corresponding 
glycoconjugate vaccines. 
When ELISA was performed using D23580 OAg as coating agent (Figure 3.7), all 
conjugates (except NVGH1791 and 2192 at 1 µg/dose) elicited anti-OAg IgG after 
the second immunization significantly higher than CRM197 alone used as negative 
control, and the immunoresponse was boosted after the third immunization. Higher 
antibody levels were detected at 8 µg/dose for all the conjugates, but for 1418 and 
2189, which exhibited similarly high anti-OAg levels at both 1 µg and 8 µg/dose 
(Figure 3.7). No statistically significant differences were found in anti-OAg IgG levels 
among all groups at 8 µg/dose. At 1 µg/dose, the only significant difference was 
found for 2189-conjugate which elicited higher anti-IgG units than LT2 (p=0.04) and 
NVGH1791 (p=0.04) conjugates.  
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Figure 3.7 Anti-OAg IgG ELISA units using D23580 OAg as coating agent. Individual 
animals are represented by the scatter plots; horizontal bars represent Geometric Mean 
Units. 
Sera collected at day 42 from groups immunized with 8 µg OAg per dose were tested 
in ELISA using OAg from all the other strains (LT2, NVGH1791, 1418, 2189 and 
2192) as coating agents (Figure 3.8). 2189 and 1418-conjugates elicited significantly 
higher anti-OAg IgG than D23580 when coating agents were LT2-OAg (p = 0.06), 
NVGH1791-OAg (p = 0.03)  and 2189-OAg (p = 0.06). Similar anti-OAg levels were 
detected for each immunization group when tested against all other coating agents, 
except for D23580-conjugate which showed a marked increase when tested against 
the homologous OAg (Figure 3.8). 
When ELISA was performed to detect anti-CRM197 IgG levels, as expected higher 
values were obtained with conjugates at 8 µg/dose, except with 1418 and 2189-
conjugates, for which anti-CRM197 levels were similar at 1 and 8 µg/dose (Figure 3.9), 
as found for anti-OAg antibodies. Unconjugated CRM197 elicited significantly lower 
antibodies than LT2, D23580, 1418, 2189-conjugates at 8 µg/dose. 
Sera collected at day 42 were also tested for serum bactericidal activity (SBA) 
against the Malawian human isolate D23580 strain (Figure 3.10). All the conjugates 
showed strong bactericidal activity, with as little as 0.1 (and less than this) ELISA 
anti-OAg antibody units. Increased SBA was found when sera from mice immunized 
with the homologous conjugate to D23580 strain was used, paralleling the strain-
specificity found by ELISA (Figure 3.10). When sera of conjugates obtained with OAg 
from animal isolates were tested against a broader panel of endemic strains, 2189 
and 1418 conjugates showed stronger activity that 2192 (data nit shown). This could 
be related to their higher glucosylation level or to the presence of a population at 
HMW. 
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Figure 3.8 Anti-OAg IgG ELISA units against all the tested S. Thyphimurium OAg coating 
agents (day 42 sera, 8 µg/dose). D23580 conjugate elicited mostly strain-specific anti-OAg 
antibodies. Individual animals are represented by the scatter plots; horizontal bars represent 
Geometric Mean Units. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Anti-CRM197 IgG ELISA units using CRM197 as coating agent coating agents (day 
42 sera). Individual animals are represented by the scatter plots; horizontal bars represent 
Geometric Mean Units. 
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Figure 3.10 SBA performed with pooled mouse sera from different immunization groups (8 
ug/dose, day 42) against D23580 strain. Data show bacterial growth inhibition by the 
immunized mice sera (heat-inactivated plus 50% BRS), normalized per anti-OAg antibody 
IgG ELISA units. SBA performed 3 times on 3 different days; graph represents the average 
of the triplicates. 
 
S. Enteritidis 
All S. Enteritidis conjugates were immunogenic in mice (Figure 3.11) and able to 
induce bactericidal activity. There was a large intergroup variation, with 1 non 
responder mouse in each group. This variability was reflected by anti CRM197 
antibody levels, which resulted lower than those obtained with S. Typhimurium 
conjugates. 
As expected, there was a lack of strain-specific responses (Figure 3.11), and this is 
not surprising considering the conjugates did not differ considerably in terms of OAg 
structural specificities (Table 3.5) in, although the anti-OAg IgG response induced by 
IV3453219 conjugate was lower at 8 ug/dose with respect to the other conjugates. 
 
Anti-OAg IgG ELISA units 
C
F
U
/m
L
 
44 
 
 
 
 
 
 
Figure 3.11 Anti-OAg IgG ELISA units against all the tested S. Enteritids OAg coating agents 
(day 42 sera). Individual animals are represented by the scatter points; horizontal bars 
represent Geometric Mean Units. 
 
 
 
3.5 Discussion 
As part of a NVGH project to develop a comprehensive conjugate vaccine against 
iNTS disease, OAg from different S. Typhimuirum and S. Enteritdis strains, major 
cause of iNTS infection in Africa, were fully characterized to investigate possible OAg 
heterogeneity related to the source and possible implication for the immunogenicity 
of corresponding conjugate vaccines. 
S. Typhimurium OAg were extracted from two lab strains (LT2 and NVGH1791), 
three animal isolates (1418, 2192 and 2189) and one human isolate (D23580). As 
reported in Table 3.1, all purified OAg were similar in terms of MW distribution, with 
two main populations at average MW 80–87 and 28–31 kDa respectively. Only 2192 
showed one main peak at average 34.5 kDa (Figure 3.1). Sugar analysis by HPAEC-
PAD and GLC–MS confirmed the composition of the tetrasaccharide repeating unit 
as Man, Gal, Rha and Abe. The analysis also showed strain specific variable 
amounts of glucosylation, ranging from 8% to 84%. The structure of the repeating 
unit was confirmed by linkage analysis which showed that the terminal Glc present 
was linked 1→4 and/or 1→6 to Gal, depending on the strain. All the OAg were O-
acetylated on C-2 Abe although to different extents depending on the strain, while 
D23580 was found to have additional OAc groups on C-2 and C-3 of Rha. The 
position of the OAc groups was established by GLC–MS (Figure 3.4) and NMR 
analysis (Figure 3.3). S. Enteritidis OAg were extracted from three animal isolates 
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(SA 502, IV3453219 and SA 618) and one human isolate (D24359). Contrary to what 
has been previously described (204) (205), S. Enteritidis isolates seemed to be more 
homogeneous than S. Typhimurium ones. In fact corresponding OAg were not only 
similar for average chain length (one prevalent population at average 29.6-32.6 kDa) 
but also for sugar composition, being all characterized by low glucosylation and O-
acetylation levels and the same O-acetylation position. (Table 3.5) 
The panel of analytical methods in place for OAg characterization performed on 
these samples will facilitate the screening of OAg structure and pattern of O-
acetylation for LPS from new strains.  
All the purified OAg were conjugated to CRM197 through the terminal KDO of the core 
region (Figure 3.6), in order to leave the OAg structure un-modified and look 
specifically at the impact of OAg specificities on the immunogenicity of the 
corresponding conjugates. It is known that saccharide structure is one of the 
parameter affecting the immunogenicity of conjugate vaccines (122). Few study have 
reported the impact of OAg O-acetylation on immunogenicity (100) (98) (185) and no 
studies have investigated on the impact of glucosylation level or position. The 
synthesized conjugates were characterized by a similar weight ratio of saccharide to 
protein, and the same carrier protein, conjugation chemistry, and MW distribution of 
the OAg (Table 3.6), so that differences in terms of immunogenicity can be attributed 
only to the different OAg structural specificities. 
When tested in mice, all the conjugates induced anti-OAg IgG antibodies with 
bactericidal activity against different NTS strains. For S. Enteritidis no differences 
were found among the conjugates, in agreement with the homogeneous structure of 
these OAg. For S. Typhimurium conjugates, differently to what has been reported in 
the literature (185), O-acetylation on C-2 and C-3 Rha seemed to affect 
immunogenicity, generating strain-specific antibodies, which cross-reacted with other 
OAg strains to a lesser degree (Figure 3.8). Paralleling the strain-specificity found in 
ELISA, increased SBA was found when the homologous conjugate to D23580 strain 
was used (Figure 3.10). 
Glucosylation of the OAg seems to be an important factor in inducing protection, with 
1418 and 2189 conjugates, characterized by the highest glucosylation level showing 
stronger SBA toward a broader panel of endemic strains when compared to 2912 
OAg similarly O-acetylated only on C-2 of Abe.  
This work indicates that the selection of the strain as OAg source for glycoconjugate 
vaccine production can be important, as different strains may result in candidate 
vaccines with different immunogenicities and antibodies with potentially different 
cross-reactivities. A screening of a larger number of strains would probably highlight 
better the importance of the OAg structure in affecting the immunogenicity of NTS 
glycoconjugate vaccines.  
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4. Impact of conjugation chemistry on the design 
of S. Typhimurium conjugate vaccines 
 
4.1 Abstract 
Salmonella Typhimurium is major cause of invasive nontyphoidal Salmonella in 
Africa. Conjugation of S. Typhimurium OAg to an appropriate carrier protein 
constitutes a possible strategy for the development of a vaccine against this disease, 
for which no vaccines are currently available. Conjugation chemistry is one of the 
parameters that can affect the immunogenicity of glycoconjugate vaccines. Herein 
different conjugates were synthesized, using CRM197 as carrier protein, to look at the 
impact of this variable on the immunogenicity of S. Typhimurium conjugate vaccines 
in mice. Random derivatization along the OAg chain was compared with site-directed 
activation of the terminal KDO sugar. In particular, two different random approaches 
were used, based on the oxidation of the PS with sodium periodate (NaIO4) and with 
2.2.6.6-tetramethylpiperidin-1-oxyl (TEMPO), which differentially impacted on the 
structure and conformation of the OAg chain. With regard to the selective conjugation 
methods, linkers of different length were compared.  
When tested in mice, all conjugates induced high levels of anti-OAg IgG antibodies 
with serum bactericidal activity. Similar anti-OAg antibodies titers were elicited 
independent of the chemistry used and a higher degree of saccharide derivatization 
did not impact negatively on the anti-OAg IgG response.  Serum bactericidal activity 
of the antibodies induced by selective conjugates was similar independent of the 
length of the spacer used. Random conjugates elicited stronger bactericidal 
antibodies than selective ones, and an inverse correlation was found between degree 
of OAg modification and antibodies functional activity.  
 
4.2 Introduction 
In many parts of Africa, NTS is the leading cause of bacteremia. Incidence of disease 
caused by different serovars varies depending upon the country but S. Typhimurium 
is overall the main cause of invasive disease (36) ((64). Antibodies directed against 
the OAg mediate killing of NTS (99) (206) (207) and confer protection against 
infections, and OAg glycoconjugate vaccines have been proposed as a vaccine 
strategy against Salmonella (98) (97). (208) (84).  
Synthesis of glycoconjugate vaccines requires covalent linkage of saccharide and 
protein components and the conjugation method used is one parameter that can 
affect the immunogenicity of the resulting vaccine (122). 
Conjugation methods proposed so far, even if differing for the functional groups and 
linkers involved, follow two main approaches: one based on random linkage of the 
protein to the saccharide chain, and the other one based on coupling of the protein to 
one single point of the saccharide (122) (209) (210) (168). Conjugation strategy is 
dependent on the functional groups present on both the sugar and the protein, and 
on their size. The choice of conjugation strategy and linker used can affect efficiency 
of conjugation, saccharide to protein ratio and glycoconjugate size, with consequent 
impact on immunogenicity (211) (212) (122). Investigating the impact of different 
chemistries on the immunogenicity can also allow a rational structure-activity based 
design of next-generation conjugates. 
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Covalent linkage of PS is generally achieved by targeting the amino groups of 
lysines, the carboxylic groups of aspartic/glutamic acids or the sulfhydryl of cysteines 
on the protein.  
Random approaches have been preferentially used for the conjugation of long 
carbohydrate antigens to proteins resulting in complex cross-linked and 
heterogeneous structures (Figure 4.1). Carboxylic or hydroxyl groups along the 
saccharide chain can be randomly activated by carbodiimide chemistry or 
cyanyilation respectively (213) (214). Alternatively, aldehydes generated on the PS 
by random oxidation can be used for reductive amination with the protein directly or 
with a linker  (215). 
Selective chemistries have been used for conjugation of shorter oligosaccharides, 
often obtained by partial hydrolysis of the native PS and fractionating a target MW 
population, and result in simplified and better defined structures of the final 
conjugates (Figure 4.1). Generally reductive amination of the terminal reducing sugar 
is performed, directly with the protein or more often using an appropriate spacer 
(216) (98). 
  
 
 
 
Figure 4.1 Schematic representation of different saccharide-protein chemical couplings 
(Figure reproduced from (122)). 
 
Based on Salmonella OAg structure (Figure 4.1), few methods have been proposed 
for the synthesis of corresponding conjugate vaccines and few studies have 
investigated the impact of this parameter on immunogenicity (98) (100) (180) (84).  
Random approaches are based on activation of the OH groups along the sugar chain 
by cyanilation using reagents such as cyanogen bromide (CNBr) or 1-Cyano-4-
dimethylaminopyridinium tetrafluoroborate (CDAP), followed by direct linkage to the NH2 
groups on the protein or by linkage to the carrier after introduction of linkers such as 
ADH and cystamine (98) (84) (100). Selective conjugates have been obtained by 
using the carboxylic or the ketone group of the terminal KDO unit. Linkers like 2-(4-
aminophenyl)-ethylamine, ADH, ADH/SIDEA, cystamine, diaminooxy cysteamine/N-
(-maleimidobutyloxy)-sulfosuccinimide ester have been introduced by carbodiimide 
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chemistry or reductive amination on the COOH or C=O group respectively (217) (98) 
(180) (84). 
Here we have compared different conjugation strategies for the linkage of S. 
Typhimurium OAg to CRM197 (178) as carrier protein and looked at the impact of the 
conjugation chemistries used on the immunogenicity of the resulting conjugates in 
mice. Two different oxidation methods and different degrees of oxidation have been 
compared, creating multiple points of attachment to the protein along the OAg chain, 
differently modifying the sugar structure (Figure 4.3a). Random chemistries have 
been compared with selective approaches, where only the terminal KDO unit of the 
sugar chain (Figure 4.3b) is involved in the linkage to the protein, leaving the OAg 
chain unmodified.  
 
 
Figure 4.2 Structure of the S. Typhimurium OAg chain linked to the core region. Core region. 
Structure taken from (218).  
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Figure 4.3 a) Structure of S. Typhimurium OAg chain and random derivatization by NaIO4 or 
TEMPO oxidation. The NaIO4-based oxidation affects vicinal diols to generate two aldehydes 
groups, opening the sugar ring. In the case of S. Typhimurium OAg, this reactivity can 
involve Rha and Glc residues. TEMPO oxidation targets primary alcohol groups, which in S. 
Typhimurium OAg are present in the sugar moieties of Man, Gal and Glc, one per 
monosaccharide. In both cases, the resulting aldehyde groups can then react with the lysine 
residues of the carrier protein to form a covalent C=N linkage, that is subsequently reduced 
to a stable C-N bond with NaBH3CN. A further step of reduction with NaBH4 was introduced 
to quench eventual unreacted C=O groups.  
b) OAg selective derivatization of the reducing end unit KDO. Reductive amination of KDO 
with NH4OAc or ADH, followed by SIDEA addition and conjugation to CRM197. The two 
investigated chemistries differ for the spacer length. 
 
 
4.3 Materials and methods 
Reagents 
The following chemicals were used in this study: triethylamine (TEA), adipic acid 
dihydrazide (ADH), sodium cyanoborohydride (NaBH3CN), sodium borohydride 
(NaBH4), sodium acetate (AcONa), dimethyl sulfoxide (DMSO), sodium phosphate 
monobasic (NaH2PO4), sodium chloride (NaCl), ammonium acetate (NH4OAc), 
sodium bicarbonate (NaHCO3), 2.2.6.6-tetramethylpiperidin-1-oxyl (TEMPO), 
trichloroisocyanuric acid (TCC), sodium periodate (NaIO4), N,N-dimethylformamide 
(DMF), hydrochloric acid 37% (HCl) [Sigma]; acetonitrile (CH3CN) [LC-MS 
Chromasolv]; adipic acid bis(N-hydroxysuccinimmide) (SIDEA) [PFANSTIEHL 
Laboratories]; absolute ethanol [Carlo Erba]. CRM197 was obtained from Novartis 
Vaccines and Diagnostics (NVD). 
b) 
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OAg purification and characterization 
S. Typhimurium OAg were purified as previously described (86), after fermentation of 
the animal isolate 2192, obtained from the University of Calgary, or of the laboratory 
strain LT2, obtained from the Novartis Master Culture Collection. OAg preparations 
were characterized by protein content <1% (by micro BCA), nucleic acid content < 
0.5% (by A260), endotoxin level < 0.1 UI/µg (by LAL). OAg structures were fully 
elucidated, as reported in Chapter 1 (203). In particular, 2192 OAg, used for the 
synthesis of the conjugates, was 100% O-acetylated on C-2 Abe and had an average 
molecular weight (avMW) distribution of 20.5 KDa, determined from the molar ratio of 
Rha (OAg chain) to GlcNAc (core sugar) and sugar composition analysis by HPAEC-
PAD and considering the level of O-acetylation by NMR analysis. OAg chains 
showed the presence of NH2 groups (NH2 to GlcNAc molar ratio % of 37.6), as 
detected by TNBS colorimetric method (219, 220), probably as 
pyrophosphoethanolamine residues in the core region (Figure 4.2). 
 
Synthesis of OAg-CRM197 glycoconjugates 
 
1) OAg-oxNaIO4-CRM197: random activation of the OAg chain with NaIO4 and 
conjugation to CRM197 
OAg (10 mg/mL in AcONa 100 mM pH 5) was stirred for 2h in the dark with 3.75 mM 
NaIO4. The mixture was desalted against water using a HiPrep™ 26/10 desalting 
column 53 mL, prepacked with Sephadex™ G-25 Superfine [GE Healthcare], and the 
pool eluted at the void volume of the column dried. The activated OAg was 
designated as OAg-oxNaIO4. For conjugation to CRM197, OAg-oxNaIO4 was added to 
CRM197 in NaH2PO4 100 mM pH 7.2 to have a final concentration of 10 and 5 mg/mL 
respectively (OAg-oxNaIO4:CRM197 = 2:1 w/w). NaBH3CN (NaBH3CN:CRM197 = 1:1 
w/w) was added immediately after, and the reaction mixture stirred ON at 37 °C. After 
this time, NaBH4 (OAg-oxNaIO4:NaBH4 = 1:1 w/w) was added and the mixture was 
stirred at 37°C for 2h. The conjugate was designated as OAg-oxNaIO4-CRM197.  
 
2) OAg-oxTEMPO-CRM197: random activation of the OAg chain with TEMPO and 
conjugation to CRM197 
OAg (3 mg/mL, corresponding to [CH2OH] of 7.69 mM) and NaHCO3 (19.47 mg/mL, 
molar ratio NaHCO3/CH2OH = 30), were added to a stirred solution of TEMPO (0.06 
mg/mL, molar ratio TEMPO/CH2OH = 0.05) in DMF. The reaction was cooled to 0 °C 
and TCC (2.88 mg/mL, molar ratio TCC/CH2OH = 1.6) was added. After 2 h of 
continuous stirring at 0 °C, the activated sugar was recovered from the reaction 
mixture by precipitation with EtOH (85% v/v in the final mixture). The pellet was 
washed twice with 100% EtOH (1.5 volumes with respect to the reaction mixture 
volume) and lyophilized. The activated OAg was designated as OAg-oxTEMPO2h. 
The same procedure, except for changing the reaction time from 2h to 12h, was used 
for the synthesis of OAg-oxTEMPO12h. For the reductive amination of OAg-
oxTEMPO2h and OAg-oxTEMPO12h with CRM197, the same conditions used for the 
conjugation of OAg-oxNaIO4 were applied. The two corresponding conjugates were 
designated as OAg-oxTEMPO2h-CRM197 and OAg-oxTEMPO12h-CRM197 
respectively. 
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3) OAg-ADH-SIDEA-CRM197: selective activation of the terminus KDO with ADH, 
followed by reaction with SIDEA and conjugation to CRM197  
The synthesis of this conjugate was performed as described in the Chapter 1. 
 
4) OAg-NH2-SIDEA-CRM197: selective activation of the terminus KDO with NH4OAc, 
followed by reaction with SIDEA and conjugation to CRM197  
OAg was solubilized in 500 mM NH4OAc pH 7.0 at a concentration of 40 mg/mL. 
NaBH3CN was added immediately (NaBH3CN:OAg = 2:5 w/w). The solution was 
mixed at 30°C for 5 days. Reaction mixture was desalted against water on a G-25 
column and OAg-NH2 was dried. The introduction of the second linker SIDEA and 
conjugation to CRM197 were performed as described for OAg-ADH-SIDEA-CRM197 
and the resulting conjugate was designed as OAg-NH2-SIDEA-CRM197. 
 
Conjugates purification 
All the conjugates were purified by hydrophobic interaction chromatography on a 
Phenyl HP column [GE Healthcare], loading 500 µg of protein for mL of resin in 50 
mM NaH2PO4 3M NaCl pH 7.2. The purified conjugate was eluted in water and the 
collected fractions were dialysed against 10 mM NaH2PO4 pH 7.2. 
 
Conjugates characterization 
Total saccharide was quantified by phenol sulfuric assay (195), protein content by 
micro BCA (using BSA as standard and following manufacturer’s instructions 
[Thermo Scientifics]) and the ratio of saccharide to protein calculated. OAg-CRM197 
conjugates profiles were compared with free CRM197 by HPLC-SEC (see Chapter 1 
for method description) and SDS-PAGE. Free protein was estimated by HPLC-SEC. 
A method for free saccharide determination is under development. 
Derivatized OAg intermediates were all characterized by phenol sulfuric assay for 
sugar content and by HPLC-SEC for verifying aggregation or degradation after 
modification (see Chapter 1 for method description). The intermediates for the 
synthesis of OAg-ADH-SIDEA-CRM197 and OAg-NH-SIDEA-CRM197 were 
characterized as previously described (Chapter 1). 6-aminohexanoic acid was used 
as standard for NH2 group quantification on OAg-NH2 by TNBS assay. 
Aldehyde groups introduced by oxidation with NaIO4 or TEMPO were quantified by 
1H NMR, HPAEC-PAD or micro BCA using Glc as standard (221).  
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Conjugation mixtures were analyzed by SDS-PAGE for verifying conjugate formation 
before performing purification. 7% Tris-acetate gels (NuPAGE, Invitrogen) were used. 
The samples (5-20 L with a protein content of 5-10 g) were mixed with 0.5 M 
dithiothreitol (1/5 v/v) and NuPAGE LDS sample buffer (1/5 v/v). The mixtures were 
heated at 100°C for 1 min.  The gel, containing loaded samples, was electrophoresed 
at 45 mA in NuPAGE Tris-Acetate SDS running buffer (20x, Invitrogen) and stained 
with Simply Blue Safe Stain (Invitrogen). 
 
O-Ag chain sugar composition analysis by High-Performance Anion-Exchange 
Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) (203) 
OAg-chain sugar composition was estimated by HPAEC-PAD after acid hydrolysis of 
the OAg (free and conjugated) samples to release the monomers that constitute the 
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saccharide chain. Rha, Gal, Glc and Man present in the OAg chain were quantified 
by this method, together with GlcNAc present as a unique sugar in the core region. 
Analysis of OAg samples after oxidation with NaIO4 allowed determining the % of 
Rha and Glc units oxidized, comparing the molar ratio of these monomers to Man 
before and after the oxidation. 
 
1H NMR spectroscopy (203) 
Nuclear Magnetic Resonance (NMR) analysis was used as a confirmation of the 
identity of the OAg samples (typical signals of the OAg chain can be detected, 
confirming the presence of the characteristic sugars) and in particular for calculating 
the molar ratio of Rha to Abe by comparing the integrals of the two peaks 
corresponding to Rha-H6 and Abe-H6, at 1.36 and 1.23 ppm respectively. O-
acetylation level of OAg samples before and after conjugation can be estimated by 
NMR too. NMR was also used to quantify the % of Rha units oxidized with NaIO4 as 
the peak of Rha-H6 of modified Rha units shifts at lower ppm and overlapps the peak 
of Abe-H6 at 1.2 ppm. Comparing the integrals of the peaks at 1.36 and 1.23 ppm 
before and after oxidation, it was possible to quantify the % of Rha units modified. 
 
Immunogenicity studies in mice 
Seven groups of 8 C57BL/6 5-weeks female mice purchased from Charles River 
Laboratory and maintained at NVD Animal Care received three subcutaneous 
immunizations at 14 days-interval with 200 µL/dose of 1 µg of OAg (5 µg/mL). 
Mice were bleed before first immunization (day 0) and on immunization days 14 and 
28. Mice were scarified and sera collected 2 weeks after 3rd immunization, on day 42. 
All animal protocols were approved by the local animal ethical committee (approval 
N. AEC201018) and by the Italian Minister of Health in accordance with Italian laws. 
 
Serum antibody analysis by ELISA 
Serum IgG levels against both OAg and CRM197 were measured by ELISA (222) 
(180). Purified OAg from 2192 (5 µg/mL) and CRM197 (2 µg/mL) were used for ELISA 
coating. Mouse sera were diluted 1:200 in PBS containing 0.05% Tween 20 and 
0.1% BSA. ELISA units were expressed relative to mouse anti-OAg or anti-CRM197 
standard serum curves, with best 4 parameter fit determined by modified Hill Plot. 
One ELISA unit was defined as the reciprocal of the standard serum dilution that 
gives an absorbance value equal to 1 in this assay. Each mouse serum was run in 
triplicate on 3 different ELISA plates. Data are presented as scatter plots of individual 
mouse IgG ELISA units, and geometric mean of each group. IgM and IgG subclasses 
antibodies were detected using a similar ELISA procedure: all the secondary 
antibodies were diluted 1:1000 in PBS containing 0.05% Tween 20 and 0.1% BSA, 
incubated 30min at room temperature followed by a further incubation of 30min at 
room temperature of the tertiary antibody antigoat AP-labeled diluted 1:30000 in the 
same dilution buffer. As only anti-OAg IgG standard reference serum was available 
for specific unit determination, IgM and IgG subclasses antibodies are presented as 
ELISA absorbance values. 
 
Serum bactericidal activity (SBA) 
Equal volumes of day 42 mouse serum, belonging to the same immunization group, 
were pooled together for SBA experiments.  S. Typhimurium D23580 strain was 
grown in Luria Bertani (LB) medium to log-phase (OD: 0.2), diluted 1:30,000 in SBA 
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buffer (50 mM phosphate; 0.041% MgCl2 6H2O; 33 mg/mL CaCl2; 0.5% BSA) to 
approximately 3 X 103 colony forming units (CFU)/mL and distributed into sterile 
polystyrene U bottom 96-well microtiter plates (12.5 µL/well). To each well (final 
volume 50 µL, ~620 CFU/mL), serum samples serially diluted 1:3 (starting from 1:20-
1:100 dilution) were added. Sera were heated at 56ºC for 30 min to inactivate 
endogenous complement. Active Baby Rabbit Complement (BRC, Pel-Freez lot 
0405/lot 12521) used at 50% of the final volume was added to each well. BRC 
source, lot and percentage used in SBA reaction mixture were previously selected by 
lowest toxicity against S. Typhimurium. To evaluate possible nonspecific inhibitory 
effects of BRC or mouse serum, bacteria were also incubated with: a. the same 
tested sera plus heat-inactivated BRC (HI-BRC); b. sera alone (no BRC); c. SBA 
buffer and active BRC.  Each sample and control was tested in triplicate. Seven 
microliter reaction mixtures from each well was spotted on LB-agar plates at time 
zero (T0) to assess initial colony forming units (CFU), and at 1.5 h (T90) after 
incubation at 37ºC. LB-agar plates were incubated overnight at 37ºC and resulting 
CFU were counted the following day. Bactericidal activity was determined as CFU 
counted in each pooled serum dilution with active/inactive BRC, compared with CFU 
of the same sera dilutions with no BRC. SBA graphs show the inhibition of bacterial 
growth as a function of anti-OAg ELISA units detected in each tested serum pool. 
 
Flow cytometry  
Bacteria were grown overnight in LB medium, diluted to OD: 0.17 and incubated in 
1:200 diluted (PBS 1% BSA) serum samples (CFU: 3x106 in 50 µL) for 1 h in ice. 
After washing with PBS, bacteria were incubated with secondary anti-mouse APC-
labeled antibody (Invitrogen, 1:400 in PBS 1% BSA) for 1 in ice. After washing, 
bacteria were resuspended in 4% formaldehyde (130 µL) and then read using a 
FACS CANTO (BD Biosciences) flow cytometer (10,000 events recorded). Negative 
control was obtained by incubating bacteria with secondary antibody only. Values 
were obtained by dividing the geometric mean of fluorescent signals of positive 
bacteria compared to negative control.  
  
4.4 Results 
 
OAg oxidation with NaIO4 and reductive amination with CRM197 
The NaIO4-based oxidation affects vicinal diols to generate two aldehydes groups, 
opening the sugar ring. In the case of S. Typhimurium OAg, this reactivity can involve 
Rha and Glc residues (Figure 4.3a). The resulting aldehyde groups can hence react 
with the lysine residues of the carrier protein to form a covalent C=N linkage, that is 
subsequently reduced to a stable C-N bond with NaBH3CN. A further step of 
reduction with NaBH4 was introduced to quench eventual unreacted C=O groups.  
 
Optimization of conjugation conditions working with LT2 OAg 
OAg purified from S. Typhimurium LT2 (a lab strain) was used for testing different 
conditions for this conjugation approach. Different NaIO4 concentrations were tested 
to obtain OAg with a different derivatization grade. With increasing concentration of 
NaIO4, increasing % of activation were obtained (Table 4.1), expressed as molar ratio 
% of oxidized Rha to total Rha. LT2 OAg has a very low degree of glucosylation 
(molar ratio of Glc to Rha = 0.11) and % of activated repeating units was calculated 
looking at Rha units modified only, both by HPAEC-PAD and 1H NMR (Figure 4.4). A 
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good correlation was found between the two methods used (Table 4.1). Higher OAg 
derivatization resulted in a shift of the peaks at lower MW, indicating partial 
depolymerization of the OAg chain after this treatment or a change in its 
conformation (Figure 4.5 and Table 4.1).  
 
Table 4.1 OAg oxidation using different NaIO4 concentration resulted in 
differently derivatized products 
[NaIO4] 
(mM) 
% 
oxidized 
sugar 
recovery 
% activation 
(HPAEC-PAD) 
% 
activation 
(NMR) 
Kd 
(HPLC-SEC) 
1.87 87 4 2.8 0.19 and 0.30 
3.75 92 14 12 0.20 and 0.31 
7.5 92 35 35 0.22 and 0.34 
% of activation was calculated as molar ratio % of oxidized Rha residues 
to total Rha. Kd values for the two main peaks of the underivatized OAg 
of 0.18 and 0.29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Characterization of LT2 OAg-oxNaIO4 by 
1H NMR (RT, 500 MHz) in comparison 
to the corresponding underivatized OAg. Signal at 1.23 ppm corresponding to CH3 Abe 
overlapped with CH3 of modified Rha units in oxidized samples. 
 
 
 
Underivatized OAg 
LT2 OAg-oxNaIO4 (35%) 
LT2 OAg-oxNaIO4 (14%) 
LT2 OAg-oxNaIO4 (4%) 
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Figure 4.5 HPLC-SEC (dRI) chromatograms of the different products obtained by oxidation 
of LT2 OAg with NaIO4. TSKgel 3000 PWXL column, 0.5 mL/min, 100 mM NaCl 100 mM 
NaH2PO4 5% CH3CN pH 7.2; Vtot 23.29 min; V0 11.20 min 
 
 
All the derivatized OAg obtained were tested for conjugation, to see if a different 
degree of derivatization could affect conjugation to the protein.  
Different conjugation conditions were tested varying OAg to CRM197 ratio, the 
concentration of LT2 OAg-oxNaIO4 and the concentration of CRM197 (Table 4.3). All 
the conjugations were performed in 100 mM Na2HPO4 pH 7.2 and adding NaBH3CN 
1:1 w/w ratio with the OAg. Conjugation mixtures were gently mixed overnight at 
37°C and then analyzed by SDS-PAGE (Figure 4.6) and HPLC-SEC to verify 
conjugate formation. Table 4.3 summarizes the results obtained. When SDS-PAGE 
and HPLC-SEC analysis did not show the presence of unconjugated protein in the 
mixture, conjugates were purified by HIC, and characterized.  
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Working with LT2 OAg-oxNaIO4 with the highest degree of oxidation (35%), and with 
a protein concentration of 5 mg/mL, only the OAg/CRM197 w/w ratio of 2:1 (exp. 1-3) 
allowed all protein conjugation. Maintaining the OAg to CRM197 ratio constant and 
increasing CRM197 concentration to 10 mg/mL did not make any difference (exp. 4 vs 
1), while at 20 mg/mL (exp. 5), protein precipitation was observed, indicating that 
high reagent concentrations should be avoided. All the purified conjugates (exp 1, 4 
and 5) were characterized by the same OAg to CRM197 ratio of 0.5 (w/w) and when 
no precipitation happened, by similar saccharide and protein recoveries. 
Also working with LT2 OAg-oxNaIO4 14% oxidized (exp. 7 and 8), all the protein was 
conjugated when a w/w ratio of OAg to CRM197 of 2:1 was used in the reaction. With 
a ratio of 1:2, even increasing the protein concentration to 10 mg/mL, not all the 
protein was conjugated.  
Using the same conditions in term of reagents concentration and OAg to CRM197 
ratio in the reaction mixture, the different % of OAg modification did not affect protein 
and OAg recoveries (exp. 1 and 8), like the OAg to CRM197 ratio in the purified 
conjugates, which were similar. Working with the less derivatized LT2 OAg-oxNaIO4 
(4%), in both tested conditions (exp. 9-10), protein precipitation was observed, 
probably indicating that OAg activation was not sufficient for conjugation to CRM197, 
which subsequently precipitated in the reaction conditions. 
Activation of 14% seemed the most appropriate condition for assuring sufficient 
quantities of activated groups for conjugation, without altering consistently the OAg 
Table 4.3 Conjugation performed with LT2 OAg-oxNaIO4 and CRM197 
n° 
exp. 
% 
oxidation 
OAg 
OAg/CRM197 
(w/w) 
[OAg] 
(mg/mL) 
[CRM]197 
(mg/mL) 
Free 
CRM197 
in the 
conj 
mixture 
CRM197 
recovery in 
the 
purified 
conj 
(%) 
OAg/CRM197 
in the 
conjugate 
(w/w) 
1 35% 2:1 10 5 No 70,1 0,54 
2 35% 1 :1 5 5 Yes   
3 35% 1:2 2,5 5 Yes   
4 35% 2:1 20 10 No 66,8 0,52 
5 35% 2:1 40 20 No* 25,8 0,49 
6 35% 1:2 5 10 Yes   
7 14% 1:2 5 10 Yes   
8 14% 2:1 10 5 No 78 0,65 
9 4% 1:2 5 10 Yes*   
10 4% 2:1 10 5 No* 32,2 1,11 
* protein precipitation was observed in the reaction mixture 
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chain structure, that could have a consequent negative impact on immunogenicity. 
This was selected as the condition for the production of the conjugate to test in mice. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 SDS-PAGE analysis of OAgox-CRM197 conjugation mixtures (1-8) in comparison 
to unconjugated CRM197 (C) and conjugation performed by direct reductive amination without 
oxidizing the sugar (0). Five g of protein were loaded per well.  
 
 
2192 OAg oxidation with NaIO4 and conjugation to CRM197 
The HPLC-SEC profile of the oxidized 2192 in comparison with the underivatized 
OAg showed a shift of the main peak to a slightly lower MW. According to micro BCA, 
which constitutes a quick test to determine whether the oxidation has happened, 14% 
of OAg repeating units resulted derivatized (calculated as number of oxidized 
monomers/total Rha *100). HPAEC-PAD analysis stated that respectively 14% of the 
Rha and 6.4% of the Glc units were oxidized, corresponding to 15.5% of repeating 
units modified. NMR was not used in this case as it does not allow determination of 
the % of Glc oxidized present for 24% of OAg repeating units of 2192 OAg. 
Performing the conjugation reaction with conditions n° 8 reported in Table 4.3, all 
CRM197 was conjugated and residual free OAg was removed by purification through 
HIC. HPLC-SEC analysis showed the shift of the conjugate at HMW in comparison to 
free protein (Figure 4.7) and free OAg and was used for estimating conjugate MW 
distribution (Table 4.4). 
 
0 C 1 M 2 3 4 5 6 
0 C 1 M 2 3 4 5 6 7 8 
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Figure 4.7  HPLC-SEC (fluorescence emission profiles) of free CRM197 (a); purified selective 
conjugates OAg-ADH-SIDEA-CRM197 (dashed line) and OAg-NH-SIDEA-CRM197 (solid line) 
(b); and random conjugates OAg-oxTEMPO2h-CRM197 (dashed line), OAg-oxTEMPO12h-
CRM197 (solid line) and OAg-oxNaIO4-CRM197 (dotted line). TSKgel 6000 PW + 5000 PW, 0.5 
mL/min, 100 mM NaCl 100 mM NaH2PO4 5% CH3CN pH 7.2; Vtot 49.004 min; V0 24.382 
min. 
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Table 4.4 O:4,5-CRM197 conjugates generated using different chemistry 
Conjugate 
OAg/CRM197 
(w/w) 
OAg/CRM197 
(mol/mol) 
Kd conjugate 
(HPLC-SEC) 
OAg-oxNaIO4(14%*)-CRM197 0.72 2.05 0.57 
OAg-oxTEMPO2h(15%*)-CRM197 0.56 1.6 0.44 
OAg-oxTEMPO12h(36%*)-CRM197 0.38 1.08 0.50 
OAg-NH2-SIDEA-CRM197 1.42 4.05 0.50 
OAg-ADH-SIDEA-CRM197 1.74 4.96 0.49 
Kd values were calculated on a TSKgel 6000 PW + 5000 PW, 0.5 mL/min,  100 mM NaCl 
100 mM NaH2PO4 5% CH3CN pH 7.2; Vtot 49.004 min; V0 24.382 min; Kd of free CRM197: 
0.72; Kd of free 2192 OAg: 0.67. * % repeating units oxidized calculated by micro BCA. 
 
 
Is NaBH3CN able to reduce residual unreacted aldehydes groups on the sugar 
chains? 
To verify if NaBH3CN, used for the reductive amination of OAgox with CRM197, was 
able to reduce residual unreacted aldehydes groups on the sugar chains, the 
reduction of OAg-oxNaIO4 with NaBH3CN was performed using the same conditions 
adopted during the conjugation step, but without adding CRM197. Aldehyde 
determination by micro BCA showed that carbonyl groups were not reduced. To 
quench the unreacted CHO groups remained after conjugation, NaBH4 was tested as 
reducing agent. NaBH4 was mixed with OAg-oxNaIO4 (NaBH4/OAg-oxNaIO4 = 1:1 
w/w) in NaH2PO4 100 mM pH 7.2 at 37°C, and the presence of aldehydes groups 
was verified after 2h and ON reaction. Already after 2h, there were no residual 
carbonyl groups. Analysis by HPAEC-PAD confirmed that the sugar composition of 
the OAg was not affected by this treatment. Therefore a 2h reduction step with 
NaBH4 (NaBH4/OAg-oxNaIO4 = 1:1 w/w, 37 °C) was added after the ON conjugation 
by reductive amination. HPL-SEC profiles of the untreated and NaBH4-reduced 
conjugates were identical (data not shown).  
 
OAg oxidation with TEMPO and reductive amination with CRM197 
The oxidation of 2192 OAg with TEMPO was tested in order to have random 
formation of CHO groups along the chain without opening the sugar rings as 
oxidation with NaIO4 does (Figure 4.3 a). TEMPO oxidation targets primary alcohols 
groups, which in S. Typhimurium OAg are present in the sugar moieties of Man, Gal 
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and Glc, one per monosaccharide. The resulting aldehyde groups can then react with 
the lysine residues of the carrier protein by reductive amination (Figure 4.3 a).  
Oxidation of 2192 OAg with TEMPO was followed over time and the % of OAg 
monomers oxidized increased from 15% after 2h to 36% after 12h (as detected by 
micro BCA). HPLC-SEC analysis showed that OAg MW distribution remained 
unchanged after oxidation, even when the reaction was performed for longer times, 
differently from what was obtained with NaIO4. 
OAg-oxTEMPO with an average percentage number of oxidized repeating units of 
36% (12h of reaction) and 15% (2h of reaction) were considered for further 
conjugation to CRM197, to look also at the impact of OAg derivatization degree on the 
immunogenicity of the corresponding conjugates.  
The same conditions for the conjugation and purification of OAg-oxNaIO4 were 
applied and in both cases all CRM197 resulted conjugated in the reaction mixtures. 
Conjugates obtained using a less derivatized OAg (both after treatment with NaIO4 or 
TEMPO) were characterized by a higher OAg to protein ratio respect with the 
conjugate obtained with the OAg more oxidized that was able to link more CRM197 
molecules (Table 4.4). 
 
Selective conjugation chemistries 
The terminal KDO residue of the core region was used for selectively linking the OAg 
to the protein without modifying the OAg chain. In one case, reductive amination with 
ADH was followed by reaction with SIDEA and conjugation to CRM197 (Figure 4.3b). 
A similar chemistry was also evaluated where the first step of reductive amination 
was conducted with NH4OAc, allowing the synthesis of a conjugate with a shorter 
linker than ADH-SIDEA (Figure 4.3b). 
The reactivity of OAg-KDO with NH4OAc was tested at pH 4.5 and pH 7.0 (124) (180) 
(Table 4.5).  
 
 
Table 4.5 OAg amination with NH4OAc comparing different reaction conditions 
 
[2192] 
(mg/mL) 
[NaBH3CN]/OAg 
w/w ratio 
 
[NH4OAc] 
(M) 
pH 
 
 
Reaction 
time 
(h) 
 
% activated OAg  
(KDO) 
 
40 1.2 0.5 4.5 
3 37.6 
24 34.0 
120 44.3 
40 2.5 0.5 7 
3 66.8 
24 80.0 
120 97.5 
 
 
Differently from ADH (180), NH4OAc gave higher activation yields at pH 7.0, in line 
with what was expected based on the % of amino groups protonated at the two 
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different pH for the two different molecules (pKa NH3 = 9.23, pKa ADH  = 2.5). At pH 
7.0, the activation degree was 67% after only 3h and 80% after 24h, indicating a 
higher reactivity of the KDO unit with respect to terminal reducing groups of other 
polysaccharide chains, that require longer reaction times and give often lower 
derivatization (124) (223). 
For the synthesis of the corresponding conjugate, the reaction of 2192 OAg with 
NH4OAc was performed for 5 days resulting in 90% of OAg chains activated and in a 
sugar recovery of 85%. Working with ADH, a sugar recovery of 80% was obtained 
with activation close to 100%, with free ADH < 5% in moles. The longer linker with 
the hydrazide functionality allowed performing the reaction in only 2h at pH 4.5. After 
the step of reductive amination, the second linker SIDEA was introduced in the same 
way for both the products. A sugar recovery >80% was obtained, with >90% of total 
NH2 groups reacted with SIDEA and free SIDEA determined to be <10% in moles, for 
both OAg-NH2 and OAg-ADH. TNBS analysis confirmed the presence of < 10% 
unreacted NH2 groups. The same conjugation conditions were applied to OAg-NH2-
SIDEA and OAg-ADH-SIDEA. The analysis of the conjugation mixtures by HPLC-
SEC confirmed conjugate formation without residual free protein in both cases. 
Unconjugated OAg was removed by HIC. The resulting conjugates were very similar 
in terms of OAg to CRM197 ratio (4-5 OAg chains linked per protein) and Kd values 
(Table 4.4, Figure 4.7). Both selective conjugates were characterized by a higher 
OAg to protein ratio than all the random conjugates (Table 4.4). 
 
Immunogenicity study in mice of OAg-CRM197 comparing different conjugation 
chemistries 
The synthesized conjugates were tested in mice, with three main objectives: 
1. compare the immunogenicity of random and selective conjugates; 
2. analyze the impact of linker chain length on the immunogenicity of conjugates 
obtained by selective linkage of the OAg through its terminal KDO unit; 
3. evaluate if the degree of random modification of the OAg chain can have an 
impact on immunogenicity.  
After three doses, all the conjugates generated high anti-2192 OAg IgG levels not 
statistically different among the groups (Figure 4.8a). Selective conjugates induced a 
similar anti-OAg IgG response compared with random conjugates and a stronger 
modification of the OAg chain did not negatively affect the immune response in mice. 
Also no differences were found regardless of the length of the linker when OAg-ADH-
SIDEA-CRM197 was compared to OAg-NH2-SIDEA-CRM197. 
Subclass antibody analysis showed that anti-2192 OAg IgG1 was the predominant 
subclass in sera from mice vaccinated with all the conjugates (Figure 4.8b), as 
expected for glycoconjugate antigens. No IgA was detected in any sera, while 
increased anti-2192 OAg IgM levels were detected at day 42 for OAg-TEMPOox 
conjugates with respect to the other groups (Figure 4.8c). 
For all the conjugates, anti-CRM197 IgG levels were very low after the first injection 
and boosted after the second dose. Already after two doses, anti-CRM197 IgG 
responses for OAg-oxTEMPO-CRM197 conjugates were higher than for the other 
groups, in line with the higher dose of protein injected compared with the other 
groups (Figure 4.8d). However at day 42, differences were significant only between 
OAg-NH2-SIDEA-CRM197 and OAg-ADH-SIDEA-CRM197 with OAg-oxTEMPO2h-
CRM197 (p=0.0025). 
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Figure 4.8 (a) Anti-OAg IgG ELISA units against 2192 OAg coating agent. Individual animals 
are represented by the points; horizontal bars represent Geometric Mean Units. (b) Anti-OAg 
IgG subclasses absorbance values against 2192 OAg coating agent (c) Anti-OAg IgM 
absorbance values against 2192 OAg coating agent. Horizontal bars represent Mean ± SD. 
(d). Anti-CRM197 IgG ELISA units against CRM197 coating agent. 
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To evaluate functional activity of elicited antibody, sera collected at day 42 were 
pooled and tested for SBA against S. Typhimurium D23580, a Malawian clinical 
isolate.. All the conjugates showed strong bactericidal activity with complete killing 
achieved with less than 0,01 IgG ELISA units, but with different extent depending on 
the conjugation chemistry used. To evaluate bactericidal specificity of the antibodies 
elicited by the various conjugates, inhibition of bacterial growth was plotted per anti-
OAg IgG units as measured by ELISA. This highlights the different functional activity 
of antibodies independent of their absolute amount (Figure 4.9). Bactericidal activity 
of the antibodies induced by selective OAg-KDO conjugates was similar independent 
of the length of the spacer used, while all the random conjugates elicited stronger 
bacterial growth inhibition than the selective conjugates. Interestingly, heavier 
modifications of the OAg chain resulted in conjugates producing a weaker 
bactericidal activity. To evaluate possible differences in cell-surface binding, pooled 
sera at day 42 from mice immunized with the different conjugates were tested by 
FACS against the homologous 2192 and two additional heterologous strains (both 
invasive clinical isolates). As shown in Figure 4.10, all sera could bind the 3 strains, 
with a bigger shift of the signal observed for random conjugates. This result indicates 
that the increased SBA found with the random conjugates may be due to a stronger 
binding affinity of the antibodies generated by those conjugates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 SBA analysis of pooled sera at day 42: CFU/mL of D23580 strain versus  
anti-OAg  IgG ELISA units. 
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Figure 4.10 Flow cytometry analysis of surface staining of live Ke238, D23580 and 2192. 
Bacteria were stained with mice day 42 pooled immune sera raised against the different 
conjugates. Sera dilution is 1:200. Target bacteria were fixed after staining. Representative 
results of three experiments are shown. 
 
4.5 Discussion 
There is increasing awareness of the significance of NTS disease as a major public 
health concern in the developing world (Feasey et al., 2012; MacLennan and Levine, 
2013; Okoro et al., 2012a). While responsible for gastroenteritis in high-income 
countries, NTS are a common cause of fatal invasive disease in low-income 
countries, particularly in Africa. Currently no vaccines are available against this 
disease and conjugation technology is one of the approaches followed at the moment 
for the development of a vaccine (84) (85) (203).  
Conjugation chemistry is one of the parameters that can impact on the 
immunogenicity of the corresponding conjugate vaccines (122). In this study the 
immunogenicity in mice of S. Typhimurium OAg-CRM197 conjugate vaccines obtained 
by different methods has been investigated. Random derivatization along the sugar 
chain was compared with one-site linkage at the terminus of the core region. 
Regarding selective approach, the length of the spacer between the sugar and the 
protein moieties was evaluated. For the random approach, a milder oxidation by 
TEMPO was compared to oxidation with NaIO4 that opens the sugar units impacting 
more on the OAg epitopes and conformation. Different percentages of OAg 
derivatization were also compared. 
In general selective chemistry is preferred because of consistency of production and 
characterization of the final product, but suffers from lower yields in terms of OAg 
sugar recovery with respect to random approaches. From a process point of view, all 
the conjugation methods tested here resulted in no residual free protein in the 
conjugation mixture. In all the procedures the carrier protein was not derivatized, but 
one step less was required for the production of random conjugates with respect to 
Ke238 D23580 2192 
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selective ones, even if sugar recoveries were good for all the derivatization steps 
performed. Much less OAg was required (w/w respect to the protein) for the random 
chemistries, with the advantage in terms of total sugar amount required for 
conjugation (about 1/5 of the sugar required for the selective approach). OAg 
conjugation yields did not improve much even when random chemistries were used 
(19-36% with respect to 15-17% for selective approaches), but consistently improved 
considering the total amount of sugar required for performing the reaction. 
Random conjugates were all characterized by lower OAg to protein ratios than 
selective conjugates (Table 4.4), in line with the presence of more points of 
attachment for the protein along the sugar chain.  
When tested in mice all the conjugates induced similar anti-OAg IgG antibodies titers 
independent from the chemistry used, and a strong modification along the sugar 
chain that could potentially impact on OAg epitopes integrity and conformation, did 
not negatively affect the immunogenicity. Random conjugates induced stronger 
bactericidal antibodies than selective ones, and FACS analysis confirmed that 
random derivatization did not impact on the ability of the corresponding conjugates to 
induce antibodies able to recognize structural epitopes. However, among the random 
conjugates, there was an inverse correlation between degree of derivatization and 
bactericidal activity of the antibodies induced. Although all the conjugates induced 
similar anti-IgG antibodies, the anti-OAg IgM levels were different, and were higher 
for TEMPO conjugates after three doses. 
Simon et al., working on S. Enteritidis conjugates, did not find differences in terms of 
antibody response and protection comparing in mice flagellin monomers conjugates 
obtained by direct random linkage or selective chemistry on the terminal KDO with a 
long linker (84). Micoli et al. also found no differences in terms of IgG titers testing in 
mice S. Paratyphi A OAg conjugates obtained by selective ADH-SIDEA chemistry or 
by random activation through CDAP and using ADH as linker (180). In this case, 
selective conjugates gave stronger bactericidal titers than random ones (180). It is 
important to underline that random derivatization by CDAP can also create sugar 
cross-linking (98). Differently, it was found that S. Typhimurium OAg-TT and S. 
Paratyphi A OAg-CRM197 conjugates produced by random activation and ADH linker 
were more immunogenic in mice than when selective chemistry with ADH linked to 
the COOH group of KDO was used (98) (180). According to Watson, immunogenicity 
is also affected by the number of OAg units modified with ADH, resulting in different 
OAg to protein ratios in the conjugates too. In this study, the difference on the 
immunogenicity profile obtained could be related to the different amount of carrier 
protein injected for the different conjugates (higher for the random than for the 
selective conjugates at the same OAg dose) or to the different structure of the 
conjugate itself: a sun-structure for the selective conjugates with few points of linkage 
between the saccharide and the protein per molecule of conjugate, against a cross-
linked heterogeneous structure for the random conjugates with possible formation of 
much more glycopeptides after processing in the B-cells. Recently it has been 
reported that T cell populations can recognize carbohydrate epitopes derived by APC 
processing of conjugate vaccines and that, when presented by MHCII, these 
epitopes recruit T cell help for the induction of adaptive immune responses. The 
outcome of this work suggests that vaccines with optimal, high-density presentation 
of carbohydrate epitopes could have a major role in prevention and control of many 
diseases (142). A random-like conjugate is likely to produce a higher number of 
glycan-peptide units than a selective one, and this could be related to the present 
results. 
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Different chemistries could also impact on the conformation of the conjugate 
components, impacting on the exposure of sugar and carrier epitopes. Furthermore, 
both the selective conjugates were characterized by the presence of a long linker 
between the sugar and the protein (NH2-SIDEA or ADH-SIDEA), while no linker was 
used for the synthesis of the random conjugate and the presence of the linker could 
be an additional factor affecting immunogenicity (100) (180). 
This study underlies the importance of conjugation chemistry in the design of S. 
Typhimurium OAg-based glycoconjugate vaccines, and suggests that a random 
strategy could be optimum. More investigations on the reasons behind this 
immunological outcome are currently ongoing in our lab. A better knowledge of the 
effective structure of the conjugates tested and the design of more defined conjugate 
vaccines could help to further understand the relation between conjugate structure 
and immunogenicity results. 
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5. Click chemistry: a powerful tool for the 
synthesis of glycoconjugate vaccines 
 
 
5.1 Abstract 
Well defined glycoconjugate vaccines, selectively modified not only on the 
saccharide but also on the protein component, are highly desirable in terms of 
consistency of production, optimal characterization of the vaccine and to facilitate 
studies of immunological mechanism. In this study we have looked for a powerful 
conjugation method that allows synthesis of such well-defined glycoconjugates, since 
selective chemistries are usually characterized by low conjugation efficiencies. The 
process was developed for the conjugation of S. Typhimurium OAg to CRM197 as 
carrier protein. Two strategies were initially investigated, both involving the linkage of 
the terminal KDO unit of the sugar to the protein: thiol chemistry and click chemistry. 
Thiol chemistry did not allow conjugation unless starting with a relative high number 
of linkers on the protein, while click chemistry allowed conjugate generation even 
when just one position on the protein was activated.  
Another advantage of the click chemistry was the possibility to recycle unconjugated 
OAg and use it for the synthesis of a new batch of glycoconjugate. Furthermore a 
solid-phase conjugation method utilizing the carrier protein bound to an ion exchange 
matrix was developed. CRM197 was adsorbed to the matrix using a batch procedure, 
and the immobilized protein was then conjugated to the OAg. Unreacted OAg was 
easily recovered and used for further conjugation, while the conjugate was eluted 
from the resin pure from both free protein and free sugar. This process has great 
advantages in terms of cost for vaccine production, allowing unreacted sugar 
recovery and simplifying the purification of the conjugate itself.  
 
 
5.2 Introduction 
“Click chemistry is a set of powerful, virtually 100% reliable, selective reactions for 
the rapid synthesis of new compounds via heteroatom links (C-X-C)…” (224). One of 
these reactions, the Huisgen 1,3-dipolar cycloaddition (225), has become the most 
popular click reaction, especially because it can proceed rapidly at room temperature 
by employing copper as a catalyst (226) (227). It is characterized by mild reaction 
conditions, high yields and simple work-up, selectivity and specificity and can be 
usually performed in water. The possibility of applying click chemistry in 
bioconjugation was first demonstrated for the preparation of peptidotriazolels via solid 
state synthesis (37). One of the most important properties of the click chemistry is its 
bio-orthogonality. The azide moiety is absent in almost all naturally existing 
compounds, lacks reactivity with natural biomolecules and undergoes ligation only 
with a limited set of functionalities, such as alkyne groups. Despite some concerns 
about stability of azide derivatives, possible immunogenicity of the spacers used, the 
need for a toxic metal in some applications, and the alkyne homocoupling side 
reaction, this reaction is very likely to be greatly used in the design of future drugs 
and biomolecules due to its specificity and effectiveness.  
Looking at the glycoconjugate vaccines licensed or in advanced development in the 
EU, US and WHO, it can be deduced that four main strategies of conjugations are 
generally used: reductive amination, active ester chemistry, thiol chemistry and 
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carbodiimide-mediated condensation (127). Conjugation often results in a mixture of 
glycoproteins due to the heterogeneity of the carbohydrate haptens and to the 
random activation along the sugar chains and on the protein. Resulting glycoforms 
may present diverse pharmacokinetic and immunological properties due to different 
epitope density and presentation. Hence, increasing attention has recently been 
made to control the conjugation site (228) (127) and provide products which are well-
defined not only in their saccharide component but also in the attachment point to the 
protein (228) (229). In this sense, pre-activation of the carrier protein and of the sugar 
hapten with bio-orthogonal linkers, such as the alkyne and the azide moieties, can 
allow a selective control of the conjugation reaction. 
The first aim of this work has been that to identify an efficient conjugation strategy 
that could allow conjugate formation targeting one single point of the saccharide 
chain and few points of attachment on the carrier protein. S. Typhimurium OAg and 
CRM197 have been used as models. The identification of this chemistry will then allow 
the production of very selective conjugates with few saccharide chains attached to 
specific points on the protein. 
Click chemistry has proved to be a powerful tool in this sense, allowing the synthesis 
of conjugates where only one position on the protein was available for linkage to the 
KDO unit of the sugar chain. Furthermore azido and alkine groups involved in the 
click chemistry are not de-activated during the conjugation reaction so that unreacted 
components can be recycled and re-conjugated. In the specific case, reactions were 
performed to have all the protein conjugated and the OAg was recovered and 
successfully re-used for conjugation. After verifying this possibility, further work was 
done to set up a synthesis on solid phase with the advantage to recover the sugar 
and at the same time obtain a conjugate pure from free saccharide without further 
purification steps.  
 
 
5.3 Material and methods 
Reagents 
The following chemicals were used in this study: cystamine dihydrocloride, 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDAC), (+)-sodium L-ascorbate, 2-(N-
morpholino)ethanesulfonic acid (MES), N-hydroxysuccinimide (NHS), tris(2-
carboxyethyl)phosphine hydrochloride solution (TCEP), propargylamine, copper(II) 
sulfate pentahydrate (CuSO4·5H2O), tris(3-hydroxypropyltriazolylmethyl)amine 
(THPTA), phosphate buffer solution (PBS), adipic acid dihydrazide (ADH), sodium 
cyanoborohydride (NaBH3CN), dimethyl sulfoxide (DMSO), sodium phosphate 
monobasic (NaH2PO4) [Sigma]; triplex III (EDTA) [Merck]; N-[β-maleimidopropionic 
acid] hydrazide trifluoroacetic acid salt (BMPH) [Thermo]; N-[ε-
maleimidocaproyloxy]succinimide ester (EMCS), succinimidyl 3-
(bromoacetamido)propionate (SBAP), NHS-PEG4-N3 [Pierce], Click-easyTM BCN N-
hydroxysuccinimide ester I [Berry & Associates]; DL-1,4-Dithiothreitol (DTT) 
[Invitrogen]. CRM197 was obtained from Novartis Vaccines and Diagnostics (NV&D). 
The clinical isolate 2192 was grown and the corresponding OAg purified and 
characterized as described in the Chapter 1. 
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Synthesis and characterization of derivatized CRM197CRM197-BMPH via EDAC 
chemistry 
10 mg of CRM197 were solubilized in MES 500 mM pH 6.0 (12 mg/mL); BMPH (42 
mg/mL, molar ratio BMPH/COOH groups CRM197 = 10.42) and EDAC (3 mg/mL, 
molar ratio EDAC/COOH groups CRM197 = 1.15) were added. Mixture was stirred for 
1h at RT, and then purified by desalting against NaH2PO4 100 mM EDTA 10 mM pH 
7.0 on a HiPrep™ 26/10 desalting column 53 mL, prepacked with Sephadex™ G-25 
Superfine (G25 53 mL) [GE Healthcare].  
 
CRM197-BMPH via EDAC/NHS chemistry 
10 mg of protein were solubilized in MES 600 mM pH 6.0 (15.56 mg/mL); NHS (10.8 
mg/mL, molar ratio NHS/COOH groups CRM197 = 5.36) and EDAC (6.2 mg/mL, 
molar ratio EDAC/COOH groups CRM197 = 1.83) were added and the solution mixed 
at RT for 1h. After this time, BMPH (2.8 mg/mL, molar ratio BMPH/COOH groups 
CRM197 = 0.53) was added and the solution stirred for 2h at RT. The mixture was 
purified by desalting on a PD-10 desalting column containing 8.3 ml of Sephadex™ 
G-25 Medium (PD 10) [GE Healthcare] against NaH2PO4 100 mM EDTA 1 mM pH 
7.0.  
 
CRM197-EMCS 
10 mg of CRM197 were solubilized in NaH2PO4 100 mM EDTA 1 mM pH 8.0 (4.7 
mg/mL); EMCS was added (0.19 mg/mL, molar ratio EMCS/Lysine groups on 
CRM197 = 0.2) after being solubilized in DMSO (final DMSO concentration of 6% v/v). 
Mixture was stirred for 2h at RT, and then purified by desalting (G25 53 mL column) 
against NaH2PO4 100 mM EDTA 1 mM pH 7.0. 
 
CRM197-SBAP 
10 mg of CRM197 were solubilized in NaH2PO4 100 mM EDTA 1 mM pH 8.0 (4.7 
mg/mL); SBAP was added (0.3 mg/mL, molar ratio SBAP/Lysine groups on CRM197 = 
0.3) after being solubilized in DMSO (final DMSO concentration of 4% v/v). Mixture 
was stirred for 3h at RT, and then purified by desalting (G25 53 mL column) against 
NaH2PO4 100 mM EDTA 1 mM pH 7.0.  
 
Synthesis and characterization of CRM197-N3 
CMR197 (20 mg/mL) was solubilized in NaH2PO4 400 mM pH 7.2, and NHS-PEG4-N3 
was added (linker solubilized in DMSO with final DMSO concentration in the mixture 
of 1% v/v). Different amount of NHS-PEG4-N3 were used to achieve a different 
degree of derivation on the protein with a molar ratio NHS-PEG4-N3/Lysine groups 
CRM197 of 0.18, 0.26, 0.39, respectively. After mixing at RT for 8h, the mixture was 
purified by desalting on a G25 53 mL column against NaH2PO4 100mM pH 7.2.  
 
Characterization of derivatized CRM197 
Protein content was estimated by micro BCA (using BSA as standard and following 
manufacturer’s instructions [Thermo Scientifics]). HPLC-SEC analysis was used to 
compare derivatized protein with underivatized CRM197. All samples were eluted on 
TSK gel G3000 PWXL column (30 cm x 7.8 mm; particle size 7 μm; cod. 808021) 
with TSK gel PWXL guard column (4.0 cm x 6.0 mm; particle size 12 μm; 
cod.808033) (Tosoh Bioscience). The mobile phase was 0.1 M NaCl, 0.1 M 
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NaH2PO4, 5% CH3CN, pH 7.2 at the flow rate of 0.5 mL/min (isocratic method for 30 
min). Void and bed volume calibration was performed with λ-DNA (λ-DNA Molecular 
Weight Marker III 0.12-21.2 Kbp, Roche) and sodium azide (NaN3, Merck), 
respectively. Protein peaks were detected at 214 nm and 280 nm (UV detection) and 
using tryptophan fluorescence (emission spectrum at 336 nm, with excitation 
wavelength at 280 nm). Linker average loading on CRM197 was determined by 
MALDI-TOF analysis. For MALDI-TOF analysis, the protein was diafiltrated, using a 
Centricon-10 (Millipore), against NaH2PO4 10 mM pH 7.2. Two microliters of protein 
(at a concentration of 5 mg/mL) were mixed with 2 L of a saturated solution of 
sinapinic acid in 50% acetonitrile solution containing 0.1% TFA. Two microliters of 
the mix was spotted on a MTP 384 stainless steel target (Bruker Daltonics GmbH, 
Bremen, Germany) and allowed to air-dry. Measurements were recorded on an 
Ultraflex III (Bruker GmBH) MALDI-TOF/TOF MS in linear mode. External calibration 
was performed by spotting 2 L of protein calibration standard II (Bruker Daltonics) 
containing the following proteins: trypsinogen (23,982 Da), protein A (44,613 Da) and 
bovine serum albumin (66,431 Da). All mass spectra were recorded by summing up 
to 400 laser shots. The Flex Analysis software packages provided by the 
manufacturer were used for data processing. 
 
Synthesis of OAg-cystamine-CRM197 conjugates 
40 mg of 2192 OAg were solubilized in NaH2PO4 100 mM pH 7.0 (40 mg/mL) and 
then cystamine (110 mg/mL, cystamine/OAg (w/w) = 2.75) and NaBH3CN (61 
mg/mL, NaBH3CN/OAg (w/w) = 1.53) were added. The mixture was stirred for 3h at 
RT and then desalted against water on a G25 53 mL column. Cystamine disulfide 
bond was reduced by mixing the OAg at a concentration of 20 mg/mL with DTT 100 
mM in NaH2PO4 100 mM EDTA 5 mM for 1h at RT. The derivatized OAg was purified 
by desalting on a G-25 53mL column against 10 mM NaH2PO4 5 mM EDTA pH 7.5. 
The amination reaction with cystamine was also performed at higher scale on 100 
mg of OAg and the mixture purified by tangential flow filtration (10k 200 cm2 
Hydrosart membrane, 10 diafiltration cycles vs NaCl 1M, followed by 10 cycles 
against water).  
Conjugation was performed solubilizing the derivatized protein in NaH2PO4 100 mM 
EDTA 1 mM pH 7.2 (10 mg/mL), and using a molar ratio of thiol groups to CRM197 of 
30 to 1. After mixing ON at RT, the mixture was purified by size exclusion 
chromatography with a Sephacryl S-300 HR column 1.6 cm x 90 cm [GE Healthcare], 
eluting with PBS pH 7.2 at 0.5 mL/min. 
 
Characterization of OAg-cystamine-CRM197 conjugates 
Total saccharide content was quantified by phenol sulfuric assay (195), protein 
content by micro BCA and the ratio of saccharide to protein calculated. OAg-CRM197 
conjugates profiles were compared with free CRM197 by HPLC-SEC (TSK gel 
6000PW + TSK gel 5000PW, see chapter 1 for method description). Free protein was 
estimated by HPLC-SEC (TSK gel 6000PW + TSK gel 5000PW, see chapter 1 for 
method description), while a method for free saccharide determination is under 
development. 
Derivatized OAg intermediates were all characterized by phenol sulfuric assay for 
sugar content and by HPLC-SEC for verifying aggregation or degradation after 
modification (TSK gel 3000PWXL, see chapter 1 for method description). 
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After the reaction with cystamine, the introduction of NH2 groups was verified by 
TNBS colorimetric method (201) using 6-aminohexanoic acid as standard and 
subtracting the number of NH2 groups already present on the un-derivatized OAg 
sample (Figure 4.2, Chapter 2). Percentage of OAg chains activated was calculated 
as moles of linked cystamine/moles of KDO (calculated by HPLC-SEC/semicarbazide 
assay (86)) %. After the reduction with DTT, introduction of SH groups was verified 
by Ellman analysis (230). Activation on the terminus KDO was calculated as moles of 
linked SH/moles of KDO %, while the ratio % between SH groups/ cystamine moles 
gave the efficiency of reduction reaction with DTT.  
 
Synthesis of OAg-propargylamine-CRM197  
2192 OAg (40 mg) was solubilized in NaH2PO4 pH 7.0 (40 mg/mL); then 
propargylamine (27.5 mg/mL, propargylamine/OAg (w/w) = 0.67) and NaBH3CN 
(62.8 mg/mL, NaBH3CN/OAg (w/w) = 1.53) were added. The reaction was stirred for 
3h at RT and purified by desalting on a G25 53 mL column against water. 
Conjugation was performed solubilizing CRM197-N3 (5 mg/mL, average of 5.2 Lysines 
activated) in NaH2PO4 400 mM pH 7.2 with THPTA 25 mM, sodium ascorbate 10 mM 
and CuSO4·5H2O 5mM, followed by OAg-propargylamine addition (molar ratio 
alkyne/N3 = 5). Reaction was stirred at RT for 6h and conjugate formation followed by 
HPLC-SEC (TSK gel 6000PW + TSK gel 5000PW). 
  
Synthesis of OAg-ADH-BCNesterI-CRM197 
2192 OAg (40 mg) was solubilized in AcONa 100 mM pH 4.5 (40 mg/mL), then ADH 
(48 mg/mL, ADH/OAg (w/w) = 1.2) and NaBH3CN (48 mg/mL, NaBH3CN /OAg (w/w) 
= 1.2) were added. The mixture was stirred for 2h at 30 °C and then purified by 
desalting on a G25 53 mL column against water. 
For introduction of the second linker, Click easy BCN NHS ester I, OAg-ADH was 
dissolved in water/DMSO 1:9 (v/v) at a concentration of 50 mg/mL. When the 
derivatized OAg was completely solubilized, TEA was added (molar ratio TEA/total 
NH2 groups = 5; total NH2 groups included both phosphoethanolamine groups on the 
OAg and the hydrazide groups introduced with the linker ADH) and then Click easy 
BCN NHS ester I (molar ratio Click easy BCN NHS ester I/total NH2 groups = 12). 
The solution was mixed at RT for 3h. The sample was purified by desalting on a G25 
53 mL column against water. 
For conjugation, CRM197-N3 was solubilized in PBS at a concentration of 10 mg/mL 
and OAg-ADH-BCNesterI added (molar ratio alkyne/N3 = 4). Mixture was stirred for 
6h at RT. 
Conjugate purification was performed by hydrophobic interaction chromatography on 
a Phenyl HP column [GE Healthcare], loading 500 µg of protein for mL of resin in 50 
mM NaH2PO4 3M NaCl pH 7.2. The purified conjugate was eluted in water and the 
collected fractions were dialysed against 10 mM NaH2PO4 pH 7.2.  
 
Characterization of OAg-CRM197 conjugates via click chemistry 
Total saccharide content was quantified by phenol sulfuric assay (195), protein 
content by micro BCA and the ratio of saccharide to protein calculated. OAg-CRM197 
conjugates profiles were compared with free CRM197 by HPLC-SEC (TSK gel 
6000PW + TSK gel 5000PW). Free protein was estimated by HPLC-SEC (TSK gel 
6000PW + TSK gel 5000PW), while a method for free saccharide determination is 
under development. 
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Derivatized OAg intermediates were all characterized by phenol sulfuric assay for 
sugar content and by HPLC-SEC (TSK gel 3000PWXL) for verifying aggregation or 
degradation after modification.  
After the reaction with ADH, the introduction of NH2 groups was verified by TNBS 
colorimetric method (201) using ADH as standard and subtracting the number of NH2 
groups already present on the un-derivatized OAg sample. Free ADH was detected 
by RP-HPLC (180). Activation on the terminus KDO was calculated as moles of 
linked ADH/moles of KDO %, indicating the % of OAg chain activated. Total alkyne 
groups introduced with BCN ester I were quantified by TNBS considering the number 
of NH2 groups remained after the derivatization. Percentage of derivatization with 
BCN ester I was calculated as molar ratio % of linked alkyne groups/total NH2 groups 
by TNBS before derivatization, indicating the moles % of NH2 groups activated with 
this reaction. Activation with propargylamine was not quantified as a method for 
alkyne quantification was not available. Derivatized OAg was directly used for 
glycoconjugation. 
 
Recycle of unreacted OAg-ADH-BCNesterI and its further click glycoconjugation 
After purification of the conjugate OAg-ADH-BCNesterI-CRM-N3(LYS10) by HIC 
chromatography; unreacted OAg was recovered in the flow through fractions. They 
were desalted against water (G25 53 mL column) and re-conjugated to CRM197 using 
same conditions adopted in the first test of conjugation ([CRM197-N3(LYS10)] = 10 
mg/mL in NaH2PO4 100 mM pH 7.2, alkyne:N3 molar ratio = 4:1, 6h, RT). Conjugate 
formation was verified by HPLC-SEC (TSK gel 6000PW + TSK gel 5000PW).  
 
Identification of conditions for conjugation on solid-phase  
A physical mixture of 2192 OAg and CRM197 was run on a HiTrap 1mL Q FF [GE 
Healthcare], loading 500 µg of protein and 2 mg of sugar per mL of resin in 100 mM 
NaH2PO4 at respectively pH 7.0 or pH 8.0 buffer and increasing the NaCl 
concentration from 0 to 1 M in linear gradient. (20 column volumes). Different 
fractions were analyzed by HPLC-SEC (TSK gel 6000PW + TSK gel 5000PW), in 
comparison with free OAg and free CRM197.  
 
Click Conjugation on solid phase 
The resin (Q Sepharose Fast Flow column [GE Healthcare]) was centrifuged to 
remove the storage solution (10000 rpm, 4 °C, 5 min), and washed two times with 
NaH2PO4 100 mM pH 8 (volume for washing equal to twice the volume of the resin). 
CRM197-N3(LYS7) (0.25 mg per mL of resin) was added at 0.5 mg/mL in NaH2PO4 
100 mM pH 8. The mixture was gently stirred ON at 4°C. The supernatant was 
removed and the resin washed two times with NaH2PO4 100 mM pH 8.0 (washing 
volume equal to 2.5 times the volume of the resin). Supernatant and washing 
solutions were analyzed by micro BCA to estimate the amount of protein present in 
solution and by difference the amount of protein attached to the resin.  
5 mg of 2192-ADH-BCNalkyne were solubilized in NaH2PO4 100 mM pH 8.0 and 
added to the resin (final OAg concentration of 50 mg/mL). The mixture was gently 
stirred ON at 4°C. The supernatant was recovered by centrifugation (10000 rpm, 4°C, 
5 min), and the resin washed 5 times with 1 mL PBS to recover unreacted sugar . All 
the solutions were analyzed by HPLC-SEC (TSK gel 6000PW + TSK gel 5000PW). 
The conjugate was then eluted from the resin washing twice with 500 L NaH2PO4 
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100 mM NaCl 1M pH 8.0 and recovered supernatant solutions pooled together and 
analyzed by HPLC-SEC (TSK gel 6000PW + TSK gel 5000PW). 
Unreacted sugar recovered was used for a further conjugation test, adding the first 
supernatant recovered to fresh protein bound on the resin. 
 
 
5.4 Results 
 
Thiol conjugation chemistry  
Thiol-conjugation chemistry was first tested as a possible conjugation approach. The 
KDO sugar was used for introducing cystamine as linker on one specific point of the 
OAg without modifying the OAg sugar chain and then the DDT-reduced form was 
used for binding the OAg to the carrier protein (Figure 5.1). 
OAg derivatization with SH functionality was characterized by good reproducibility 
both in terms of sugar recovery and percentage of activation. In all the preparations, 
sugar recovery was >75% for both the first activation step and the reduction with 
DTT. After the activation with cystamine, TNBS analysis indicated that 70-80% of 
OAg chains were activated. After DDT reduction, the activation degree was also 
confirmed by the analysis of SH groups introduced. The reduction was always 
complete. 
 
 
 
Figure 5.1 Introduction of thiol group on the reducing end of the sugar. 
 
CRM197 was derivatized using different hetero bi-functional linkers, with a functional 
group able to react with the thiol unit on the OAg. Different amino acids were 
activated (Figure 5.2) with different protein loading (Figure 5.3). In all cases, protein 
recovery was >90%.Reaction of CRM197 with BMPH by EDAC chemistry resulted in 
the introduction of an average number of 3.4 linkers per protein. When NHS was 
added to EDAC for activating the COOH groups on the protein, trying to increase the 
activation degree, an average of 5.1 linkers was introduced. A higher number of 
linkers was introduced per mole of protein when derivatization was performed on 
Lysine residues: with an average number of 8 SBAP and 11.3 EMCS. (Figure 5.3) 
Thiolated OAg was then conjugated to derivatized CRM197 where different amino 
acids were activated with different linker loading. Together with the modified proteins 
synthesized at NVGH, the conjugation was tested with CRM197 modified on tyrosines 
and lysines with low linker loading, 4.1 on tyrosine and 3.1 on lysines respectively 
(Figure 5.3), provided by Global Discovery chemistry (GDC) group in Boston.  
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Using this conjugation chemistry, it was not possible to obtain conjugate formation 
unless the linker loading on the protein was pretty high (at least an average of 8 
linkers introduced per protein molecule). 
The two conjugation reactions that succeeded, both based on lysine chemistry, 
indicated that a higher number of linkers per CRM197 resulted in a higher OAg to 
CRM197 ratio in the purified corresponding conjugate. However, the linkers used for 
the synthesis of these conjugates were different and an impact of the type of linker 
on conjugate formation cannot be excluded. In both cases all the protein was 
conjugated with residual un-reacted sugar chains. Even if the number of linkers per 
CRM197 was high (8 and 11.3) corresponding conjugates were characterized by a low 
OAg to protein molar ratio (1.6 and 2.7 respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D and E  residues 
CRM197 
CRM197 
CRM197 
a) 
b) 
c) 
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Figure 5.2 CRM197 was derivatized using different hetero bi-functional linkers able to react 
with thiol-activated OAg. a) CRM197-COOH activation via EDAC with BMPH. b) CRM197-
COOH activation via EDAC/NHS with BMPH. c) CRM197-NH2 activation with EMCS. d) 
CRM197-NH2 activation with SBAP. 
 
 
Figure 5.3 Thiol-conjugation chemistry for the synthesis of glycoconjugates targeting 
different amino acids on the protein.  
 
Looking at the HPLC-SEC profiles (dRI) of the conjugation mixtures, even when 
conjugation was successful, the presence of a sugar population at higher MW was 
observed, probably deriving from oxidation of the thiolated OAg to generate a sugar 
dimer. Different methods were tried in order to avoid the generation of the oxidation 
product and hence of a unreactive OAg form, trying to see if this could then result in 
higher conjugation efficiency too. Conjugation of DTT-treated OAg-cystamine with 
CRM197 
d) 
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CMR197-BMPH under N2 caused precipitation of the protein; one-pot-two-step OAg-
cystamine reduction with TCEP as reducing agent and conjugation to CRM197-BMPH 
(5.2 linkers) did not work. When DTT-treated cystamine was conjugated with CRM197-
BMPH in the presence of TCEP, the formation of the disulfide aggregate was 
avoided, but the major part of the protein remained unconjugated. 
In summary thiol conjugation strategies did not allow to get all the panel of wanted 
conjugates and it became needed to identify a different conjugation approach. 
 
Click chemistry  
There are two main ways of performing the click 1,3-dipolar reaction: by employing 
metal as a catalyst (usually copper), or alternatively lowering the activation barrier for 
[3+2] cycloaddition by employing intrinsically highly strained cyclic alkynes that 
readily react with azide groups. Both the approaches were initially compared for the 
reaction of 2192 OAg with CRM-N3 (Figure 5.4). CRM197 was derivatized on lysine 
amino acids using NHS-PEG4-N3 (Figure 5.5). Different loadings were obtained, in 
the range of 5-10 linker introduced per protein, depending on the amount of linker 
added. In all cases, protein recovery was >90%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Two glycoconjugation strategies differing for the chemistry involved and the 
spacer length. a) Copper-free click reaction. b) Copper-catalyzed click reaction, using a 
shorter spacer.  
b) 
a) 
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Figure 5.5 Modification of CRM197 with NHS-PEG4-N3 to introduce azido groups on CRM197 
and generate CRM197-N3.  
 
For the copper click chemistry, the OAg was derivatized with propargylamine by 
reductive amination on the terminal KDO (Figure 5.4b). For the copper-free approach 
instead, the alkyne linker was introduced on the OAg-ADH, with activation >80% 
(Figure 5.4a). 
CRM197 with an average number of 5.2 linkers introduced (CRM197-N3(LYS5.2)) was 
used at 5 mg/mL for comparing these two approaches. Despite a lower sugar to 
protein ratio, the copper free conjugation resulted more efficient (Table 5.1). Reaction 
time did not seem to have a strong impact on conjugate formation.  
 
 
Table 5.1 Reaction conditions used for the comparison of the copper 
free and copper-catalyzed glycoconjugation reactions. 
Copper 
Alkyne:N3 
ratio 
(mol/mol) 
Reaction time 
(h) 
Conjugate 
(%) 
Free CRM197 
(%) 
Yes 5 
2 28 72 
4 36 64 
6 40 60 
No 1 
2 69 31 
4 75 25 
6 78 22 
Conjugate and free CRM197% calculated by comparing corresponding 
peak areas in HPLC-SEC fluorescence emission profiles on a TSK gel 
6000-5000 PW column. Both reactions performed with [CRM197-
N3(LYS5.2)] of 5 mg/mL at RT. 
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Because of the higher conjugation efficiency and to avoid the use of a toxic metal, 
the copper-free approach was selected for further experiments. 
Maintaining protein concentration at 5 mg/mL and increasing the alkyne to N3 molar 
ratio from 1 to 2, conjugation efficiency remained the same after 6h of reaction, with 
78% of CRM197 conjugated according to the area of the peaks by HPLC-SEC (Table 
5.2). Increasing protein concentration from 5 to 10 mg/mL and the alkyne to N3 molar 
ratio from 2 to 4, conjugation was substantially complete. When a protein with a 
higher average number of linkers was used (from 5.2 to 10), no free CRM197 was 
detected in the conjugation mixture (Table 5.2 and Figure 5.6).  
 
Table 5.2 Reaction conditions optimized for the copper free 
conjugation. 
N3 per 
CRM197 
[CRM197] 
(mg/mL) 
Alkyne:N3 
(mol/mol) 
Conjugate 
(%) 
Free CRM197 
(%) 
5.2 5 1:1 78 22 
5.2 5 2:1 78 22 
5.2 10 4:1 90 10 
10 10 4:1 100 nd 
Conjugate and free CRM197 % calculated by comparing 
corresponding peak areas in HPLC-SEC fluorescence emission 
profiles on a TSKgel 6000-5000 PW column. All the reactions 
performed at RT for 6h. nd: not detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 HPLC-SEC profiles of OAg-ADH-BCNesterI-CRM197 conjugation mixtures after 6h 
at RT, using CRM197-N3(LYS5.2) (green) or CRM197-N3(LYS10) (blue) at 10 mg/mL  and with 
a alkyne to N3 molar ratio of 4 in comparison to free CRM197 (black). TSKgel 6000 PW + 5000 
PW columns, 0.5 mL/min, 100 mM NaCl 100 mM NaH2PO4 5% CH3CN pH 7.2; Vtot 48.829 
min; V0 24.125 min. 
SampleName: n3cooh 6H 
SampleName: N3 +10 6h  
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Optimal conditions identified by this work of screening via HPLC-SEC (protein 
concentration of 10 mg/mL with alkyne to azide molar ratio of 4) were used for the 
synthesis and purification of a conjugate.  
CRM-N3 with an average number of 7.1 linkers was used; all CRM197 resulted 
conjugated and residual free OAg was removed by purification through HIC. Table 
5.3 showed the main features of the resulting conjugate. 
 
Table 5.3 Main characteristics of OAg-CRM197 conjugate generated by 
using click chemistry. 
Conjugate 
OAg/CRM197 
(w/w) 
OAg/CRM197 
(mol/mol) 
OAg-ADH-BCNesterI-CRM197(LYS7.1) 0.72 2.0 
 
Similarly to what obtained by thiol chemistry activating lysine groups on CRM197, also 
in this case the obtained conjugate was characterized by a low OAg to protein molar 
ratio (2.0), even if the protein was activated with an average of 7 linkers. 
 
Conjugation of CRM197 with low linker loading to 2192 OAg by click chemistry 
Conjugation conditions selected were tested for the conjugation of CRM197-N3 with 
lower average number of linkers per protein. CRM197-N3(TYR4.3) and CRM197-
N3(LYS3.8) were successfully conjugated to OAg-ADH-BCNesterI obtaining 
respectively 91% and 81% conjugation yields (as quantified by comparing the area of 
conjugate and free protein peaks by HPLC-SEC). Furthermore, performing the 
conjugation with a protein with only one linker CRM197-N3(LYS1), 38% of CRM197 
resulted conjugated after 6h (Table 4.4). Either in this case or when the activation 
loading on the protein was higher (Table 5.1, no copper reactions), the reaction 
proceeded fast, since no huge differences were seen after 2, 4 or 6h.  
 
Table 5.4 Reaction conditions tested for the copper free conjugation 
with CRM197-N3(LYS1),. 
Reaction time (h) 
Conjugate  
(%) 
Free CRM197  
(%) 
2 34 66 
4 35 65 
6 38 62 
Conjugate and free CRM197 % calculated by comparing 
corresponding peak areas in HPLC-SEC fluorescence emission 
profiles on a TSKgel 6000-5000 PW column. Reaction performed 
over time at RT, with protein concentration of 10 mg/mL and alkyne 
to N3 molar ratio of 4. 
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Click conjugation: recycle of the sugar 
One of the advantages of the click chemistry is that the functional groups involved 
are not de-activated during the conjugation. This opens the possibility to recycle 
unreacted reagents. After purification of OAg-ADH-BCNesterI conjugate by HIC, 
unreacted OAg was recovered in the flow through, not containing traces of proteins, 
as verified by HPLC-SEC analysis. Flow through fractions were desalted against 
water (G25 53 mL column) and re-conjugated to CRM197-N3(LYS10) using same 
conjugation conditions adopted for the synthesis of the first batch (10 mg/mL protein 
concentration, alkyne to N3 molar ratio of 4, RT, 6h). Conjugate formation was 
verified by HPLC-SEC and also in this case no traces of free protein in the reaction 
mixture were detected (Figure 5.7) 
 
Figure 5.7 HPLC-SEC profile of the conjugation mixture obtained by reacting recycled OAg-
ADH-BCNesterI with CRM-N3(LYS10) (blue), in comparison with free protein (black ). TSKgel 
6000 PW + 5000 PW columns, 0.5 mL/min, 100 mM NaCl 100 mM NaH2PO4 5% CH3CN pH 
7.2; Vtot 48.829 min; V0 24.125 min. 
 
Click conjugation on solid phase 
The possibility to perform click conjugation on solid phase was investigated. As a first 
step, the best conditions for attaching the protein on the resin avoiding the linking of 
the sugar were identified, running a physical mixture of CRM197 and 2192 OAg on a 
Q Sepharose Fast Flow column. It was speculated that the behavior on the resin of 
2912 OAg - CRM197 - and OAg-ADH-BCNesterI - CRM197-N3 was similar, since their 
structural modification is modest considering the interaction with this kind of resin. 
CRM197 resulted attached to the resin in 100 mM NaH2PO4 pH 8.0, while in these 
conditions 2192 OAg was recovered in the flow through. Increasing NaCl 
concentration, protein elution started at 100 mM salt concentration.  
Conjugation on solid phase was performed in batch, using a Fast Flow Q resin. After 
incubating CRM197-N3(LYS7) on the resin ON at 4°C, analysis of the supernatant by 
micro BCA revealed 50% of protein bound. OAg-ADH-BCNesterI  was then added 
(molar ratio alkyne/N3 = 25) at a concentration of 50 mg/mL in 100 mM NaH2PO4 pH 
8.0. 
After ON at 4°C, analysis of the supernatant and washing PBS solutions by HPLC-
SEC showed the presence of only unreacted OAg. The conjugate was eluted in 100 
mM NaH2PO4 1M NaCl pH 8.0 and analysis by HPLC-SEC revealed that conjugation 
reaction was quantitative, with no free protein. No free OAg seemed to be present 
too (dRI detection by HPLC-SEC), however a more sensitive and accurate method 
will be used when a batch of conjugate produced by solid phase will be fully 
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characterized and tested in mice. In case the number of washing will be not enough 
to purify the conjugate, further steps will be added to the current procedure. 
Interestingly, unreacted OAg recovered from the first supernatant was recycled for 
solid-phase conjugation with fresh resin-bounded CRM197-N3(LYS7). Although the 
sugar added in this experiment was lower (considering that part reacted in the first 
conjugation experiment), conjugation was again quantitative with no free CRM197 
detected by HPLC-SEC in the eluted conjugate. 
 
5.5 Discussion 
The term click chemistry describes a set of reactions tailored to obtain high degree of 
selectivity and specificity, simple work-up, the possibility of carrying out experiments 
in eco-friendly conditions (such as at room temperature and in water) and with good 
yields (224). These are indeed important parameters to be considered in a strategy 
for the synthesis of functionalized compounds, in order to reduce the cost-
effectiveness and to minimize the use and generation of hazardous substances. The 
emerging importance of click chemistry in many areas of science, such as 
bioconjugation, drug discovery material science and radiochemistry, underlies the 
unique specificities of this class of reactions (231) (232) (233) (234) (235). Recently, 
the click chemistry has been identified as a powerful method for the synthesis of 
glycoconjugates where few points of attachment are targeted on the protein too (236) 
(127). In this study this has been confirmed for the linkage of a longer sugar chain 
such as 2192 OAg (20.5 kDa) selectively activated on the terminal KDO unit to 
CRM197. Copper-free chemistry was preferred because it gave better conjugation 
yields in preliminary tests and avoids the use of a toxic metal. Differently from the 
thiol chemistry tested, the click chemistry allowed the linkage of the terminal sugar 
end of the OAg chain to the protein with good conjugation yields (>80%) even when 
few linkers were present on the protein (average number of 4) and to have conjugate 
formation with just one linker on the protein (38% of CRM197 resulted conjugated). 
This finding opens the possibility of synthesizing a panel of well-defined OAg-CRM197 
conjugates, targeting different amino acids on the protein. The insert of a different 
linker loading on the protein could also drive the number sugar of units attached per 
protein, with potential impact on the immunogenicity of the glycoconjugate. This is 
indeed an important goal not only for glycoconjugates development (consistency of 
production, better characterization and rational design of optimal candidate 
vaccines), but also to gain a better understanding about the complex mechanism of 
conjugate vaccines in vivo.  
In order to further exploit the potentiality of the click chemistry, unreacted OAg, 
having alkyne groups not de-activated during conjugation, was successfully recycled 
for conjugation. In addition, the possibility to perform conjugation in solid phase was 
verified. Solid-phase bioconjugation has been previously reported for the synthesis of 
peptides directly on carrier proteins (237), conjugation to carrier proteins pre-
adsorbed to aluminum hydroxide (238), and by ion exchange matrix adsorbed carrier 
proteins (239). Here, CRM197 was adsorbed to an anion exchange matrix using a 
batch procedure, and the immobilized protein was then conjugated to the OAg. 
Unreacted OAg was easily recovered and used for further conjugation, while the 
conjugate was eluted from the resin pure from both free protein and free sugar. The 
absence of free protein in the eluted conjugate confirmed the efficiency of this 
conjugation strategy. In this way, the purification of the conjugate is reduced to a 
simple washing/elution procedure, where unreacted sugar is removed from the resin-
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bound conjugate, and the matrix-bound conjugate can be then simply eluted and use 
for immunization.  
When the conjugates are intended for use as vaccines, removal of unconjugated 
saccharide is particularly important to obtain consistent products without affecting the 
immune response too. Several methods are in use for the separation of free 
saccharide from conjugate vaccines. These methods often involve complex steps, 
and some of them may result in the selection of sub-populations of conjugates. This 
may result in low recoveries and reduction of immunogenicity of the purified 
conjugate preparations. There is thus a need for further and improved processes for 
purifying saccharide-protein conjugates, and particularly for processes that would be 
simple, requiring the minimum number of steps between conjugation and purification, 
resulting in minimal selection of sub-populations of conjugates retaining effective 
immunogenicity. The possibility of recycling the unreacted sugar for further 
conjugation adds cost-effectiveness to the entire process. 
To sum up, a conjugation methodology that allows the synthesis of highly defined 
OAg glycoconjugate vaccines with good yields was developed. The process has 
great advantages in terms of cost for vaccine production, allowing unreacted sugar 
recovery and making easy the purification of the conjugate. 
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6. Discussion 
 
Vaccination has had an unparalleled impact on global health (240) and vaccines 
have the greatest potential for further improvement in health in the poorest countries 
of the world (50). Infectious diseases account for around half of all deaths in these 
countries with around 90% of this mortality being attributed to diarrheal and 
respiratory diseases, AIDS, tuberculosis, malaria and measles (2). 
Glycoconjugate vaccines are among the safest and more efficacious vaccines 
developed during the last 30 years against infectious diseases. They have been 
developed to improve the immunogenicity of polysaccharide vaccines which are T-
cell independent, poorly immunogenic in infants and young children < 2 years of age 
(241) (242) and do not induce immunological memory (243). It is likely that 
glycoconjugates will replace all polysaccharide vaccines in the next future (179). 
There is no other example where the introduction of a new approach to vaccine 
development has had such a rapid and positive effect in preventing infections by a 
series of human pathogens (244) and this accomplishment has triggered studies on 
new possible applications such as therapeutic vaccines for cancer and Alzheimer 
and conjugate vaccines for drug abuse, which are currently under development (245) 
(246) (247).  
In addition to effectiveness and safety profile, there are other features of 
glycoconjugate vaccines that contribute to their success. The lack of interference with 
other routine vaccination together with the ability to induce herd protection by 
reducing nasopharyngeal carriage are also important parameters that contribute to 
improving the final cost-benefit ratio. 
Following the use of Haemophilus influenzae type b (Hib), Meningococcus group C 
(MenC) and pneumococcal glycoconjugate vaccines in national immunization 
programmes, drastic reductions in serious infections in target risk groups, especially 
infants, children and adolescents, have been observed (179). Following the licensure 
of MenACWY and PCV13-CRM197 conjugates, robust protection has been observed 
in adults and elderly (248) (249) (250). The Hib-MenCY-TT vaccine, which has been 
licensed by the FDA in June 2012, now offers broader protection against MenY 
disease from as early as 6 weeks of life (251).  
As yet there is still the need for more investment in glycoconjugate vaccines which 
protect against neglected enteric diseases, such as typhoid fever, shigellosis and 
infection with enterotoxigenic E. coli and nontyphoidal Salmonella, which pose a 
significant threat to millions of children, especially in the developing world. Tiered 
pricing and subsidization of vaccines by public-private partnerships and non-profit 
organizations would be crucial in addressing persisting inequities in vaccine 
availability between industrialized and developing countries (179). Continued 
surveillance following introduction of glycoconjugates in national immunization 
programs is also crucial to detect changes in the epidemiology of infectious diseases 
and in guiding appropriate interventions, since it is reported that conjugate vaccines 
may exert an increased selection pressure favoring a capsular switch. In the future, 
multivalent vaccine approaches targeting different well conserved antigens will be 
probably necessary to counteract further serotype replacement. Genome mining and 
reverse vaccinology are alternative technologies that have been successfully 
exploited to design a promising recombinant protein based vaccine (252). If their 
affordability as protein carrier will be confirmed, glycoconjugates that use 
homologous pathogen protective antigens (e.g., flagellins, porins for Salmonella) as 
carrier proteins can enhance protection by concomitantly eliciting immune responses 
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to a second relevant antigen, thereby providing greater protective efficacy than 
conjugates constructed with heterologous carrier proteins (e.g., tetanus toxoid, 
CRM197) (84). 
Currently two vaccines are widely licensed targeting S. Typhi: the live attenuated 
vaccine, Ty21a, and the Vi capsular PS vaccine, but neither is licensed for use in 
children under the age of two years. New vaccines, such as glycoconjugates, new 
generation live attenuated and protein based vaccines (Martin, 2012; McGregor et 
al., 2013; Szu, 2013), are currently under development against enteric disease, 
including S. Paratyphi A for which no vaccine is currently available (55), and hold 
promise for the future availability of these vaccines for use in endemic areas. 
Whereas licensed vaccines are available to prevent typhoid fever, no vaccines are 
available against NTS serovars. 
NTS, with the most common serovars being Typhimurium and Enteritidis, typically 
cause gastroenteritis in healthy children and adults in industrialized countries but in 
certain hosts (e.g., young infants, the elderly, immunocompromised individuals) they 
also cause invasive infections. The situation is much more complicated in many 
regions of sub-Saharan Africa, where they are important cause of invasive bacterial 
disease, especially among children with less than three years of age (71) (72) (73) 
(74) (75) and HIV infected individuals (65) (76). Prior to the introduction of 
programmatic immunization with Hib or Streptococcus pneumoniae conjugate 
vaccines in countries of sub-Saharan Africa, invasive NTS disease was as common 
as invasive Hib or pneumococcal disease (66) (253) (254) (255) (256) (257).  
Despite being a significant global health problem, NTS is surprisingly an 
underestimated disease. This is probably related with the very diverse clinical 
presentation of this illness which makes diagnosis and treatment a challenge for 
health-care workers in low-resource setting (36) (77). In addition, blood culture and 
microbiological diagnosis of Salmonella require technical expertise and investment in 
infrastructure, consumables, and quality control, all of which must be strengthened 
(78). In a recent study around 90% of invasive NTS isolates in Malawi have been 
found to be multidrug resistant (63), emphasizing the need for development of 
alternative interventions. 
The OAg of LPS is the main surface polysaccharide for NTS species. OAg are poor 
immunogens in animal models and do not generate immunologic memory (100) (84) 
(98). Conjugation of Salmonella OAg to appropriate carrier proteins results in 
vaccines that have been effective in generating anti-OAg antibodies in animal models 
protecting against mortality in the mouse model of lethal Salmonella (101) (102) 
(103) (98) (84). 
Glycoconjugate vaccines in development against NTS are at preclinical stage. 
However, Phase 1 and 2 clinical trials of another Salmonella OAg-based 
glycoconjugate vaccine, S. Paratyphi A linked to TT as carrier protein, was shown to 
be safe and immunogenic in Vietnamese adults and children (100) (208), 
demonstrating the goodness of this approach. 
However there are some issues regarding the use of OAg-based conjugate vaccines 
to prevent invasive NTS diseases, related to the activity and ability of OAg antibodies 
to confer protection in humans, and whether antibodies to an OAg-based vaccine 
made with purified OAg from one serovar cross-protect against other serovars within 
the same O serogroup (258).  
Although Salmonella are intracellular pathogens, they are vulnerable while 
extracellular when IgG and IgM directed against the surface polysaccharides of 
Salmonella can bind them leading to bacteriolysis or opsonophagocytosis. The 
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importance of serum immunity is highlighted by the increased virulence seen for 
Salmonella that can evade the alternative pathway of complement through alteration 
in the length and structure of their OAg and expression of the resistance to 
complement killing (rck) gene (259) (260) (261) (262). Antibodies to Salmonella 
surface carbohydrates mediate opsonophagocytosis through Fc receptors on 
phagocytes that can kill by oxidative burst (95). Activation of the antibody mediated 
complement pathway by IgM and IgG can also kill directly via formation of the C9 
membrane attack complex; surface deposition of C3b also enhances 
opsonophagocytosis (71)  (263). 
Antibody to S. Typhimurium LPS from HIV positive individuals in Africa was shown to 
interfere with complement mediated bactericidal killing of a serum sensitive prototype 
African S. Typhimurium strain (83). Anti LPS IgG however does not interfere with 
opsonophagocytosis and oxidative burst in human neutrophils with either 
complement resistant or sensitive S. Typhimurium strains (95). NTS isolates from the 
blood also frequently display marked resistance to complement mediated bactericidal 
killing (264). Further work is needed to better define the role of anti-OAg in serum 
bactericidal and opsonophagocytic killing in immunity to invasive NTS infection in 
humans. While glycoconjugates are set to make a major impact, the possibility of 
serovar replacement and the challenge of invasive NTS disease among HIV-infected 
Africans, where lack of antibodies to Salmonella is not the issue, support the 
development of new generation vaccines. These include new live-attenuated, 
protein-based and GMMA-based vaccines, which could potentially induce broader 
protection together with Salmonella-specific T cell responses. 
Several variables can affect the immunogenicity of a glycoconjugate vaccine. 
Parameters like saccharide chain length, saccharide to protein ratio in the purified 
conjugate, conjugation chemistry, the nature of the linkers used for saccharide and/or 
protein derivatization and of the protein carrier confer to the glycoconjugate different 
physico-chemical characteristics that may result in different immunological properties.  
A rational understanding of the effects of these different parameters could lead to 
improved rational design of glycoconjugate vaccines, with consequent enhanced 
vaccine efficacy and long term protection. However, this is not trivial for different 
reasons. First, the immune response is highly antigen dependent, and so contrasting 
findings can be obtained working with different sugar haptens. In addition, studies 
performed so far have compared the immunogenicity of vaccines differing for multiple 
parameters at the same time, making therefore difficult to assign the relative 
importance of the single variable to the immunogenicity. Moreover, parameters like 
saccharide chain length, saccharide to protein ratio and conjugation chemistry are 
strongly interconnected complicating the look for a clear correlation. Because of this 
complexity, the relative importance of each variable should be investigated for each 
carbohydrate antigen, whenever a glycoconjugate vaccine is under development.  
As part of a NVGH project to develop a comprehensive conjugate vaccine against 
invasive NTS disease, OAg from different S. Typhimurium and S. Enteritidis strains, 
major cause of invasive NTS in Africa, were fully characterized and the impact of 
OAg heterogeneity on the immunogenicity of corresponding conjugate vaccines 
evaluated in mice.   
NTS OAg were extracted from different sources: lab strains, animal and human 
isolates. S. Typhimurium OAg showed a similar bimodal molecular weight 
distribution, but differed with respect to the amount and position of O-acetylation and 
glucosylation. For D23580 strain, a clinical isolate from Malawi, O-acetyl groups were 
found not only on C-2 of abequose (factor 5 specificity), but also on C-2 and C-3 of 
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Rhamnose. Glucose was found to be linked 1→4 or 1→6 to galactose in different 
amounts according to the strain of origin. S. Enteritidis isolates were more structurally 
homogeneous, being all characterized by low glucosylation and O-acetylation levels 
and the same O-acetylation position. 
Glycoconjugates were synthesized using CRM197 as carrier protein by a selective 
derivatization on the KDO moiety of the OAg, allowing the rational design of 
structurally defined conjugates which differed uniquely for their OAg fine specificities. 
All NTS glycoconjugates resulted immunogenic in mice and able to elicit bactericidal 
antibodies. OAg fine specificities seemed to influence glycoconjugate 
immunogenicity. In particular, the presence of additional O-acetyl groups on 
rhamnose for S. Typhimurium D23580 OAg resulted in the production of strain-
specific anti-OAg antibodies. O-acetylation and glucosylation seemed also to have an 
impact on the bactericidal activity when antibodies produced in mice were tested 
against a broad panel of S. Typhimurium endemic strains. This work underlines how 
the selection of the strain as OAg source for glycoconjugate vaccine production can 
be important, as different strains may result in candidate vaccines inducing 
antibodies with potentially different cross-reactivities and different immunogenicity. A 
screening of a bigger number of strains would probably highlight better on the 
importance of the OAg structure in affecting the immunogenicity of NTS 
glycoconjugate vaccines.  
To investigate on the impact of conjugation chemistry on the immunogenicity of S. 
Typhimurium glycoconjugate vaccines, conjugates obtained by different random 
derivatizations along the sugar chain or selective activation of the KDO introducing 
linkers of different length were compared in mice. All the conjugates induced high 
anti-OAg IgG antibodies with strong serum bactericidal activity. However, random 
conjugates induced stronger bactericidal antibodies than selective ones, and FACS 
analysis confirmed that the random derivation did not impact on the ability of the 
corresponding conjugates to induce antibodies able to recognize structural epitopes. 
However, an inverse correlation between the degree of OAg chain modification and 
the ability of elicited antibodies to protect against the infection was found. 
In the development of a vaccine it is important also to consider the product yield, the 
total number of steps involved in the process and the issues related to the purification 
and characterization of starting materials, intermediates and final vaccine. Random 
chemistry can be preferred also in terms of manufacturing process: less number of 
steps and higher conjugation yield, even if the complexity of the resulting cross-linked 
structures make more difficult the vaccine characterization. 
The synthesis of structurally defined, homogeneous glycoconjugate vaccines is 
desirable not only for production but also as biochemical tools to study conjugates 
processing by the immune system. The development of methods which allow 
saccharide coupling to precise amino acids of proteins/peptides with controlled 
saccharide/protein ratio can be a key aspect of the structure–activity relationships 
(SARs) (127). Moreover, new insights coming from immunology demonstrate that the 
connectivity between the saccharide and the protein may be crucial to the 
immunogenicity of carbohydrate-based conjugate vaccines (160). 
The synthesis of well-defined glycoconjugates requires powerful conjugation 
chemistry. Two strategies were initially investigated for the conjugation of S. 
Typhimurium OAg to CRM197, both involving the linkage of the terminal KDO unit of 
the sugar to the protein: thiol chemistry and click chemistry. Thiol chemistry did not 
allow conjugation unless starting with a relative high number of linkers on the protein, 
while click chemistry allowed conjugate generation even when just one position on 
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the protein was activated. Another advantage of the click chemistry was the 
possibility to recycle unconjugated OAg and use it for the synthesis of a new batch of 
glycoconjugate. Furthermore a solid-phase conjugation method utilizing the carrier 
protein bound to an ion exchange matrix was developed. This methodology holds 
promise for a big impact on reducing the cost and the complexity of vaccine 
production, since it allows the recycling of unreacted sugar and it simplifies the 
conjugate purification.  
Using this conjugation methodology, in the near future we are planning to selectively 
target different amino acids on CRM197 (Figure 6.1)  and introducing a precise number 
of different sugar chains per protein in selective positions.  
 
 
 
 
Figure 6.1 Different amino acids of CRM197 can be activated with different loading 
 
 
These conjugates will represent the first example of well-defined glycoconjugate 
vaccines against NTS, selective on both saccharide and protein component. The 
impact of these highly structural-defined conjugates on the immunogenicity and the 
possibility to control OAg/protein ratio are very attracting. 
In addition to the relevance on the development of NTS glycoconjugate based 
vaccines, this study can add useful informations about factors that influence antigen 
presentation, processing, and cooperation between B and T cells and drive the 
rational design of the next generation conjugate vaccines. 
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Salmonella Typhimurium is the major cause of invasive nontyphoidal Salmonella disease in Africa, with
high mortality among children and HIV-infected individuals. Currently, no vaccine is available for use
in humans. Antibodies directed against the O-polysaccharide of the lipopolysaccharide molecule of Sal-
monella mediate bacterial killing and are protective, and conjugation of the O-polysaccharide to a carrier
protein represents a possible strategy for vaccine development.
Here we have puriﬁed the O-polysaccharide from six different strains of S. Typhimurium and fully char-
acterized them using analytical methods including HPLC–SEC, HPAEC-PAD, GC, GC–MS, 1D and 2D NMR
spectroscopy. All the O-polysaccharide samples showed a similar bimodal molecular mass distribution,
but differed with respect to the amount and position of O-acetylation and glucosylation. For some strains,
O-acetyl groups were found not only on C-2 of abequose (factor 5 speciﬁcity), but also on C-2 and C-3 of
rhamnose; glucose was found to be linked 1?4 or 1?6 to galactose in different amounts according to the
strain of origin.
This structural variability could have an impact on the immunogenicity of corresponding glycoconju-
gate vaccines and different strains need to be evaluated in order to identify the appropriate source of
O-polysaccharide to use for the development of a candidate conjugate vaccine with broad coverage
against S. Typhimurium.
 2013 Elsevier Ltd. All rights reserved.Salmonella Typhimurium is the main Salmonella serovar respon-
sible for invasive nontyphoidal Salmonella (NTS) disease in
Africa.1,2 The case fatality rate for bacteremia caused by NTS is
20–25% for children1,3 and increases to 50% for children with NTS
meningitis.4 Young children with malaria, anaemia and malnutri-
tion5–9 and HIV infected individuals10,11 are particularly affected.
The most recent multisite data on the incidence of Salmonella bac-
teremia among African children, from the RTS,S-AS01 malaria vac-
cine Phase 3 trials, gives rates of around 500/100,000 children/
year.12 These incidence rates are similar to those reported from a
recent single-site study fromMozambique, that found an incidence
of 388/100,000 in children under one year and 262/100,000 in
those aged one to ﬁve years.13 There is no distinctive clinical syn-
drome association with this disease,1,3 making diagnosis and treat-
ment a challenge for health-care workers in low-resource settings.
Around 90% of invasive NTS isolates in Malawi have been found tobe multidrug resistant,14 emphasizing the need for development of
alternative interventions.
Salmonella lipopolysaccharide (LPS) is both a virulence factor
and a target for protective antibodies. Lipid A is linked to the
3-deoxy-D-manno-octulosonic acid (KDO) terminus of the
conserved core region,15 which in turn is attached to the
O-polysaccharide chain. Lipid A is highly conserved and has endo-
toxic activity, while the O-polysaccharide chain differs between
species and is responsible for the serological speciﬁcity of bacteria.
Antibodies directed towards the O-polysaccharide mediate killing
of NTS16–18 and confer protection against NTS infections, and
O-polysaccharide glycoconjugate vaccines have been proposed as
a vaccine strategy against Salmonella.19–22
The S. Typhimurium O-polysaccharide chain is a polymer of
tetrasaccharide repeating units. ?2)-b-D-Manp-(1?4)-b-L-Rhap-
(1?3)-a-D-Galp-(1?, common to Salmonella A, B and D, consti-
tutes the backbone, associated with the factor 12 speciﬁcity of
the Kauffmann–White scheme.23 The serogroup B speciﬁcity is
conferred by the a-D-Abep, an a-3,6-dideoxyhexose (1?3) linked
Figure 1. Structure of the repeating unit of S. Typhimurium O-polysaccharide. The
structural features that vary with the strain of origin are shown in curved brackets.
Table 2
Determination of glycosidic linkages in S. Typhimurium O-polysaccharide by GLC–MS
of PMAA derivatives
Linkage RRTa 1418 2189 2192 D23580 LT2 NVGH1792
t-Abeb 0.45 0.16 0.05 0.42 0.07 0.15 0.46
4-Rha 0.72 0.87 0.84 1.12 1.00 1.40 1.00
t-Glc 0.73 0.63 0.29 ndc ndc ndc ndc
3-Gal 0.91 0.22 0.56 0.91 0.76 0.85 1.10
2,3-Man 1.00 1.00 1.00 1.00 1.00 1.00 1.00
3,4-Gal 1.03 0.05 0.37 0.10 0.26 0.04 0.04
3,6-Gal 1.14 0.59 0.06 0.08 — — —
a Relative retention time
b t-Abe = the amount of this derivative is underestimated because it is acid labile.
c nd = not determined because t-Glc peak overlaps with that of 4-Rha and was
not quantiﬁed in samples with a low level of glucosylation.
2 F. Micoli et al. / Carbohydrate Research 385 (2014) 1–8to the mannose (Man) of the backbone (Fig. 1). This side chain con-
fers the factor 4 speciﬁcity.23
Bacterial LPS can demonstrate high levels of heterogeneity, par-
ticularly LPS from S. Typhimurium. O-Polysaccharide can vary in
chain length and other modiﬁcations, like glucosylation and
O-acetylation of the repeating units, which can constitute addi-
tional speciﬁc O-polysaccharide factors.24 For S. Typhimurium,
the abequose (Abe) may be 2-O-acetylated, which adds O:5 speci-
ﬁcity in the Kauffman–White scheme. Wollin et al.25 reported the
O-acetylation of C-2 and C-3 of rhamnose (Rha) as a new, hitherto
unknown modiﬁcation of S. Typhimurium O-polysaccharide chain.
Galactose (Gal) may be a(1?6) or a(1?4) glucosylated, giving the
factor 1 or factor 122 speciﬁcity, respectively.23,24,26
Here O-polysaccharide chains puriﬁed from six different strains
of S. Typhimurium have been fully characterized to verify how
much the O-polysaccharide structure can differ according to the
strain of origin. Two of the structures have been fully elucidated
by use of NMR spectroscopy.
The results obtained have conﬁrmed the structural variability of
LPS expressed by different isolates of S. Typhimurium which will
have an impact on the selection of S. Typhimurium strains for
O-polysaccharide conjugate vaccine development.
1. Results
All puriﬁed O-polysaccharide samples exhibited high levels of
purity, with protein and nucleic acid content <1% (weight to weight
respect to the sugar) and endotoxin level <0.1 EU/lg of sugar, indi-
cating complete removal of the lipid A.
A similar bimodal molecular mass (MM) distribution (Fig. S1)
was obtained for all O-polysaccharide strains except for 2192;
the Kd values are listed in Table 1. Using dextrans as calibrants,
the average MM for the species of higher (HMM) and lower MMTable 1
Main differences detected for O-polysaccharide puriﬁed from different S. Typhimurium st
O-Polysaccharide source Glc% Glc linkage
1418 84 1?4 Gal (8%)
1?6 Gal (92%)
2189 51 1?4 Gal (86%)
1?6 Gal (14%)
2192 24 1?4 Gal (56%)
1?6 Gal (44%)
D23580 39 1?4 Gal
LT2 11 1?4 Gal
NVGH1792 8 1?4 Gal
Glucosylation level calculated as molar ratio % to Man by HPAEC-PAD analysis. Glc linka
calculated by 1H NMR of de-O-acetylated samples (integral of acetate ion peak compared
column (ﬂow rate: 0.5 mL/min; eluent: 100 mMNaH2PO4 100 mMNaCl 5% CH3CN pH 7.2
Average molecular mass (avMM) expressed in kDa using dextrans as standards on the T(LMM) were in the range of 80–87 and 28–30 kDa, respectively,
whereas the O-polysaccharide from strain 2192 showed one main
population with an average MM of 34.5 kDa. However, based on
the average degree of polymerization (DP) and the mass contribu-
tion from O-acetylation, the average MM for this homogeneous
sample was 20.5 kDa. The average DP was determined from the
molar ratio of Rha (O-polysaccharide chain) to GlcNAc (core sugar)
from sugar composition analysis by High-Performance Anion-
Exchange Chromatography with Pulsed Amperometric Detection
(HPAEC-PAD) and the level of O-acetylation was determined by
NMR analysis.
Sugar composition analysis by HPAEC-PAD conﬁrmed the pres-
ence of Rha, Gal and Man, the sugars constituting the backbone of
the O-polysaccharide chain, in a ratio 1:1:1 for all O-polysaccha-
rides examined, while a variable amount of glucosylation was
found depending on the origin of the O-polysaccharide strain (Ta-
ble 1). This composition was conﬁrmed by Gas Liquid Chromatog-
raphy (GLC) analysis of the alditol acetates derivatives (Table S1).
In the absence of a monomer standard, Abe was quantiﬁed by 1H
NMR analysis which yielded the expected molar ratio of 1:1 with
respect to Man for all samples (Fig. 1).
The linkage positions for the constituent sugars of the O-poly-
saccharide samples were determined by GLC and GLC–MS of the
partially-methylated alditol acetate (PMAA) derivatives (Table 2).
As expected,26 the O-polysaccharide chains from all sources con-
tained terminal non-reducing 3,6 dideoxyhexose, identiﬁed as
Abe by NMR (t-Abe), 4-linked Rha (4-Rha), terminal non-reducing
glucose (t-Glc) (its peak overlaps with that of 4-Rha and was not
quantiﬁed in samples with a low level of glucosylation), 3-linked
Gal (3-Gal), 2,3 linked Man (2,3-Man). Glc was found to be linked
to Gal in position 4 or 6, in different amounts according to therains
OAc on Rha % OAc Kd (avMM)
No 73 0.16 and 0.28
(87.0 and 30.4 kDa)
No 58 0.17 and 0.27
(80.8 and 31.6 kDa)
No 100 0.26
(34.5 kDa)
Yes 142 0.17 and 0.28
(82.6 and 28.3 kDa)
No 65 0.17 and 0.28
(82.6 and 28.3 kDa)
Yes 149 0.17 and 0.28
(82.6 and 28.3 kDa)
ge to Gal determined by GLC–MS analysis of PMAA derivatives. O-Acetylation level
to Rha-H6 peak). Kd values calculated after HPLC–SEC analysis on TSK gel 3000 PWXL
using k-DNA and NaN3 for determining void volume and total volume, respectively).
SK gel 3000 PWXL column. HPLC–SEC proﬁles are shown in Figure S1.
Figure 2. GLC chromatograms of the PMAA derivatives from D23580 OAg obtained without (A) and with (B) retention of O-acetyl position. Peak assignments are reported:
t-Abe = terminal non-reducing Abe; t-Abe-2Ac = terminal non-reducing Abe acetylated on C-2. The numbers indicate the position of hydroxyl functions engaged in linkages.
Similar chromatograms were obtained for the other O-polysaccharide and the results are summarized in Table 3.
Table 3
Deduced OAc position and quantiﬁcation of substitution based on the relative molar
ratios of O-polysaccharide PMAA derivatives obtained with and without retention of
O-acetyl substituents
Residue 1418 2189 2192 D23580 LT2 NVGH1792
t-Abe 48% 63% 20% 37% 37% 20%
t-Abe-2Ac 52% 37% 80% 63% 63% 80%
4-Rha 100% 100% 100% 22% 100% 13%
4-Rha-3Ac — — — 43% — 48%
4-Rha-2Ac — — — 35% — 39%
F. Micoli et al. / Carbohydrate Research 385 (2014) 1–8 3strain of origin. LT2, D23580 and NVGH1792 had Glc linked 1?4 to
Gal, as shown by the presence of 3,4-Gal (Table 2). For 1418
O-polysaccharide, Glc was predominantly linked 1?6 to Gal, as
shown by the presence of 3,6-Gal rather than 3,4-Gal (Table 2),
while the opposite was found for 2189 O-polysaccharide. 2192
sample showed equal amounts of Glc linked 1?4 and 1?6. The
amount of t-Glc determined was variable in the different O-poly-
saccharide samples27 and the sum of 3,4-Gal and 3,6-Gal for each
sample was in agreement with the total amount of Glc determined
by GLC analysis of the alditol acetates (Table S1). The results are
consistent with the structural variations reported for the S.
Typhimurium O-polysaccharide23,24,26; the structure of the general
repeating unit is shown in Figure 1.
GLC analysis of the chiral glycosides of all the O-polysaccharide
samples showed that the hexoses were in the D absolute conﬁgu-
ration and Rha in the L absolute conﬁguration. As before, the ab-
sence of a standard meant that this analysis could not be
performed for Abe, and its D conﬁguration was established by
NMR glycosylation shifts.
Analysis by 1H NMR performed after the addition of 200 mM
NaOD28 revealed different O-acetylation levels according to the
source of O-polysaccharide (Table 1). In D2O all samples contained
the characteristic signal near 2.13 ppm assigned to OAc on C-2 Abe,
with D23580 and NVGH1792 O-polysaccharide having additional
OAc signals at 2.23 and 2.19 ppm. In order to determine the posi-
tion of these additional O-acetyl groups and to conﬁrm that OAc
on Abe was at C-2, the O-polysaccharides were permethylated fol-
lowing the method of Prehm,29 which leaves the O-acetyl groups intheir native positions. Analysis of the corresponding PMAA deriva-
tives was performed by GLC and GLC–MS. Figure 2 shows the GLC
chromatograms of the PMAA derivatives for the D23580 O-poly-
saccharide, as an example, obtained without (A) and with (B)
retention of the O-acetyl groups. Comparison of the two chromato-
grams showed that new peaks were present when PMAA deriva-
tives were obtained with retention of O-acetyl position. 2-Abe
was a new signal, conﬁrming esteriﬁcation with O-acetyl on C-2
of the terminal Abe. In addition, the expected 4-Rha, 3,4-Rha and
2,4-Rha were also present, indicating partial esteriﬁcation of the
4-linked Rha on C-2 or C-3. Separation of the 4-Rha into three
derivatives also resulted in the partial separation of the peak as-
signed to t-Glc from that of 4-Rha. In the chromatogram obtained
without retention of O-acetyl groups (Fig. 2A), t-Glc was a shoulder
on the side of the 4-Rha peak and therefore its integration was not
possible (Table 2).
4 F. Micoli et al. / Carbohydrate Research 385 (2014) 1–8This analysis was performed on all the O-polysaccharide sam-
ples (Table 3) and conﬁrmed the results from 1H NMR analysis (Ta-
ble 1): all O-polysaccharides were variably O-acetylated on C-2
Abe, whereas only the D23580 and NVGH1792 O-polysaccharides
had additional OAc groups on Rha (Table 3). According to the anal-
ysis, OAc were on C-2 and C-3 of Rha (Fig. 1).
The structure of the O-polysaccharide produced by S. Typhimu-
rium strains 2192 and D23580 was investigated by use of 1D and
2D NMR spectroscopy as these samples are representative of OAg
O-acetylated only on C-2 Abe and on Abe with additional O-acety-
lation on C-2 and C-3 Rha, respectively. Both samples analysed
contained low levels of glucose. The O-acetylation was demon-
strated by O-acetyl signals at 2.11 ppm (for strain 2192, Fig. 3A)
and 2.23, 2.19 and 2.13 ppm (for strain D23580, Fig. 4A) and the
associated ring protons in the anomeric region of the spectra.
Due to the spectral complexity introduced by O-acetylation, the
structure (linkages and sequence) of the sugar backbone was ﬁrst
elucidated by analysis of the corresponding de-O-acetylated sam-
ples (Supplementary information). The 1H and 13C NMR spectra
of the O-polysaccharide 2192 showed key spectral differences aris-
ing from O-acetylation (Fig. 3, Table 4). Comparison of the relative
areas of the O-acetyl singlet at 2.11 ppm (and H-3 of Abe) com-
pared to H-6 of Rha and Abe indicated approximately 95% O-acet-
ylation. Use of COSY, TOCSY and HSQC (Fig. S2) experimentsFigure 3. 1H NMR spectra of S. Typhimurium strain 2192 OAg with O-acetylation (A) 219
and de-O-acetylated (D). Some assignments are labelled; the sugar residues are labelled
and lower case for the unacetylated repeating unit.permitted full assignment of the O-acetylated repeating unit and
showed the presence of a single O-acetyl group on C-2 of Abe
(cross-peak H-2/C-2 of Abe2Ac at 5.09/68.0 ppm). Some of the
minor peaks due to the presence of the unacetylated repeating unit
are labelled in Figure 3C. The major spectral differences between
O-polysaccharide 2192 and the de-O-acetylated polysaccharide
are the expected deshielding of H-1 (+0.19 ppm) and H-2
(+1.1 ppm) and C-2 (+3.2 ppm) of Abe (at the position of substitu-
tion) and shielding of the adjacent carbons C-1 (2.7 ppm) and C-3
(3.0 ppm).30 In addition, H-1 of a-Man was deshielded from
5.31 ppm (de-OAc 2192) to 5.39 ppm for 2192, otherwise
O-acetylation resulted in only minor chemical shift differences
for the other residues. The assignments (Table 4) for the major
repeating unit [?2)[a-D-Abep2Ac-(1?3)]-a-D-Manp-(1?4)-a-L-
Rhap-(1?3)-a-D-Galp-(1?] agree with those reported for the
same O-acetylated repeating unit isolated from several species of
Edwardsiella tarda and recently for Salmonella enterica.31,32
Comparison of the 1H and 13C NMR spectra of O-polysaccharide
D23580 with 2192 showed additional O-acetyl signals at 2.23 and
2.19 ppm for O-polysaccharide of D23580 and several other spec-
tral differences arising from O-acetylation (Fig. 4). Comparison of
the relative peak areas of the total O-acetate signal to H-6 of Rha
and Abe for de-O-acetylated D23580 sample indicated a total of
150–180% O-acetylation per repeating unit. The major O-acetyl2 de-O-acetylated (B) and the corresponding 13C NMR spectra with O-acetylation (C)
upper case for the O-acetylated repeating unit (A = Abe, G = Gal, M = Man, R = Rha)
Figure 4. 1H NMR spectra of S. Typhimurium strain D23580 (A) and 2192 OAg (B) and the corresponding 13C NMR spectra of strain D23580 (C) and 2192 OAg (D). Some
assignments are labelled; the sugar residues are labelled as before with upper case for the Abe2Ac containing repeating unit and the Rha O-acetylation is labelled with dashes
(R = Rha, R0 = Rha3Ac, R00 = Rha2Ac, etc.) with lower case for the unacetylated repeating unit.
Table 4
NMR data of S. Typhimurium 2192 [de-OAc (upper panel) and native (lower panel)]
Residue H-1 H-2 H-3 H-4 H-5 H6 O-Acetyl
C-1 C-2 C-3 C-4 C-5 C-6 Methyl CO
4)-a-L-Rhap-(1? 5.05 4.07 3.97 3.56 3.94 1.33
(r) 103.3 71.8 70.4 82.9 69.3 18.5
3)-a-D-Galp-(1? 5.18 3.93 3.93 4.06 4.08 3.72
(g) 102.6 69.3 78.5 70.4 72.7 62.3
2,3)-a-D-Manp-(1? 5.31 4.02 4.02 4.02 3.98 3.86, 3.82
(m) 101.0 80.7 79.5 67.7 74.9 62
a-D-Abep-(1? 5.09 4.02 1.98 3.87 4.12 1.18
(a) 102.1 64.8 34.5 69.7 68.2 16.9
4)-a-L-Rhap-(1? 5.07 4.09 3.96 3.58 3.94 1.36
(R) 103.3 71.9 70.5 83.0 69.4 18.5
3)-a-D-Galp-(1? 5.18 3.92 3.97 4.09 4.11 3.75
(G) 103.1 69.4 78.4 70.5 72.9 62.4
2,3)-a-D-Manp-(1? 5.39 3.99 4.05 4.05 3.98 3.88, 3.83
(M) 100.8 81.8 79.0 67.5 75.1 62.0
a-D-Abep2OAc-(1? 5.28 5.09 2.09 3.94 4.17 1.23 2.11
(A) 99.4 68.0 31.5 69.6 68.6 16.9 21.1 174.6
The residues of the major de-O-acetylated repeating unit (upper panel) are indicated by lower case and the O-acetylated residues (lower panel) by capitals. Minor peaks due
to the presence of low amounts of glucose present are not listed. Deshielded ring carbons (linkage positions) are underlined. The spectra were recorded at 303 K and
referenced to added acetone or sodium acetate (after de-O-acetylation).
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Figure 5. Expansion of the HSQC spectrum of O-polysaccharide from S. Typhimurium strain D23580. Major crosspeaks corresponding to the Abe2Ac repeating unit are
labelled with the Rha O-acetylation labelled with dashes (R1 = H-1/C-1 of Rha, R01 = H-1/C-1 of Rha3Ac, R001 = H-1/C-1 of Rha2Ac, etc.). The key crosspeak at 1H/13C 5.09 ppm/
68.0 ppm is due to O-acetylation on C-2 of Abe (labelled A2), at 5.21 ppm/74.2 ppm is due to O-acetylation on C-3 of Rha (labelled R30) and at 5.23 ppm/74.2 ppm is due to O-
acetylation on C-2 of Rha (labelled R200).
6 F. Micoli et al. / Carbohydrate Research 385 (2014) 1–8signal at 2.13 ppm was assigned to Abe2Ac with a characteristic
cross-peak for H-2/C-2 at 5.10/68.1 ppm in the HSQC spectrum
(Fig. 5, Table 5). This assignment was supported by the 1D NOESY
experiment which showed correlations to H-1 and H-2 of Abe2Ac
(Fig. S3A) although these peaks may also be due to correlations
with the overlapping H-3 of Abe2Ac at 2.12 ppm. Further proof
came from the HMBC experiment (not shown) which contained
cross-peaks from the O-acetyl methyl group at 2.13 ppm to the car-
bonyl resonance at 174.6 ppm, which also correlated to H-2 of
Abe2Ac at 5.10 ppm. Owing to the complexity of the proton spec-
trum in the O-acetyl region, the amount of O-acetylation on C-2 of
Abe was estimated as 90% from the relative intensities of C-3 sig-
nals of Abe2Ac at 31.6 ppm and Abe at 34.5 ppm (Fig. 4C). This is
slightly lower than the 95% O-acetylation estimated for strain
2192 (Fig. 4D).
Two additional O-acetyl signals were present at 2.23 and
2.19 ppm, although, only a single extra HSQC cross peak was ob-
served (at 5.22/74.2 ppm) (Fig. 5), compared to strain 2192
(Fig. S2). Detailed analysis by use of COSY, TOCSY (1D and 2D),
NOESY (1D and 2D), HSQC-TOCSY and HMBC experiments revealed
the presence of multiple Rha spin systems and consequently the
cross-peak could be assigned to partially overlapped correlations
from Rha2Ac (H-2 at 5.23 ppm) and Rha3Ac (H-3 at 5.21 ppm) to
the same carbon at 74.2 ppm. Three H-6 Rha resonances could be
discerned which were assigned to H-6 of Rha3Ac (1.41 ppm, C-6
at 18.8 ppm), Rha2Ac (1.38 ppm, C-6 at 18.5 ppm) and Rha
(1.35 ppm, C-6 at 18.5 ppm). Use of a series of 1D and 2D experi-
ments elucidated the spin system for Rha3Ac and Rha2Ac as de-
tailed in Supplementary information.
Overlap of the O-acetyl signals of O-polysaccharide D23580
with H-3 and core signals in the same region precluded determina-
tion of the relative amounts of O-acetylation on C-2 and C-3 of Rha
by direct integration. Instead this was estimated from the relative
areas of the anomeric protons of Rha2Ac (30%), Rha3Ac (50%), and
Rha (20%) in the 1D TOCSY experiment obtained from all three H-6signals (Supplementary information). This estimation was sup-
ported by the equal intensities of the C-6 Rha signals at 18.8 ppm
(due to C-6 of Rha3Ac) and 18.5 ppm (due to C-6 of Rha2Ac and
Rha) in Figure 4C and is in agreement with the quantiﬁcation per-
formed by PMAA derivatives (Table 3). The presence of Rha2/3Ac is
consistent with the facile migration of O-acetyl groups from C-2 to
C-3 of Rha described in NMR studies conducted on O-acetylated
methyl rhamnosides33; however, the possibility that the acetyl-
transferase involved can modify both positions cannot be ex-
cluded. Thus the major repeating unit of Salmonella Typhimurium
D23580 is deﬁned as [?2)[a-D-Abep2Ac-(1?3)]-a-D-Manp-
(1?4)-a-L-Rhap2/3Ac-(1?3)-a-D-Galp-(1?].
As part of our project to develop a comprehensive conjugate
vaccine against invasive NTS disease, we report the full character-
ization of the O-polysaccharide from 6 different strains of
S. Typhimurium. The sugar chains of O-polysaccharide were ex-
tracted from two lab strains (LT2 and NVGH1792), three animal
isolates (1418, 2192 and 2189) and one human isolate (D23580).
As reported in Table 1, all puriﬁed O-polysaccharides were similar
in terms of MM distribution, with two main populations at average
MM 80–87 and 28–31 kDa respectively. Only 2192 showed one
main peak at average 34.5 kDa (Fig. S1). Sugar analysis by
HPAEC-PAD and GLC–MS conﬁrmed the composition of the tetra-
saccharide repeating unit as Man, Gal, Rha and Abe. The analysis
also showed strain speciﬁc variable amounts of glucosylation,
ranging from 8% to 84%. The structure of the repeating unit was
conﬁrmed by linkage analysis which showed that the terminal glu-
cose present was linked 1?4 and/or 1?6 to Gal, depending on the
strain. All the O-polysaccharides were O-acetylated on C-2 Abe
although to different extents depending on the strain, while
D23580 and NVGH1792 were found to have additional OAc groups
on C-2 and C-3 of Rha. The position of the OAc groups was estab-
lished by GLC–MS and NMR analysis. Finally detailed 1D and 2D
NMR studies elucidated the structure of the major repeating unit
backbone and the location and extent of the O-acetyl groups of
Table 5
NMR data of S. Typhimurium (D23580) with Rha, Rha2Ac and Rha3Ac
Residue H-1 H-2 H-3 H-4 H-5 H-6 O-Acetyl
C-1 C-2 C-3 C-4 C-5 C-6 Methyl CO
4)-a-L-Rhap-(1? 5.09 4.11 3.99 3.59 3.96 1.35
(R) 102.9 71.7 70.5 83.0 69.4 18.5
4)-a-L-Rhap3Ac-(1? 5.10 4.23 5.21 3.85 4.05 1.41 2.23
(R0) 102.9 69.7 74.2 79.5 69.4 18.8 22.2 175.0
4)-a-L-Rhap2Ac-(1? 5.12 5.23 4.22 3.63 4.04 1.38 2.19
(R00) 100.3 74.2 68.8 83.0 69.4 18.5 21.9 174.6
3)-a-D-Galp-(1? 5.18 3.96 3.99 4.11 4.14 3.76
(G) 103.1 69.4 78.5 70.5 72.7 62.4
2,3)-a-D-Manp-(1? 5.39/5.35 3.99/3.96 3.99 4.03 3.98 3.87, 3.83
(M00/M,M0) 101.0/101.3 81.9/81.7 78.7 67.3 75.2 61.8
a-D-Abep2Ac-(1? 5.27 5.10 2.12 3.90 4.19 1.23 2.13
(A) 99.4 68.1 31.6 69.6 68.6 16.9 21.8 174.6
The residues of the major O-acetylated repeating unit are indicated by capitals; minor peaks due to the presence of low amounts of glucose present are not listed. The Rha,
Rha3Ac and Rha2Ac spin systems are represented by R, R0 and R00 , respectively, and the corresponding spin systems of Man by M, M0 and M00 . Deshielded ring carbons (linkage
positions) are underlined. The NMR spectra were recorded at 303 K and referenced to the HOD signal.
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and D23580. These assignments will facilitate screening of O-poly-
saccharide structure and pattern of O-acetylation for LPS from new
strains of S. Typhimurium.
Due to the structural variability found in this study, future stud-
ies will investigate whether these O-polysaccharide structural dif-
ferences impact on the immunogenicity of corresponding
glycoconjugate vaccines. If this is so, then different strains of S.
Typhimurium will need to be evaluated in order to identify which
are optimal as the source of O-polysaccharide for the development
of the most promising candidate glycoconjugate vaccines against S.
Typhimurium.
2. Experimental
2.1. Origin and growth of S. Typhimurium strains
The clinical isolate D23580 was obtained from the Malawi–Liv-
erpool–Wellcome Trust Clinical Research Programme, Blantyre,
Malawi. D23580 is a typical and representative Malawian invasive
NTS isolate belonging to ST313 sequence type and pathovar.34
1418, 2189 and 2192 are animal isolates35,36 and were obtained
from University of Calgary. The laboratory strains NVGH1792 and
LT237 were obtained from the University of Birmingham, UK, and
Novartis Master Culture Collection, respectively.
All S. Typhimurium bacterial strains were grown in a chemically
deﬁned medium, using glycerol as the carbon source. All strains
were fermented in a 7 L bioreactor (EZ-Control, Applikon) to OD
35 as previously described.38,39
2.2. O-Polysaccharide puriﬁcation
S. Typhimurium O-polysaccharides were puriﬁed as previously
described.38 Brieﬂy, mild acid hydrolysis (2% acetic acid at 100 C
for 3 h) to cleave the acid-labile KDO-lipid A linkage was per-
formed directly on the fermentation culture instead of the isolated
LPS. The O-polysaccharide chains linked to the core sugars released
into the supernatant, were recovered following centrifugation.
Lower MM impurities were removed and the supernatant concen-
trated by tangential ﬂow ﬁltration (TFF), using a Hydrosart 30 kDa
membrane. Protein and nucleic acid impurities were co-precipi-
tated in citrate buffer 20 mM at pH 3. The protein content was fur-
ther reduced by ion exchange chromatography. Nucleic acids were
further removed by precipitation in 18 mM Na2HPO4, 24% EtOH
and 200 mM CaCl2, pH >4.5. O-Polysaccharide was then recovered
in water by a second TFF 30 kDa step.2.3. O-Polysaccharide size analysis and chemical
characterization
Phenol sulfuric acid assay was used for total sugar quantiﬁca-
tion40; micro BCA for protein quantiﬁcation (using bovine serum
albumin as a reference following the manufacturer’s instructions
[Thermo Scientiﬁc]); UV spectroscopy for nucleic acid content
(assuming that a nucleic acid concentration of 50 lg/mL gives an
OD 260 = 1) and chromogenic kinetic LAL (Limulus Amoebocyte
Lysate) for endotoxin level (Charles River Endosafe-PTS instru-
ment). Size-Exclusion High Pressure Liquid Chromatography
(HPLC–SEC) with differential refractive index (dRI) detection was
used to estimate the molecular size distribution of O-polysaccha-
ride populations.38 Samples were run on a TSK gel G3000 PWXL
column (30 cm  7.8 mm; particle size 7 lm; cod. 808021) with
TSK gel PWXL guard column (4.0 cm  6.0 mm; particle size
12 lm; cod.808033) (TosohBioscience). The mobile phase was
0.1 M NaCl, 0.1 M NaH2PO4, 5% CH3CN, pH 7.2 at the ﬂow rate of
0.5 mL/min (isocratic method for 30 min). Void and bed volume
calibration was performed with k-DNA (k-DNA Molecular Weight
Marker III 0.12–21.2 Kbp, Roche) and sodium azide (NaN3, Merck),
respectively and dextrans were used as standards. For Kd determi-
nation, the following equation was used: Kd = (Te  T0)/(Tt  T0)
where: Te = elution time of the analyte, T0 = elution time of the big-
gest fragment of k-DNA and Tt = elution time of NaN3.
The sugar monomers constituting the O-polysaccharide repeat-
ing unit and N-acetyl glucosamine (GlcNAc), a unique sugar of the
core region, were quantiﬁed by use of HPAEC-PAD.38 1D 1H NMR
analysis was recorded on all O-polysaccharide samples to conﬁrm
identity and purity and to calculate the level of O-acetylation.38
Addition of NaOD to the sample caused rapid de-O-acetylation
(the sample was heated at 37 C for 20 min to have complete de-
O-acetylation) and the degree of O-acetylation was calculated
comparing the integrals of acetate and Rha-H6 peaks.
Sugar composition analysis was also performed by GLC, after
hydrolysis of the polysaccharides with 2 M TFA at 125 C for 1 h,
and derivatization to alditol acetates.41 The sugar linkage positions
were determined by GLC–MS after per-methylation of the sam-
ples,42 hydrolysis with 2 M TFA at 125 C for 1 h, followed by
reduction and per-acetylation to obtain the partially methylated
alditol acetates (PMAA) derivatives. Peak areas were corrected by
using the effective carbon response factors43; for Abequose the re-
sponse factor of 6-deoxy hexose were applied. Determination of
the absolute conﬁguration of the sugar residues of OAg samples
(strains D23580, NVGH1792 and LT2) was performed as previously
described.44
8 F. Micoli et al. / Carbohydrate Research 385 (2014) 1–8In order to determine the position of the O-acetyl groups, the
O-polysaccharides were per-methylated following the method of
Prehm,29 which leaves the O-acetyl groups in their native posi-
tions. Samples were then treated as above to obtain the PMAA
derivatives, which were then analysed by GLC and GLC–MS.
Analytical GLC was performed on a Perkin Elmer Autosystem XL
gas chromatograph equipped with a ﬂame ionization detector and
a SP2330 capillary column (Supelco, 30 m), using He as carrier gas.
The following temperature programs were used: for alditol ace-
tates, 200–245 C at 4 C/min; for PMAA, 150–250 C at 4 C/min.
Separation of the trimethylsilylated (+)-2-butyl glycosides, for
determining the absolute conﬁguration of the sugars, was obtained
on a HP1 column (Hewlett–Packard, 50 m), using the following
temperature program: 50 C 1 min, 50–130 C at 45 C/min, hold
1 min, 130–240 C at 1 C/min, hold 20 min. GC–MS analyses were
carried out on an Agilent Technologies 7890A gas chromatograph
coupled to an Agilent Technologies 5975C VL MSD.
2.4. NMR spectroscopy
Samples (20–40 mg) were lyophilized and exchanged twice
with 99.9% deuterium oxide, then dissolved in 600 lL of D2O and
introduced into a 5 mm NMR tube for data acquisition. 1D (1H
and 13C) and 2D, TOCSY, NOESY, HSQC, HMBC and hybrid HSQC-
TOCSY NMR spectra were obtained using a Bruker Advance III
400 NMR with an Ultra Shield 400 Plus magnet. The probe temper-
ature was set at 303 K and the 1D and 2D spectra recorded and pro-
cessed using standard Bruker software (Topspin 2.1). 2D TOCSY
experiments were performed using mixing times of 120, 180 ms
or 200 ms and the 1D variants using mixing times ranging from
30 to 250 ms. Long mixing times were employed to permit the
transfer of magnetization from H6 to H1 of Rha. The HSQC and
HMBC experiments were optimized for J = 145 and 8 Hz respec-
tively. De-O-acetylation was performed by the addition of 4 lL so-
dium deuteroxide (NaOD, Sigma Aldrich) to the tube containing
the O-polysaccharide sample in D2O. Spectra were referenced to
the HOD signal or to added acetone or sodium acetate (after de-
O-acetylation).45
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